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Cognitive functioning is impaired in schizophrenia spectrum disorders, with cognitive 
symptoms a core part of schizophrenia. Cognitive impairment is associated with 
poorer daily life functioning and prognosis, making it an important treatment goal. As 
opposed to positive symptoms, cognitive symptoms have proven quite resistant to 
antipsychotic drug treatment. It is also unclear how cognitive functioning changes 
throughout the course of psychosis, from the prodromal stage, during acute psychosis 
and after the onset of medical treatment. The aim of this thesis was to investigate 
cognitive impairment and change during these three important stages of illness.  
Paper I aimed to investigate the relation between cognitive and symptomatic change 
in patients with psychotic disorders (n=84) during the early acute phase of illness. 
Psychotic symptoms in the sample were due to schizophrenia spectrum disorders 
(F20-29), psychoactive substance use (F12-19), and affective disorders with 
psychosis (F31-33). We administered the tests of the Repeateble Battery for the 
Assessment of Neuropsychological Status (RBANS) on admission and again at acute 
ward discharge (mean time 4.1 weeks, SD 1.86 weeks), using the Positive and 
Negative Syndrome Scale (PANSS) to assess symptomatic change. We found 
cognitive impairment (t < 35) in 28.6% of participants at baseline and 13.1% at 
follow-up. PANSS negative symptoms change significantly predicted total RBANS 
performance improvement (beta = -.307, p = .016). There was no significant 
difference in cognitive change between subjects with schizophrenia and those with 
other psychotic disorders. Findings thus indicated that the proportion of subjects with 
mild to moderate impairment in cognitive test performance is reduced across the 
acute phase of psychosis, and that improvement is related to amelioration of negative 
symptoms. 
Paper II compared the cognitive functioning and profile of subjects deemed at ultra 
high risk for psychotic disorder (UHR, n=51) to a sample with schizophrenia (F20), 
split into two groups based on duration of illness (n=19 and 22). Comparisons were 
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made using coordinated norms based on healthy controls (n=61) reflecting the 
younger UHR age spectrum. A comprehensive neurocognitive test battery aiming to 
measure speed of processing, working memory, verbal learning, reasoning, and 
problem solving, as well as visual problem solving were used. UHR subjects showed 
impaired speed of processing (p<.001), working memory (p=.042) and verbal 
learning, reasoning and problem solving (p=.007) as compared to the control group. 
Visual problem-solving skills appeared unimpaired. UHR subjects significantly 
outperformed the schizophrenia group with duration of illness >3 years for speed of 
processing and working memory (both p<.001). There were no significant differences 
in performance between the UHR group and the group with duration of schizophrenia 
< 3 years. It can be concluded that cognitive performance is impaired in UHR 
subjects and should thus be monitored by clinicians. If spatial skills are less impaired, 
this could be useful to know when facilitating academic and work participation for 
this group.  
Paper III compared cognitive change in three groups of participants with 
schizophrenia spectrum disorder (F20-F29) receiving amisulpride (n=33), 
aripiprazole (n=32), and olanzapine (n=39) over 12 months. A short neurocognitive 
test battery was administered at baseline and again at 6, 26 and 52 weeks. Sample 
average cognitive test t-scores improved from 42.20 to 46.39 over the year, rising 
significantly to 6 (Δ2.0; p= .002), 26 (Δ3.4; p< .001) and 52 (Δ4.2; p< .001) weeks, 
corresponding to a medium effect size Cohen’s d of .53. There were no significant 
between-drug changes in the amount of improvement. Nor were there any significant 
differences in change between subjects with schizophrenia and those with other 
psychotic disorders. Our findings thus indicate that despite significant improvements 
in cognitive test performance, there were no significant between-drug differences in 
cognitive change in the 12 months following onset of a new course of treatment. 
Conclusion 
The findings from the present thesis suggest that cognitive impairment in psychosis is 
present before the appearance of positive symptoms, with a similar but less severe 
profile of impairment than in established psychotic disorders. Cognitive impairment 
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appears to fluctuate alongside the course of psychosis, with improvement seen during 
the first weeks of treatment in acute psychosis, and further improvement with the 
onset of medical treatment.  
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The phenomenon of psychosis encompasses a diverse set of disturbances to 
perception, cognition, emotions, and behaviour, where a person develops 
inappropriate interpretations of their environment and sense of self and falls out of 
touch with reality. Adverse life events and psychosocial stressors may trigger a 
psychotic episode, but symptoms may also arise spontaneously. It may form part of a 
primary psychotic disorder of which psychosis is the most prominent expression, with 
schizophrenia considered the most severe form. Psychosis may also occur as part of 
an affective disorder (e.g. depression or bipolar disorders), or in relation to 
psychoactive substance use or somatic health issues. Gathering good quality 
longitudinal data about psychosis is difficult due to the fluctuating nature of psychotic 
disorders, as well as the challenging life circumstances of many subjects. Despite 
research efforts across several decades, the pathway or pathways to psychosis 
remains unclear. Outcomes of schizophrenia and psychotic disorders are 
heterogeneous (Lepage, Bodnar, & Bowie, 2014), and the expected progression or 
treatment response of each person is often uncertain at the point of diagnosis. 
1.1.1 Symptom dimensions in psychosis 
Symptoms associated with psychosis are often categorised as positive, negative, 
affective, disorganised, and cognitive (Shevlin, McElroy, Bentall, Reininghaus, & 
Murphy, 2016). A psychotic episode may entail symptoms falling under some or all 
of these symptom dimensions, yielding a clinically diverse population. The 
comprehensive and heterogenous symptomatology leaves psychosis a complicated 
phenomenon to study. For the purposes of paper II on symptomatic change and 
cognition, this thesis used a five-factor symptomatic model with affective symptoms 
split into depressive and excitatory symptoms (Wallwork, Fortgang, Hashimoto, 
Weinberger, & Dickinson, 2012). 
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Positive symptoms occur in addition to normal behaviour. They commonly manifest 
as delusions and / or hallucinations. Delusions are firmly held beliefs which are 
upheld contrary to conflicting evidence, and which cannot be explained by a person’s 
cultural or religious background. Bizarre delusions in particular were identified as 
one of Schneider’s first-rank schizophrenia symptoms in the 50s. A bizarre delusion 
according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV) entails something which is “clearly implausible” (American Psychiatric 
Association, 2000), e.g. believing one’s brain is missing and stored in the fridge. 
Such delusions were previously considered to satisfy on their own the diagnostic A-
criteria for schizophrenia until being downplayed in the Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM5) (American Psychiatric Association, 
2013). Delusions about external control, thought insertion or theft are common in 
schizophrenia. Other common delusions have grandiose or paranoid content, often 
with self-referencing aspects, e.g. believing that objects in the environment are placed 
to express a “secret message”. Hallucinations are perceptual disturbances where the 
person perceives e.g. sound or images in lieu of external stimuli. The third-generation 
dopamine theory of schizophrenia by Howes and Kapur (Howes & Kapur, 2009; 
Howes & Nour, 2016) describe positive symptoms as arising from abnormal 
mesostriatal dopamine functioning. Excess dopaminergic activity in the mesolimbic 
pathway, which regulates reward responses in the brain, causes otherwise innocuous 
stimuli to gain aberrant salience. The person thus falsely perceives these stimuli as 
having “special meaning”. Similarly, internal stimuli may gain sensory properties, 
giving rise to e.g. hearing non-existent voices. Given that antipsychotic drugs all rely 
on dopamine 2 (D2) receptor antagonism, positive symptoms respond better to 
medication than the other symptom dimensions (Miyamoto, Duncan, Marx, & 
Lieberman, 2005). 
Negative symptoms involve a loss of normal behaviour and motivation including 
social withdrawal, diminished emotional expression and avolition (Foussias & 
Remington, 2008). Negative symptoms are thought to arise partly due to low levels of 
dopamine in the prefrontal cortex, dopamine D1 receptor dysfunction and reduced 
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mesocortical pathway activity (Howes & Kapur, 2009; Lally & MacCabe, 2015), but 
the biological underpinnings remain only partly clarified. Negative symptoms were 
previously thought to appear and worsen as illness progressed, but current research 
indicates that they are present already at the prodromal stage (Piskulic et al., 2012). 
They in fact fluctuate less throughout the course of illness than do positive symptoms 
(Austin et al., 2015). Negative symptoms are more strongly correlated with poor 
functional outcome than are positive symptoms (Fervaha, Foussias, Agid, & 
Remington, 2014) and respond poorly to antipsychotic treatment (Fusar-Poli et al., 
2014). 
Affective symptoms are similar to those seen in both depressive and maniform 
affective disorders, e.g. feelings of guilt, anxiety, tension and poor impulse control 
(Wallwork et al., 2012). Some have also noted that anxious symptoms may form a 
meaningful separate dimension (Emsley, Rabinowitz, & Torreman, 2003), illustrating 
perhaps a non-categorical partition between affective and non-affective psychosis. 
The Kraepelinian model of mental illness stipulates a schism between affective 
disorders and psychotic disorder. Still, about one third of patients with schizophrenia 
spectrum disorders may suffer from depressive symptoms (Conley, Ascher-Svanum, 
Zhu, Faries, & Kinon, 2007), although reviewed findings have varied widely from 
7% to 75% . Symptoms of anxiety and depression are also common during the 
prodromal stage of psychosis (Falkenberg et al., 2015). Depressive symptoms in 
schizophrenia are associated with risk of suicidality, poorer functional outcomes, 
more frequent relapse and lower quality of life (Conley et al., 2007; Hor & Taylor, 
2010). 
Disorganized symptoms may in extreme cases result in bizarre behaviour, but are 
more commonly expressed as problems organising conversation and actions, partly 
due to conceptual disorganization (Wallwork et al., 2012). Formal thought disorder 
entails impairments in the capacity to sustain coherent discourse, expressed through 
disturbed organization of written or spoken language. Formal thought disorder may 
be seen as a positive symptom, but is classed as disorganized because it affects the 
organization of thoughts rather than their content, which sets it apart from e.g. 
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delusions. Certain expressions like poverty of speech and interrupted thoughts may 
also be seen as related to negative symptoms. During acute psychosis, some display 
so-called word salad, a severe breakdown of syntactic or semantic language content 
and use of neologisms. Milder forms of disorganization may be expressed in a 
loosening of associations or difficulties in maintaining targeted conversation, either 
veering off or return constantly to the same point. One study linked disorganized 
symptoms to reduced dorsolateral prefrontal grey matter, which in turn was 
associated with childhood neglect (Cancel et al., 2015). The association was stronger 
in the psychosis group than in healthy controls, illustrating an aspect of the stress-
vulnerability hypothesis of psychosis whereby childhood stressors have a greater 
impact in those with a genetic predisposition for psychosis. Disorganization is closely 
tied to neurocognitive processes, possibly more so than any other symptom 
dimension (Minor & Lysaker, 2014). 
Cognitive symptoms, on which this thesis is written, are expressed as impaired 
cognitive functioning in many people with schizophrenia and other psychotic 
disorders (Kahn & Keefe, 2013). Problems with verbal abilities, processing speed and 
working memory are particularly common. In the International Statistical 
Classification of Diseases, 11th edition (ICD-11), cognitive symptoms are explicitly 
coded for in primary psychotic disorders, including a severity qualifier (World Health 
Organization, 2018a). This symptom dimension is described in more detail in section 
1.9. 
1.2 Schizophrenia spectrum disorders 
Schizophrenia has been described as a “global” condition, which is true both 
geographically and physiologically. It affects more than 21 million people worldwide, 
with an estimated lifetime prevalence of about 1% (World Health Organization, 
2018b).  Schizophrenia likely represents the tail end of a spectrum of disorders. The 
DSM/5 reflects this, having renamed the DSM-IV heading “Schizophrenia and other 
psychotic disorders” to “Schizophrenia Spectrum and Other Psychotic Disorders” 
(American Psychiatric Association, 2000, 2013). Schizophrenia spectrum disorders 
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may entail positive, negative, disorganized and cognitive symptoms alongside 
impaired psychomotor functions (World Health Organization, 2018a). Affective 
symptoms including poor emotional rapport and disharmony are common but not 
considered a primary aspect of schizophrenia spectrum disorders. 
The ICD and DSM systems both classify schizophrenia spectrum disorders as distinct 
from psychosis related to substance use and affective disorders (American Psychiatric 
Association, 2000, 2013; World Health Organization, 2009, 2018a). The 
schizophrenia spectrum (F20 – F29) includes schizophrenia itself as well as related 
disorders like acute and transient schizophrenia-like psychosis (F23), delusional 
disorder (F22), schizotypal disorder (F21) and schizoaffective disorders (F25). 
Diagnostic criteria of SSD are based on the primary symptomatic criteria for 
schizophrenia, with duration and severity varying. Historically, psychosis research, 
including that on cognition, has often focused rather narrowly on schizophrenia or 
schizophrenia spectrum disorders alone (Hagger et al., 1993; Mesholam-Gately, 
Giuliano, Goff, Faraone, & Seidman, 2009; Rajji, Miranda, & Mulsant, 2014; Riedel, 
Schennach-Wolff, et al., 2010). This in part because of the severity and great personal 
and societal impact of schizophrenia, but also because the stringent diagnostic criteria 
make for more homogenous and comparable groups of subjects. In line with this, 
Paper II I compared cognitive performance in a group of youth at ultra high risk for 
psychotic illness (UHR) to that of a group with schizophrenia. 
Schizophrenia (F20) is set apart in the main diagnostic manuals by its longer 
duration, greater symptom load and more severe functional loss. Positive symptoms 
often appear in the late teens and early 20s. For some, full or partial recovery is 
possible, while others have a more chronic course. Schizophrenia is associated with 
anomalies in large neurotransmitter systems, brain physiology and connectivity, 
which again are linked to positive, negative and cognitive symptoms (Schaefer, 
Giangrande, Weinberger, & Dickinson, 2013). Affected individuals also have a 
higher odds ratio for a wide range of physiological conditions including metabolic 
syndrome, diabetes, heart disease and Alzheimer’s disease (Hjorthøj, Stürup, 
McGrath, & Nordentoft, 2017). A link to chronic inflammation has also been 
suggested, as inflammation is both a state and trait phenomenon in schizophrenia 
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(Kirkpatrick & Miller, 2013). The link between somatic issues and schizophrenia 
may be due to a combination of lifestyle issues, shared genetic risk factors (Dieset, 
Andreassen, & Haukvik, 2016), side effects of psychotropic drug use (Huhn et al., 
2019) as well as challenges in accessing adequate somatic health care (Swildens, 
Termorshuizen, de Ridder, Smeets, & Engelhard, 2016). The suicide rate is also high 
with 5% a conservative measure, and some reviews finding a rate of up to 13% 
(Popovic et al., 2014), up to tenfold that of the general population (Chesney, 
Goodwin, & Fazel, 2014). Added together these factors all contribute to shortened 
life expectancy: A Nordic study estimated life expectancy of patients with 
schizophrenia to be from 15.6 to 16.9 years shorter than that of the general population 
(Laursen, Nordentoft, & Mortensen, 2014).  
1.3 Other psychosis: Affective and substance incuded 
psychotic disorders 
Psychotic disorders as a whole have a worldwide prevalence of about 3% (Bonnett, 
Varese, Smith, Flores, & Yung, 2019). Schizophrenia spectrum disorders make up 
only part of these. Our developing understanding of psychosis might however benefit 
from a broader conceptualisation also encompassing psychotic symptoms due to 
psychoactive substance use (F12-19) and affective disorders with psychotic 
symptoms (F31-33). This thesis therefore chose to include participants with substance 
induced psychosis in the sample for Paper I. Inclusion in the schizophrenia spectrum 
disorders group required a primary ICD-10 diagnosis of F20, F23.0 or F23.2, with 
SIP and affective disorders with psychotic symptoms (F31-33), grouped as other 
psychotic disorders. 
The Kraepelinian affective/non-affective distinction is reflected in the description of 
ICD-10 diagnoses F20-F29 as the “non-affective psychoses”. This created a need for 
a diagnosis to describe cases straddling the affective and psychotic symptom 
dimensions, and this task fell to schizoaffective disorder (F25). Where the ICD-10 
which asks for symptoms insufficient to “justify a diagnosis of either schizophrenia 
or a depressive episode”, the DSM/5 outlines that schizoaffective disorder be used 
 21 
where A-criteria for schizophrenia are met. The DSM-IV-TR conceded that 
schizoaffective disorder “unfortunately does not do its job very well” and struggles 
with low reliability and poor temporal stability and clinical stability (Malaspina et al., 
2013). High affective symptom scores are also common in non-affective diagnoses 
(van Os et al., 2000), and the two disorder spectrums share genetic factors 
(Kavanagh, Tansey, O'Donovan, & Owen, 2015). This thesis therefore included 
participants with affective disorder and psychotic symptoms (F31-33) in the sample 
of papers I, aiming of giving a broader and more clinically representative view of 
cognition during acute psychosis.  Similarly, in paper III, inclusion of affective 
psychosis gives a more representative view of the group actually receiving 
antipsychotic drugs in clinical settings. 
Substance induced psychosis diagnoses (F11-19 with signifier x.x5) are used when 
psychotic symptoms are thought to be triggered by psychoactive substance use, 
although not as a direct effect of intoxication. Importantly, to differentiate from 
primary psychosis disorders like F20-29, symptoms should subside within a certain 
timeframe. This time is set at “about a month” for the DSM/5 and for the ICD-10, 
partial remission within a month and full remission within six months. During the 
acute phase of psychosis, it is difficult to clinically differentiate between the 
symptom profiles of substance induced psychosis and psychosis with comorbid 
substance use, and the validity of this distinction has been questioned. About 25% of 
substance induced psychosis diagnoses are re-assigned as primary psychosis after one 
year (Caton et al., 2007) rising to 50% after two years (Alderson et al., 2017). Initial 
diagnoses of these disorders thus appear to drift towards schizophrenia spectrum 
diagnoses over time (Niemi-Pynttari et al., 2013). Due to this diagnostic instability, 
patients with substance induced psychosis were included in paper I where inclusion 
happened during the acute phase of illness.  
Diagnostic instability in general has long presented a major challenge to clinical 
schizophrenia research, with each update to new diagnostic manuals introducing new 
imperfections in categorical overlap (Rund, 1998). A core aim of DSM editions, 
including the DSM-5, has thus been to create reliable diagnostic criteria. However, 
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controversy remains over how to categorise psychotic illness, and whether these 
categories are sound. The diagnostic criteria of ICD-10, ICD11 and DSM-5 also 
allow for a great deal of heterogeneity in the diagnosing of psychotic disorders, 
meaning that even persons diagnosed with the same illness may differ considerably 
from one another. The Kraepelinian divide and the concept of schizophrenia itself 
have also been subject to criticism (Bentall, 2004; Boyle, 2014). An in-depth 
discussion of this important debate falls outside the scope of this thesis. However, a 
shift away from a singular focus on schizophrenia may more closely reflect a clinical 
reality where schizophrenia forms only a small and shifting, although significant, part 
of the puzzle of psychosis. Cognitive symptoms also exist across the psychotic 
spectrum, and not just in schizophrenia (Bora, Yucel, & Pantelis, 2009; Simonsen et 
al., 2009). This thesis has therefore aimed to investigate both schizophrenia spectrum 
psychosis as well as high risk youth and the wider range of psychotic disorders 
presented in acute clinical settings.  
1.4 Disability and the societal impact of schizophrenia 
Despite the prevalence of only 1%, schizophrenia is one of the costliest mental health 
disorders. Worldwide, schizophrenia is among the 20 leading causes of disability, 
with 0.5% of disability-adjusted life years  attributed to it in 2017 (Institute for Health 
Metrics and Evaluation, 2019). Disability arises not only from psychotic symptoms 
including cognitive impairment, but also from somatic conditions associated with it 
(Hjorthøj et al., 2017). In Norway alone, the cost p.a. of schizophrenia has been 
estimated to USD 890m, including USD19.5m spent on antipsychotic medication 
(Evensen et al., 2015). In addition, expenses include medical and psychosocial 
treatment, hospital admissions and social support. Schizophrenia also contributed to 
about 12.7 million years lived with disability measured globally in 2017 (James et al., 
2018), illustrating the great impact of this disorder on each person’s life. Only about 
10% of this patient group in Norway is in ordinary paid employment (Evensen et al., 
2015), and up to 85% of worldwide costs related to schizophrenia may be attributed 
to such indirect sources (Chong et al., 2016).  
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Progress in attaining functional recovery in schizophrenia has not kept pace with the 
alleviation of positive symptoms by antipsychotic drugs, perhaps because neither 
negative nor cognitive symptoms have responded well to drug treatment (Foussias & 
Remington, 2008). Cognitive deficits are likely responsible for a considerable part of 
lingering functional impairment. Cognitive functioning is a better predictor of 
outcome than either positive and negative symptoms  (Green & Harvey, 2014; 
Lepage et al., 2014). In first-episode psychosis, working memory, attention, and 
speed of processing performance appears to predict over half of longitudinal variance 
in school or work participation (Nuechterlein et al., 2011). Working memory and 
attention may be especially important to work skills (Bowie et al., 2008). However, 
other factors including the number and duration of psychotic episodes, any residual 
positive and negative symptoms, as well as the gradual erosion of academic and 
social opportunities most likely also compound effects of cognitive problems on 
functioning. Better knowledge about these symptoms and how to facilitate improved 
functioning would reduce both societal and personal costs of psychotic illness.  
1.5 Modelling psychosis: A continuum and stages 
Psychotic disorders and schizophrenia appear to represent the severe end of an 
experiential continuum, and psychosis-like symptoms may occur in about 5% of the 
general population (van Os, Linscott, Myin-Germeys, Delespaul, & Krabbendam, 
2009) The majority of people experiencing these phenomena do not however come to 
the attention of mental health care services (Løberg, Gjestad, Posserud, Kompus, & 
Lundervold, 2019). However, experience of psychosis-like symptoms may be 
associated with increased risk of later psychotic disorder (van Os & Reininghaus, 
2016). Phenomena like the 6% of healthy people reporting non-distressing 
hallucinatory experiences (Linscott & van Os, 2013) are difficult to contain within 
traditional and categorical models of psychopathology as represented by the ICD and 
DSM diagnostic systems. This has motivated the development of an alternative model 
of psychosis as a range of experiences of varying severity and intensity. The 
continuum would range from sub-clinical phenomena to full-blown psychosis with 
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functional impairment and high levels of distress (Yung et al., 2012), perhaps based 
on an extended psychosis phenotype (Howes & Kapur, 2009). Psychosis may thus be 
described as a highly heterogenous phenomenon which may vary hugely not just in 
presentation but also in severity and course. 
Schizophrenia has shifted from historically being a “grim diagnosis with a poor 
prognosis” to currently being one which offers hopes of remission and recovery 
(Green & Harvey, 2014). This shift necessitated a more complex model of illness 
course, and motivated the development of the current staged model of psychotic 
illness. Full-blown psychosis is regularly preceded by a prodrome in which attenuated 
positive symptoms or self-disturbance are accompanied by cognitive deficits and 
often functional decline (Møller & Husby, 2000; Yung & McGorry, 1996). For some 
individuals, this prodromal state develops into acute psychosis, characterised by 
florid positive symptoms. First episode psychosis has been a particular topic of 
research interest, especially for efforts to ameliorate illness course by early 
intervention (González-Blanch et al., 2010; McGorry, Killackey, & Yung, 2008; ten 
Velden Hegelstad et al., 2012). Although the vast majority of first episode psychosis 
patients achieve symptomatic remission over a year, over 50% are likely to relapse 
and have another acute episode within three years, rising to 80% over five year 
(Alvarez-Jimenez et al., 2012).Whereas chronic psychotic disorder and schizophrenia 
were previously thought to be superseded by a progressive deterioration of negative 
symptomatology, functioning and cognition (Bilder et al., 1992; McGlashan & 
Fenton, 1993) a more optimistic view now prevails of fluctuating but not 
deteriorating symptomatology in those who experience multiple psychotic episodes 
of acute psychosis (Crumlish et al., 2009).  
1.5.1 The psychosis prodrome and ultra high risk groups 
In medical terms, a prodrome describes the phenomenon of signs and symptoms 
preceding acute or fully developed illness (Yung & McGorry, 1996). The word itself 
originated from the Latin prodromus, which describes a written work preliminary to 
another larger work (OED, n.d.-b). For psychotic disorders more specifically, the 
prodrome encompasses the time between a notable change in behaviour from 
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baseline, to the development of full-blown psychotic symptoms (Beiser, Erickson, 
Fleming, & Iacono, 1993). The idea of a prodrome has been described as part of the 
phenomenon of schizophrenia since the time of Bleuler (Yung & McGorry, 1996).  
The late 1990s saw renewed interest in the prodromal phase of psychotic disorder. 
Research and clinical efforts aiming at providing early interventions for first episode 
psychosis patients noted that many first episode psychosis patients had experienced 
lengthy periods of subclinical disturbances before falling ill (Joa, Gisselgård, 
Brønnick, McGlashan, & Johannessen, 2015). In addition, it was discovered that 
early intervention services in first-episode psychosis might shorten the duration of 
untreated psychosis and thereby ameliorate the course psychotic disorders (Larsen et 
al., 2011). By extension, being able to intervene before the development of de facto 
symptoms might prove useful.  
Having identified a prodromal phase in psychosis, work began on to identify risk 
factors for prediction of so-called “conversion” to full-blown psychotic disorders. 
This led to the conceptualisation of a state of Ultra High Risk for psychosis (UHR) 
(Yung & McGorry, 1996), which may be screened for in much the same way as first-
episode psychosis. This state is currently conceptualised encompassing sub-clinical or 
attenuated positive symptoms, which may be less pronounced, more infrequent or of 
briefer duration than the diagnostic cut-offs, as well as a related decline in social, 
academic or professional functioning (T. J. Miller et al., 2003). Research has also 
focused on so-called basic symptoms of the prodromal phase, i.e. subjective deficits 
in stress reactivity, perception and cognition (Hambrecht, Lammertink, Klosterkötter, 
Matuschek, & Pukrop, 2002). Known risk factors include genetic risk combined with 
functional decline, attenuated psychosis symptoms like unusual thought content and 
suspiciousness, poor social functioning, anhedonia and substance abuse, with the 
addition of neurocognitive measures further improving predictions (Fusar-Poli, 
Borgwardt, Bechdolf, & et al., 2013).  
Despite work to map out risk factors, accurately identifying those at risk of imminent 
psychotic illness has proved challenging, with only about 25% of identified UHR 
individuals actually developing psychotic illness (Simon et al., 2011). It has been 
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suggested that this is due to UHR selection often focusing on attenuated positive 
symptoms rather than state deficits causing social withdrawal and anhedonia, which 
may be a less distinct but more permanent indicator of psychosis risk (Simon & 
Umbricht, 2010). Still, it should be noted that UHR individuals often struggles with 
mental health and functional issues outside that of psychotic disorder, and still require 
from follow-up even if they do not develop psychotic symptoms (Falkenberg et al., 
2015; Ruhrmann et al., 2008).   
1.5.2 First-episode psychosis 
First-episode psychosis usually refers to the first time a person experiences clinically 
significant positive symptom. Early  first episode psychosis research suggested that 
this phase was a critical period in which treatment and treatment response might 
determine long-term prognosis (Birchwood, Todd, & Jackson, 1998). More recent 
reviews and research support the efficiency of targeted first episode psychosis 
programs aiming to reduce DUI and the risk of relapse (Álvarez-Jiménez, Parker, 
Hetrick, McGorry, & Gleeson, 2009; Crumlish et al., 2009; ten Velden Hegelstad et 
al., 2012). Longer duration of untreated psychosis is associated with poorer clinical 
and functional outcomes (Penttilä, Jääskeläinen, Hirvonen, Isohanni, & Miettunen, 
2014). For the purposes of Paper III of this thesis we have compared first episode 
psychosis to non-first episode psychosis subjects in terms of cognitive response to 
medication. Another meaningful distinction may be made between groups with recent 
onset and more distant onset schizophrenia (Sponheim et al., 2010), which formed the 
basis of group comparisons in paper II. 
1.6 Aetiology and risk factors in schizophrenia  
The idea of a biological basis for schizophrenia or madness may have been with us 
since prehistoric times. The discovery of ancient human skulls with trepanations have 
been hypothesized to represent crude surgery to alleviate spirits plaguing the brain 
(Faria, 2013). However, centuries later, we still do not fully understand the 
mechanisms or aetiology of psychosis.  
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Twin studies have indicated schizophrenia to have a high heritability of nearly 80% 
(Hilker et al., 2018). No causative genes for schizophrenia have been isolated, 
suggesting both polygenic inheritance and genetic heterogeneity (Greenwood, Braff, 
Light, & et al., 2007). There is significant genetic overlap between schizophrenia and 
other mental health problems, e.g. bipolar disorder and autism spectrum disorders 
(Carroll & Owen, 2009). Schizophrenia is also more common in populations with 
general learning disabilities, and overrepresented in groups with childhood learning 
disabilities (Welch, Lawrie, Muir, & Johnstone, 2011). It should however be noted 
that learning disabilities in themselves are not indicative of ultra-high risk for 
psychosis.  
The broad range of symptoms has allowed investigators to focus on one part of the 
elephant while ignoring others, with schizophrenia famously being deemed in the 70s 
“the graveyard of neuropathologists” (Plum, 1972). However, pharmacological and 
technological progress have since motivated massive research efforts. Later in the 
70s, early computed tomography imaging studies found enlarged lateral ventricles in 
chronic schizophrenia (Johnstone, Frith, Crow, Husband, & Kreel, 1976; Weinberger, 
Torrey, Neophytides, & Wyatt, 1979). However, enlarged ventricles also exist in 
mood disorder (Elkis, Friedman, Wise, & Meltzer, 1995) and came to be seen as 
indicative of an underlying risk factor rather than a cause (Chua & McKenna, 1995). 
The advent of magnetic resonance imaging in the 80s led to abnormalities being 
identified in temporal structures including the amygdala, hippocampus, and the 
temporal neocortex as well as in prefrontal grey matter, the orbitofrontal cortex, and 
subcortical areas including the basal ganglia and cavum septi pellucidi (Shenton, 
Dickey, Frumin, & McCarley, 2001). Again, the specificity of magnetic resonance 
imaging findings to schizophrenia was unclear.  
More recently, diffusion tensor imaging and functional magnetic resonance imaging 
(fMRI) technology made possible detailed studies of white matter integrity as well as 
brain connectivity patterns in schizophrenia. Studies using fMRI have found 
impairments in both task related and resting state brain network connectivity in first-
episode illness (Mwansisya et al., 2017). UHR fMRI studies have similarly found 
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differences in resting state connectivity (Shim et al., 2010) and white matter integrity 
(Karlsgodt, Niendam, Bearden, & Cannon, 2009; Rigucci et al., 2016), with authors 
suggesting links to functional outcome and the appearance of hallucinations. Studies 
combining fMRI with diffusion tensor imaging indicate dysconnectivity especially in 
frontal and temporal regions, with findings more consistent for chronically ill groups 
(Fitzsimmons, Kubicki, & Shenton, 2013). Although a specific underlying 
neurobiological white matter deficit for psychosis has yet to be identified (Samartzis, 
Dima, Fusar-Poli, & Kyriakopoulos, 2014), symptoms have been suggested to arise 
from brain dysconnectivity and dysregulation (S. Li et al., 2019). 
Positive symptoms have long been linked to neurotransmitter abnormalities. The 
chance discovery of dopamine antagonistic antipsychotic drugs in the 1950s 
motivated intense theoretical and research efforts aimed at exploring the role of 
dopamine in psychosis (Lally & MacCabe, 2015; Snyder, 1976). It also became clear 
that certain dopaminergic stimulants, e.g. amphetamine, could induce psychosis-like 
symptoms. The current third-generation dopamine hypothesis still places aberrant 
salience driven by dopaminergic dysfunction at the core of psychotic symptoms 
(Howes & Kapur, 2009). A meta-analysis of positron emission tomographystudies 
found strong evidence for elevated presynaptic dopamine synthesis in schizophrenia, 
including in drug-naïve subjects (Howes et al., 2012) Synaptic dopamine levels and 
dopamine release was also found to be elevated. Although the reason for this 
dysfunction remains unknown, decreased prefrontal dopaminergic neurotransmission 
(Fusar-Poli et al., 2010; Meyer-Lindenberg et al., 2002) and glutamatergic 
dysfunction (West, Floresco, Charara, Rosenkranz, & Grace, 2003) have both been 
suggested as potential causal mechanisms (Stone et al., 2010). 
Neuroinflammation and immunology in psychosis are currently subject to intense 
research efforts (Dickerson et al., 2015; Orlovska-Waast et al., 2019). Certain 
maternal infections during the prenatal phase increase risk of later psychosis (Brown 
& Derkits, 2010). Inflammation affecting foetal brain development was suggested as 
a common mediator of this effect, motivating further explorations of immunological 
abnormalities as an endophenotype of schizophrenia. (B. J. Miller, Culpepper, 
 29 
Rapaport, & Buckley, 2013). Microglia activation and release of cytokines may for 
instance be causing dopaminergic and glutamatergic dysregulation by causing 
damage to glial cells, though post mortem findings of such damage in schizophrenia 
are equivocal (Trépanier, Hopperton, Mizrahi, Mechawar, & Bazinet, 2016). 
Schizophrenia is also linked to autoimmune disease and immune related genetic 
markers (Khandaker et al., 2015). Inflammation thus provides a potential unifying 
mechanism for previous findings of both genetic, structural and neurotransmitter 
abnormalities. It may also potentially provide a bridging between physiological 
findings and known environmental risk factors for psychosis, e.g. childhood adversity 
(Mondelli et al., 2011). However, these mechanisms remain poorly understood. 
The two-hit model of schizophrenia, a version of which was suggested already in the 
60s by Mednick and McNeil (1968) suggests that genetic risk factors are 
compounded by subsequent stressors to produce psychotic symptoms (van Os, Kenis, 
& Rutten, 2010). Twin studies support the existence of a considerable environmental 
component, with a risk of 33% in monozygotic twins (Hilker et al., 2018). Although 
evidence is somewhat equivocal, childhood adversity is likely a major risk factor 
especially for positive symptoms  and also for being at UHR for psychosis (Kraan, 
Velthorst, Smit, de Haan, & van der Gaag, 2015). Urbanicity and ethnic minority 
status also contribute to increased risk, with authors suggesting that these factors 
impact the brain during sensitive periods of development (van Os et al., 2010). Use of 
recreational drugs, especially cannabis (Volkow et al., 2016) and amphetamine 
(Niemi-Pynttäri et al., 2013) also increases risk although the exact mechanisms 
remain unclear. Cannabis abuse or addiction may also increase the risk of conversion 
to psychosis in UHR groups (Kraan et al., 2016). Effects of drug use are likely 
compounded by genetic vulnerabilities (Misiak et al., 2017) to produce psychosis. 
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1.7 Treatment of psychotic disorders 
1.7.1 Antipsychotic drug treatment 
Medical treatment in psychotic disorders aims to reduce symptoms in the acute phase, 
while maintaining this improvement through the recovery phase. Preventing or 
reversing functional loss is also central to attaining the best quality of life possible. 
Antipsychotic drugs were discovered in the 50s and have since been a mainstay of 
psychosis treatment according to clinical guidelines (NICE, 2014; Norwegian 
Directorate of Health, 2013). First-generation antipsychotics had sedative effects as 
well as dampening positive symptoms like hallucinations and delusions, and were a 
big improvement to existing treatments, which were mainly based on containment or 
heavy sedation of the patient. The advent in the late 80s of clozapine (Kane, 
Honigfeld, Singer, & Meltzer, 1988) and subsequently a wider range of second-
generation or atypical antipsychotic drugs brought more tolerable drugs promising 
fewer extrapyramidal side effects, which was a problem with First-generation 
antipsychotic drugs (Leucht et al., 2009). However, extrapyramidal side effects 
remain an issue (Divac, Prostran, Jakovcevski, & Cerovac, 2014; Rummel-Kluge et 
al., 2012). Although current Norwegian national guidelines stipulate that patients be 
offered non-pharmacological interventions if they wish (Norwegian Directorate of 
Health, 2013), antipsychotics remain the cornerstone of first-line treatment of acute 
psychosis, as well as for the maintenance phase (APA, 2006; Kreyenbuhl, Buchanan, 
Dickerson, & Dixon, 2010; NICE, 2014; Sohler et al., 2016). Due to the symptomatic 
complexity and severity in this patient group, many will also receive other 
psychotropic drugs including mood stabilizers, anxiolytics, sedatives, or 
antidepressants.  
Antipsychotic treatment is often continued for several years after an acute episode in 
order to minimise risk of relapse, and guidelines recommend continuing medication 
for 1-2 years after a first episode, or up to 5 years after a relapse (NICE, 2014; 
Norwegian Directorate of Health, 2013). Still, discontinuation of drugs or poor 
compliance is common in psychotic disorders: as symptoms improve, disadvantages 
like weight gain and metabolic syndrome may seem to outweigh benefits (Sendt, 
 31 
Tracy, & Bhattacharyya, 2015), even though discontinuation increases the risk of 
relapse. Although some studies also show that dose reduction or cessation of 
antipsychotics is associated with higher rates of functional recovery (Wunderink, 
Nieboer, Wiersma, Sytema, & Nienhuis, 2013) it is difficult in general to untangle 
whether this is due to the drug, or due to the fact that dose reduction in itself is a 
symptom of a budding recovery process.  
Despite existing guidelines, the ideal length of antipsychotic treatment for each 
individual cannot easily be determined based on current knowledge (Bjornestad et al., 
2017). Atypical antipsychotic drugs are quite effective for the treatment of acute 
positive symptoms, with about 50-80% of recipients experiencing improvement in 
positive symptom load, as compared to 5-40% of groups receiving placebo treatment 
(Buchanan et al., 2010; Dixon, Lehman, & Levine, 1995; Leucht et al., 2012). 
However, for patients requiring the trial of a second antipsychotic due to non-
response, the response rate may fall to below 20% (Agid et al., 2011). Although on a 
group level, several factors including female gender, drug naivety and shorter DUP 
appear to predict a better response (Zhu et al., 2017), it is still uncertain on an 
individual level why certain patients respond well to antipsychotics while others do 
not. Despite large metastudies indicating that some AA are more effective than others 
(Leucht et al., 2013), we also do not know how to predict individual responses to 
individual drugs. The Bergen Psychosis Project 2 aimed amongst other things to 
investigate factors which might affect individual drug responses.  
1.7.2 Psychosocial treatment 
Non-pharmacological and psychosocial interventions are an important part of 
psychosis treatment, and physical exercise, social contact, art and music therapy are 
recommended by guidelines (Norwegian Directorate of Health, 2013). Talking 
therapies are important tools in reducing symptom load, but unlike medication they 
may also build life skills and support the person and their social surroundings to 
understand and cope with the disorder.  
The main recommended psychotherapeutic approach for psychotic disorders is 
cognitive behavioural therapy (NICE, 2014; Norwegian Directorate of Health, 2013) 
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Although these recommendations have been criticized (Jauhar et al., 2014), 
cognitive-behavioural therapy (CBT) has shown consistently positive effects on 
positive symptoms of schizophrenia spectrum disorders (Zimmermann, Favrod, 
Trieu, & Pomini, 2005) and may also reduce the risk of developing psychosis in high-
risk groups (Hutton & Taylor, 2014).  CBT primarily aims to reduce symptom load 
and distress, but also to improve general functioning. Other approaches include 
metacognitive narrative therapy, which aims to ameliorate impairments in the ability 
to organize information about self, others and the world into complex ideas, allowing 
the person to build intrinsic and personal motivation for recovery (Lysaker & 
Dimaggio, 2014). Mindfulness based interventions are a third-wave cognitive therapy 
which encourage presence in the moment, acceptance, detachment, and compassion 
in placement of reactivity, struggling and judgement, aiming to alleviate distress 
arising from stressful attempts at controlling psychotic symptoms (Khoury, Lecomte, 
Gaudiano, & Paquin, 2013). Psychoeducative family based interventions have been 
successful in reducing relapse rates through the reduction of expressed emotion 
(McFarlane, 2016), in addition to building coping skills in both the patient and their 
next of kin (Onwumere, Bebbington, & Kuipers, 2011). Multiple-family groups have 
been found superior to single family groups, indicating a positive effect of social 
interaction between families (McFarlane, 2016). Psychosocial treatments may also 
improve drug compliance by reducing paranoid though patterns and building 
therapeutic relations and illness insight (Higashi et al., 2013). 
Despite decades of intense efforts, the aetiology and pathogenesis of psychosis 
remains unclear, which impedes the development of treatment for schizophrenia. 
However, new non-medical treatments are continually being developed, partly in 
response to scientific and technological advancement. Non-invasive transcranial 
magnetic stimulation may have a moderate effect on negative symptoms (Aleman, 
Enriquez-Geppert, Knegtering, & Dlabac-de Lange, 2018) and may potentially also 
ameliorate cognitive impairment, although previously reported effects on auditory 
hallucinations have been limited (Slotema, Blom, van Lutterveld, Hoek, & Sommer, 
2014). Avatar based virtual reality treatment and other digitally delivered 
interventions are also an interesting and promising addition to available treatments 
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(Rus-Calafell & Schneider, 2020). Cognitive remediation interventions have also 
shown promising results and is described in more detail in section 1.8.7.  
1.8 Current views of psychosis -a more optimistic path 
Despite the number of important jigsaw pieces still to be placed in the puzzle of 
psychosis, the former view of psychotic disorders as synonymous with a life spent 
medicated or with debilitating residual symptoms has fortunately shifted in a more 
optimistic direction. Also, the continued presence of early intervention and 
information services may help destigmatize psychotic disorders. The singular focus 
on remission of symptoms alone has shifted to a broader view of recovery and 
coping. This has left more space for subjective experiences of psychosis and 
treatment to be heard (Read & Sacia, 2020), while paving the way for interventions 
aiming to strengthen coping skills and social and professional participation despite 
any residual symptoms. For instance, programs of individual placement and support 
have shown promising results (Killackey et al., 2017). Studies have found the 
majority of first episode psychosis participants to remain in paid employment at the 
end of follow-up, although authors warn that follow-up ideally should be open-ended 
in order to maintain positive outcomes over time (Hegelstad, Joa, Heitmann, 
Johannessen, & Langeveld, 2019). This shift is in line with first episode psychosis 
groups and user perspectives reporting that functional recovery is their most valued 
treatment outcome (Iyer, Mangala, Anitha, Thara, & Malla, 2011), which underscores 
the importance of learning more about the key factor of cognitive impairment.  
1.9 Cognitive impairment in psychosis 
1.9.1 What is cognition and cognitive impairment 
The English expression cognition comes from the Latin word cognoscere, meaning to 
get to know in-depth or to investigate. Cognition entails “the action or faculty of 
knowing taken in its widest sense, including sensation, perception, conception, etc., 
as distinguished from feeling and volition” (OED, n.d.-a). In psychology, cognition is 
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widely used to mean the processing of information as well as the application of 
information and knowledge in tasks requiring conscious thought activity. Cognition is 
thus a multifaceted concept, tangential to or including a range of conscious mental 
functioning, deliberation and capability, for instance intelligence, attention, learning, 
memory, perception, decision making and planning, as well as aspects of social 
interaction dependent on understanding the intentions and actions of others. 
Cognition arises from neurological activity, both at the neuronal and system level 
(Lezak, Howieson, Loring, & Fischer, 2004). Any significant disturbance of brain 
activity, be it on a structural or neurotransmitter level, is thus likely to affect 
cognitive functioning. Cognitive neuropsychology is concerned with understanding 
how brain functioning relates to psychological processes or deficits. The most widely 
used form of assessment is neurocognitive testing.  
What constitutes cognitive impairment 
Neurocognitive impairment may be conceptualised and measured either as 
underperformance in relation to a given population norm, or as an individual loss of 
functioning over time, e.g. as seen in someone with traumatic brain injury following a 
car accident. Variability in both cut-offs and measuring instruments means that the 
proportion of individuals in a group deemed to show signs of cognitive impairment 
may vary from study to study. For the purposes of this thesis, cognitive impairment 
has been set to scoring 1.5 SD below the healthy population mean in accordance with 
Heaton, Grant, and Matthews (1991).  
1.9.2 Cognition in schizophrenia  
Regardless of whether one believes that Shakespeare used cognitive disorganization 
in his portrayal of a schizophrenia-like malingerer in King Lear (Bark, 1985), 
cognitive impairment has been central to the idea of schizophrenia since its invention 
as an explicit entity. Kraepelin’s text on dementia praecox (1919) described in a form 
of precocious cognitive disintegration (Falkai et al., 2015). Bleuler suggested the 
existence of “fundamental” symptoms in schizophrenia, including disturbances in 
association and attention (Green & Harvey, 2014). He tested word association in a 
way resembling contemporary neurocognitive assessment, taking note of response 
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times as well as the actual associations (Moskowitz & Heim, 2011). In their 
retrospective on cognition and schizophrenia, Green and Harvey (2014) describe the 
post-World War II period as focusing on assessing and measuring cognitive 
impairments, drawing on models of healthy cognition as well as clinical 
neuropsychology.  
The last decades of the 1900s saw a flourishing of studies targeting cognition in 
schizophrenia in a much more integrated way. This came partially as a response to 
technological developments in brain imaging and findings of ventricular enlargement 
hinting at underlying physiological factors contributing to psychosis (Palmer, Dawes, 
& Heaton, 2009; Tandon, Nasrallah, & Keshavan, 2009). Also, it arose from a 
recognition that level of cognitive impairment predicts functional outcomes (Green, 
1996; Green, Kern, & Heaton, 2004; Heaton & Pendleton, 1981). An early 
metanalysis of cognitive deficits in schizophrenia was published in 1998 (Heinrichs 
& Zakzanis) and found schizophrenia as entailing general cognitive impairment as 
well as deficits across tested subdomains. Cognitive impairment is currently 
considered a core aspect of schizophrenia (Kahn & Keefe, 2013), and is also seen to a 
lesser extent in other disorders with psychosis, e.g. bipolar disorder (Bortolato, 
Miskowiak, Köhler, Vieta, & Carvalho, 2015).  
Despite individual heterogeneity, schizophrenia groups appear to perform at about 1 
SD below the expected population mean (Tandon et al., 2009), with an estimated 
premorbid IQ of about 0.5 SD below the mean (Woodberry, Giuliano, & Seidman, 
2008). However, although some with schizophrenia perform at the population norm 
(Reichenberg et al., 2008), some argue such subjects still perform worse than would 
be expected from their reading scores and parental education levels (Kremen, 
Seidman, Faraone, Toomey, & Tsuang, 2000), with one study finding that about 95% 
of a group with schizophrenia showed signs of cognitive underperformance when 
measured in this way (Keefe, Eesley, & Poe, 2005). Surfing on the rise of vast 
genetic cohort studies, cognition studies have also become more international, with 
schizophrenia being linked to general cognitive ability (Lencz et al., 2014), although 
cognitive impairment in itself is not specific to psychotic disorders (Millan et al., 
2012). However, the firm consensus that cognitive impairment exists ahead of and in 
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schizophrenia is matched by a corresponding disagreement on the nature and course 
of this impairment.  
1.9.3 Cognitive impairment in UHR 
Cognitive underperformance is one of the earliest identifiable signs of psychosis risk, 
as indicated by large longitudinal cohort studies such as the Dunedin study, which 
found cognitive deficits at the age of 7 and stable through the age of 13 in individuals 
later diagnosed with schizophrenia (Reichenberg et al., 2010). These early cognitive 
deficits have been argued to be behavioural expressions of developmental 
abnormalities increasing the risk of developing psychosis (Bora, 2015). Cognitive 
performance in UHR groups falls below that of healthy controls but is better than in 
groups with both first episode psychosis (Hou et al., 2016) and schizophrenia 
(Giuliano et al., 2012). Falling behind academically or socially due to cognitive 
impairment is a considerable stressor for this group. Poorer baseline scores (Giuliano 
et al., 2012) as well as poorer attention and working memory abilities as well as 
problems with language skills and declarative memory have been found to indicate 
higher risk of conversion to full psychosis (Koutsouleris et al., 2011; Seidman et al., 
2016). Knowledge of cognitive functioning in groups at risk of psychosis is thus 
important both as an indicator of prognosis and as a tool for implementing tailored 
support for UHR youth (Hartmann et al., 2019).  
1.9.4 Assessment of cognitive performance in psychosis 
Studies have used a vast array of tests to assess cognition in psychosis, spanning both 
established test batteries (Hagger et al., 1993; Johnstone et al., 1976) and purposely 
designed composite batteries (Davidson et al., 2009; Keefe et al., 2003). Like the 
main diagnostic manuals, commonly used neuropsychological measures have also 
undergone regular major revisions, e.g. WAIS III to IV (Wechsler, 1997a, 2008). In 
addition, views evolve over time of what tests are seen as optimal for investigating 
cognitive changes in psychosis. The great variety in tests used has complicated 
comparison of results across tests. In response to this, Nuechterlein and Green (2006) 
presented the MATRICS Consensus Cognitive Battery into which a working group of 
field experts selected sub-tests based on reliability, validity and feasibility for clinical 
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trials, including suitability for repeated measurement, potential sensitivity to 
pharmacological effects, relationship to functional measures as well as tolerability. 
With this they aimed to unify neuropsychological research by making single study 
test results more comparable. 
1.9.5 Impairment in specific cognitive domains  
The majority of studies looking at impairment in specific cognitive domains have 
focused on groups with established schizophrenia. Detangling specific impairments 
from each other is a challenge for all neurocognitive research. For instance, psychosis 
groups perform especially poorly for processing speed, particularly digit symbol 
coding tasks, which most likely contributes to the general deficit seen (Dickinson, 
Ramsey, & Gold, 2007). Digit-symbol coding tasks in turn place demands on several 
processes including motor speed, attention, working memory motor speed and to 
some extent executive functions for strategic planning, all of which also been found 
to be impaired in this patient (Heinrichs & Zakzanis, 1998; Tandon et al., 2009). 
Working memory is in itself a complex process relying on various processes like 
attention, encoding, representation and maintenance (Baddeley, 2002). Impairment in 
schizophrenia is especially evident in tests of processing speed, working memory, 
executive functioning and language abilities (Schaefer et al., 2013), although deficits 
have been found across a wide range of domains (Mesholam-Gately et al., 2009).  
1.9.6 What affects cognitive functioning in psychosis 
Genetic factors and IQ 
The heritability of adult IQ is at least 60%, perhaps as much as 80% (Plomin & 
Deary, 2015). Low adult IQ is an established risk factor for schizophrenia (Barnett, 
Salmond, Jones, & Sahakian, 2006; Khandaker, Barnett, White, & Jones, 2011). 
There is a genetic overlap between schizophrenia and general IQ (Lencz et al., 2014) 
and cognitive impairment has also been found in healthy first-degree relatives of 
people with schizophrenia (Snitz, MacDonald III, & Carter, 2006). More specifically, 
studies of endophenotypes indicate heritability estimates of up to 55% for 
performance in groups with schizophrenia on various cognitive tests including word 
recall, letter number sequencing task and spatial skills (Greenwood et al., 2007). 
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Better cognitive reserve may be a protective factor (Khandaker et al., 2011). Given 
the genetic overlap found between psychotic disorders and other mental health 
conditions (Carroll & Owen, 2009), the phenotype for cognitive impairment in 
psychosis is likely to be at least in part shared across conditions. However, premorbid 
deficits may be more specific to schizophrenia (Mollon & Reichenberg, 2018). 
Brain physiology 
Global cognitive impairment has been associated with reduced volume of the 
dorsolateral prefrontal cortex, inferior frontal gyrus, hippocampus, and white matter 
in both schizophrenia groups and healthy individuals (Jirsaraie, Sheffield, & Barch, 
2018). This study also found reduced hippocampal volume in the schizophrenia 
group, suggesting that cognition relying on this structure may be particularly affected. 
A review also concluded that abnormal connectivity between resting state and task 
networks appear to be linked to impaired attention, working memory and executive 
functioning, with abnormal pathways between the prefrontal cortex, thalamus and 
striatum additionally related to deficits in processing speed (Sheffield & Barch, 
2016). However, the neural correlates of cognitive impairment in psychosis remain 
poorly understood. 
Positive and negative symptom dimensions 
A major systematic review concluded in 2009 that neither positive nor depressive 
symptom dimensions were associated with neurocognitive measures (de Gracia 
Dominguez, Viechtbauer, Simons, van Os, & Krabbendam, 2009). However, negative 
and disorganized symptoms were moderately correlated with cognitive impairment. 
This pattern held true across cognitive domains, independently of age, gender, and 
duration of illness. Negative symptoms were associated in particular with poor verbal 
fluency while disorganized symptoms were related to reasoning and problem solving, 
attention/vigilance. The review authors suggested that differential brain mechanisms 
drive positive and affective symptoms vs. disorganized and negative symptoms, and 
that neurocognitive symptoms are somehow related to the latter. 
Both negative and cognitive symptoms commonly occur ahead of development of 
positive symptoms, and are similarly associated with prognosis (van Os et al., 2010). 
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They may arise from common structural and functional brain abnormalities. 
Hypofrontality in schizophrenia is linked to impaired cognitive task performance 
(Ortiz-Gil et al., 2011; Samartzis et al., 2014). Negative symptoms have also been 
associated with reduced dorsolateral prefrontal grey matter (Bergé et al., 2011) and 
prefrontal white matter (Carletti et al., 2012). Both cognitive and negative symptoms 
also respond to antipsychotic treatment to a lesser extent than do positive symptoms 
(Foussias & Remington, 2008). Cognitive impairment might also take longer to 
respond to medication (Désaméricq et al., 2014). Cognitive impairment and negative 
symptoms thus appear to be related although separate constructs. 
Psychosocial and environmental factors 
Cognitive reserve and the ability to compensate for any impairment are affected by 
socioeconomic status and access to education, lifestyle, nutrition and physical 
activity, as these in turn influence neuroplasticity (Vance, Roberson, McGuinness, & 
Fazeli, 2010). Multiple types of childhood trauma may affect cognitive change in 
psychosis (Mørkved, 2020). A complex relationship exists between cognition and 
recreational drug use. Cannabis users with psychotic disorders may in fact be 
outperforming non-drug using psychosis groups, with review authors suggesting that 
this demonstrates that the former group enters psychosis via an alternative cannabis 
triggered pathway (Løberg & Hugdahl, 2009). 
1.9.7 Treatment of cognitive impairment 
Antipsychotic drug treatment  
It has been argued that studies of first-generation antipsychotic drug effects on 
cognition served mostly to demonstrate the treatment resistant nature of these 
symptoms (Keefe, Bollini, & Silva, 1999). When so-called second generation or 
atypical antipsychotics were launched on the market in the 80s, they were purported 
to positively affect cognitive functioning (Gallhofer, Bauer, Lis, Krieger, & Gruppe, 
1996; Meltzer & McGurk, 1999). Clozapine was found to both improve cognitive 
performance as well as reducing negative symptoms (Kane et al., 1988; Sharma & 
Mockler, 1998). Early studies of atypical antipsychotics even searched for positive 
effects of specific drugs within specific cognitive domains, e.g. olanzapine for verbal 
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fluency (Meltzer & McGurk, 1999) or effects of clozapine on attention (Sharma & 
Mockler, 1998). The serotonin receptor antagonism and stimulation associated with 
some atypical antipsychotics s were also thought to potentially improve cognition 
(Meltzer, 1999). Recent reviews however note that early findings on atypical 
antipsychotics effects might have been related to participants changing from high 
doses of cognition impairing first-generation antipsychotics, and that although 
atypical antipsychotics s outperform first-generation antipsychotics for cognitive 
symptoms, effects sizes have been small (Désaméricq et al., 2014). 
Even with the advent of atypical antipsychotics s, functional striatal dopamine D2 
antagonism remains the main pharmacological mechanism of all antipsychotic drugs. 
Interaction between prefrontal areas and dopaminergic circuits supports cognitive 
problem solving strategies, and any impairment would thus affect e.g. verbal and 
working memory (Barch & Ceaser, 2012). Atypical antipsychotics s however differ 
in their pharmacological profiles and might plausibly have differential positive and 
negative effects on cognition (Steen et al., 2017). Partial D2 agonists, e.g. 
aripiprazole, may simultaneously reduce striatal hyperdopaminergia and boost 
prefrontal hypodopaminergia, thus targeting both aspects of the third generation 
dopamine hypothesis (Howes & Kapur, 2009). This sets these drugs apart from strict 
D2 blockers, e.g. amisulpride and olanzapine, which only target striatal 
hyperdopaminergia, and improved prefrontal dopaminergic function has been found 
in animal models using aripiprazole (Z. Li, Ichikawa, Dai, & Meltzer, 2004). While 
amisulpride has a narrow affinity profile limited to dopamine, olanzapine also affects 
5-hydroxytryptamine, adrenergic, muscarinic acetylcholine and Histamine1 receptors, 
which may cause impaired psychomotor speed and memory (Chew et al., 2006; Van 
Ruitenbeek, Vermeeren, & Riedel, 2010). It would therefore still be useful to further 
examine between-drug differences for cognition. 
A considerable proportion of atypical antipsychotics drug studies, including projects 
looking at cognitive impairment, have been funded by the pharmaceutical industry, 
e.g. (Kern et al., 2006; Riedel, Spellmann, et al., 2010). Industry funded research is 
more likely to be commercially motivated, favouring drugs still within their patent 
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period. Investigations of existing expired patent drugs like amisulpride are 
comparably scarce. Industry studies are also often based on small, selective samples 
of schizophrenia patients with chronic phase disorder, which fails to accurately reflect 
clinical drug use. Treatment algorithms in Norway and elsewhere indicate 
antipsychotic drug treatment during acute psychosis, when an exact diagnosis often 
cannot be determined e.g. due to diagnostic criteria related to duration. Industry 
studies also frequently have short follow-up periods, e.g. two months (Riedel, 
Spellmann, et al., 2010). This fails to reflect recommendations that antipsychotic 
drugs be used for at least a year in clinical settings.  
Independently funded, updated knowledge on differential atypical antipsychotics’ 
effects on cognition would be useful. Sampling and follow-up duration should be as 
close to treatment as usual as possible. A longer-term head-to-head drug comparison 
for cognitive effects of atypical antipsychotic drugs would also have a better chance 
of separating acute phase spontaneous cognitive recovery from drug-specific effects. 
Examining between-drug differences might thus yield clinically important knowledge 
in the search for individually tailored treatment of psychotic disorders. 
Cognitive remediation training 
Given the inadequacies of antipsychotic drug treatment for cognitive impairment, 
non-pharmacological interventions are of particular importance. One promising 
avenue to amelioration of cognitive symptoms is cognitive remediation, i.e. 
nonpharmacological interventions aimed at improving neurocognitive functioning 
(Galletly and Rigby, 2013). Based on behavioural training, cognitive remediation 
interventions often aim at improving specific cognitive processes like memory, social 
cognition, or metacognition, with the ultimate aim to generalize any learning to other 
real-life situations. Approaches can aim at restitution or repair of damaged neural 
pathways, or teaching new skills to compensate for existing impairment (Medalia & 
Saperstein, 2013). Treatment effects are moderate for both neurocognitive 
functioning (.41-.45) and functional outcome (.36) as well as for negative symptoms 
(.36) (Morin & Franck, 2017). Effects are compounded by implementation of other 
rehabilitative interventions. 
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1.10 Cognitive change in psychosis 
For almost as long as cognitive impairment has been studied in psychotic disorder, 
disagreement has existed about the nature of psychosis related cognitive change. A 
main controversy is whether cognitive impairment is present from birth or early 
childhood or arises shortly before the onset of psychotic illness. A second question is 
whether cognitive functioning remains relatively stable, fluctuates, or deteriorates in 
chronic illness. Some authors have argued that psychosis in itself is neurotoxic and 
damaging to cognitive processing, whilst others have found deficits to be relatively 
stable from first episode psychosis onwards (Bozikas & Andreou, 2011). Psychosis 
has thus been modelled as arising from either neurodevelopmental or 
neurodegenerative processes. 
The neurodegenerative view of psychosis was founded in part on early brain imaging 
studies showing progressive ventricular enlargement in psychosis patients (Shenton et 
al., 2001), but also from cross-sectional comparisons between first episode psychosis 
and chronic schizophrenia groups (Lieberman, 1999) . Also, functional decline during 
the prodrome and first episode of psychosis is common, with functional loss 
associated with poorer prognosis (Addington, van Mastrigt, & Addington, 2003; 
Keshavan, DeLisi, & Seidman, 2011). In addition, some have found multiple 
psychotic episodes to be associated with lower levels of cognitive functioning 
(Heaton et al., 1994). Comparison between medicated and non-medicated trajectories 
of schizophrenia led some to argue that active psychosis in itself is neurotoxic 
(Wyatt, 1991).  
However, the relative stability of cognitive deficits after the onset of psychosis, 
identified during the upsurge of cognitive testing studies from the 80s onward has 
drawn criticism to the neurodegenerative model (Rund, 1998). The presence of 
cognitive impairment before the advent of positive symptoms is also an argument 
against the view of neurotoxicity of untreated psychosis (McGlashan, 2006). Also, 
any decline across the course of illness may also be related to factors other than 
neurodegeneration, e.g. psychoactive substance or antipsychotic use. Illustrating this, 
dose reduction and controlled discontinuation of atypical antipsychotics is potentially 
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associated with cognitive improvement outside the acute phase (Takeuchi et al., 
2013).  
Any exacerbation in deficits may also result from genetically driven changes in 
cognition which may manifest at multiple points along the developmental trajectory 
(Mollon & Reichenberg, 2018). Early abnormalities or delays in the development of 
basic cognitive skills will also affect the subsequent development of more complex 
cognitive operations, especially as tested against healthy population norms (Bora, 
2015). Prodromal deficits and any later impairment may thus both result from 
developmental lag, not the loss of previously acquired skills. This argument fits well 
with McGlashan’s (2006) suggestion the brain process underlying loss of cognitive 
capacity would be one of dysconnectivity in the form of “disuse atrophy”.  
This alternative neurodevelopmental view thus conceptualizes cognitive impairment 
as an expression of aberrant neurodevelopment in childhood and early adulthood 
(Bora, 2015). Further support for this model is found e.g. in a large 10-year follow up 
study finding no significant long-term decline (Barder et al., 2013) and other studies 
finding no change beyond normal ageing (Sponheim et al., 2010). A large meta-
analysis recently concluded that longitudinal data overall do not firmly support 
progressive decline, with the possibility that function may even improve within 
certain domains after the onset of illness (Bortolato et al., 2015). The 
neurodevelopmental model leaves greater room for the fluctuations and change seen 
throughout the course of psychotic illness. 
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2. STUDY AIMS 
This PhD aimed to investigate cognitive changes in psychosis, from the prodromal 
stage through acute phase psychosis to established psychotic disorders. A central aim 
was to investigate whether cognitive impairment is static or fluctuates across the 
course, stages, and treatment of psychosis. 
2.1 Research questions 
1. What characterises the neurocognitive profile in the ultra-high risk for 
psychosis state? (Paper II)  
2. How does cognitive functioning change during the acute phase of psychotic 
disorder? (Paper I) 
3. Do different second-generation antipsychotic medications differentially affect 
cognitive performance in psychotic disorders? (Paper III)  
4. Does cognitive change differ between groups with schizophrenia and those 
with other psychotic disorders? (Papers I, II and III) 
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3. METHODS 
3.1 RESEARCH PROJECTS/SETTING 
This PhD was based on data from three different projects: The Bergen Psychosis 
project (BPP), the Prevention of Psychosis Project (POP) and the Bergen Psychosis 
project 2 (BP2) including the BestIntro antipsychotic drug trial, of which the PhD 
work formally formed a part.  
3.1.1 Bergen Psychosis Project 
Study design 
The Bergen Psychosis Project (BPP) was a pragmatically randomized, rater-blinded 
comparison of the four first-line second-generation antipsychotics quetiapine, 
olanzapine, risperidone, and ziprasidone.  
Recruiting centres 
Participants were consecutively invited to participate from the acute psychiatric 
emergency ward of Haukeland University Hospital, Bergen, Norway (n=226). The 
Regional Committee for Medical Research Ethics allowed inclusion of eligible 
patients ahead of informed consent, in order to give a clinically relevant 
representation of patients with acute psychosis. Participants were asked for their 
written informed at first follow-up before being enrolled in the full 24-month project 
follow-up programme. Participants involved in the current project were included 
between March 2004 and January 2009. 
Inclusion and exclusion criteria 
Participants were required to be aged ≥ 18, to present with acute psychotic symptoms 
and to understand Norwegian language. For the sub-study forming part of this thesis 
they also had to have a completed Positive and Negative Syndrome Scale (PANSS) 
interview and neurocognitive testing both at baseline and at first follow-up.  
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Diagnostic process 
Active psychosis was defined by a PANSS (Kay, Fiszbein, & Opler, 1987) score of ≥ 
4 on the items for either Delusions, Hallucinatory behaviour, Grandiosity, 
Suspiciousness/persecution, or Unusual thought content. Diagnoses were assessed by 
trained clinicians, with study data gathered from participants’ medical records at the 
time of discharge.  
Exclusion criteria 
Ineligibility for oral antipsychotics, organic brain disease, manic psychosis, 
substance-induced psychosis resolving within a few days of admission, inability to 
cooperate reliably during investigations, indication for electroconvulsive therapy, or 
being medicated with clozapine on admittance.  
Withdrawal criteria 
The participant was able to withdraw from further follow-up at any time. Other 
withdrawal criteria included serious somatic events requiring non-protocol follow-up, 
as well as pregnancy. Regular concomitant use of multiple antipsychotic drugs also 
led to exclusion. However, any change in antipsychotics for reasons of efficacy, 
safety or side effects was not a reason for exclusion, in line with the study pragmatic 
design. Details related to such changes were however considered important 
information. 
3.1.2 Prevention of Psychosis project 
Study design 
The Prevention of Psychosis (POP) project was a detection and intervention study 
aiming to reduce incidence of psychotic disorders in high-risk youth through 
appropriate early support. Details can be found in its published study protocol (Joa et 
al., 2015) Building on the existing infrastructure of the TIPS early intervention in 
psychosis programme (Joa, Johannessen, Larsen, & McGlashan, 2008), POP used 




Participants were recruited from Stavanger University Hospital.  
Inclusion and exclusion criteria 
Eligible candidates were invited to participate if they were aged 13–65 years, with IQ 
≥ 70 and ability to speak / understand Norwegian as well as to understand and sign an 
informed consent / assent for minors document.  
Diagnostic and symptom assessment 
Participants were required to meet prodromal syndrome diagnostic criteria according 
to the Structured Interview For Prodromal Syndromes (SIPS) (T. J. Miller et al., 
2003) with either 1) brief, intermittent positive symptoms of psychosis scoring ≥ 6 on 
the Scale of Prodromal Symptms, 2) attenuated positive symptoms scored 3–5 on the 
P1–P5 SOPS scales or (3) genetic risk and deterioration syndrome with a first-degree 
family history of nonaffective psychotic disorder and ≥ 30% functional loss over the 
past 12 months, as measured by the Global Assessment of Functioning scale.  
Diagnostic interviews were performed after inclusion, with Kiddie Schredule for 
Affective Disorders and Schizophrenia (Kaufman et al., 1997) or Structured Clinical 
Interview for the DSM-IV (SCID) (Spitzer, Williams, Gibbon, & First, 1992) 
assessment being administered by trained clinicians or researchers. 
Exclusion criteria 
Current or lifetime psychotic disorder or symptoms better accounted for by 
neurological, endocrine, axis I, II, or substance use disorders. The exception was 
schizotypal personality disorder, which was not an exclusion criterion. Participants 
were also required never to have used antipsychotic medication for more than 4 
weeks in a lifetime perspective. 
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3.1.3 Bergen Psychosis Project 2/ Bergen-Stavanger-Innsbruck-
Trondheim study 
Study design 
Bergen Psychosis Project 2/ Bergen-Stavanger-Innsbruck-Trondheim (BP2/ Best 
Intro) study was a pragmatically randomized, rater-blinded head-to-head comparison 
of amisulpride, aripiprazole and olanzapine. Participants were followed-up for 12 
months, with assessment at baseline, 1, 3 and 6 weeks and then 3, 6, 9 and 12 months.  
Study population 
Participants were included if they had been diagnosed with a current psychotic 
episode with clinical indications for oral antipsychotic treatment. 
Recruiting centers 
BP2/ Best Intro participants were consecutively recruited from Haukeland University 
Hospital, Bergen (n=75), Stavanger University Hospital, Stavanger (n=14), 
Medizinische Universität Innsbruck, Innsbruck (n=15). Numbers given are for those 
included in the current thesis. St. Olav’s University Hospital, Trondheim recruited 
participants but did not perform cognitive testing. A comparison group receiving 
treatment as usual was also recruited in Bergen, and contributed data to Paper I. 
Inclusion and exclusion criteria 
Participants were invited to participate if they were aged  18 and eligible for oral 
antipsychotic drug treatment as determined by their attending clinician, with 
symptoms indicating non-affective psychotic disorder according to the ICD-10 (F20-
29) (World Health Organization, 2007) or DSM-IV (American Psychiatric 
Association, 2000) and ability to provide informed written consent. They were also 
required to speak and write the site language.  
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Diagnostic process 
Trained clinicians or researchers administered the Structured Clinical Interview for 
the DSM-IV (SCID)(First, Spitzer, Gibbon, & Williams, 1997). The SCID was 
performed as early as possible after inclusion. 
Exclusion criteria 
Exclusion criteria were inability to use oral antipsychotics, being medicated with 
clozapine on admission, inability to cooperate reliably during investigations, 
indication for electroconvulsive therapy, organic brain disorder causing the psychotic 
symptoms, pregnancy or breastfeeding or hypersensitivity to study drug substances. 
Participants were also excluded from the study if the SCID interview indicated that 
their symptoms were due to mania with psychosis or other diagnoses not compatible 
with the inclusion criteria range of disorders.  
Withdrawal criteria 
In line with the pragmatic study design, change of antipsychotic medication for 
whatever reason was considered important information though not grounds for 
withdrawal. However, serious somatic events indicating follow-up outside the study 
protocol or use of concomitant use of antipsychotic drugs would cause a person to be 
excluded from further follow-ups. Pregnancy would cause withdrawal from the study.  
3.2 Treatment 
BPP & BP2/ Best Intro: Participants received oral tablets based on randomization. 
Study drug dosage, the further treatment trajectory with any changes to other 
antipsychotic drugs or use of non-antipsychotic concomitant drugs was at the 
attending clinician’s discretion in order to closely resemble treatment as usual. In line 
with Norwegian treatment guidelines, antipsychotic polypharmacy was however not 
permitted except for in the case of cross-titration at antipsychotic drug switching.  
POP: Participants were given the opportunity to participate in one or more of the 
interventions: monthly comprehensive independent clinical assessments, case 
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management support with psychosocial needs including familial and vocational 
issues, omega-3 fatty acids (12-week daily dose of 2g fish oil capsules), 26 sessions 
of individual cognitive behavioural therapy over 6 months, single-family psycho-
education, and anxiolytics and antidepressants if indicated by symptom load. 
Antipsychotic medication was to be administered open-label if a person either entered 
the study or was rated during follow-up to have a SIPS positive symptom score of ≥5. 
However, none of the participants included in the current thesis received 
antipsychotic medication. 
3.3 Data and variables 
3.3.1 Clinical variables 
Psychotic symptoms: For the BPP and BP2/ Best Intro, trained clinicians and 
research staff administered the Structured Clinical Interview: Positive and Negative 
Syndrome Scale (Opler, Kay, Lindenmayer, & Fiszbein, 1999) to assess psychotic 
symptoms at each follow up. For POP, the SIPS (T. J. Miller et al., 2003) was used to 
assess attenuated psychotic symptoms. 
Drugs and alcohol use: The BPP and BP2/ Best Intro used the Clinical Drug and 
Alcohol Use Scales  (Mueser et al., 1995) to assess drug and alcohol use during the 
follow-up period. The Alcohol Use Disorders Identification Test (AUDIT) (Bush, 
Kivlahan, McDonell, Fihn, & Bradley, 1998) and Drug Use Disorders Identification 
Test (DUDIT) (Berman, Palmstierna, Källmén, & Bergman, 2007) were also 
administered at baseline. BP2/ Best Intro also used this instrument again at 6 weeks, 
26 weeks, and 52 weeks. POP used AUDIT and DUDIT. 
Functioning and symptom severity: The Global Assessment of Functioning-Split 
Version, Functions scale (American Psychiatric Association, 2000) was scored at 
every follow-up for all three projects, yielding a subscale score for function and 
symptom severity.  
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3.3.2 Cognitive performance and change 
The BPP used the Repeatable Battery for the Assessment of Neuropsychological 
Status (RBANS) (Gold, Queern, Iannone, & Buchanan, 1999; Randolph, 1998), 
administered by trained and experienced raters at baseline and follow-up. The battery 
can be completed in 30 minutes and yields a total score as well as subscales for 
immediate and delayed memory, visuospatial skills, language, and attention. Subtests 
are word list learning and recall, story memory and recall, figure copying and recall, 
line orientation, picture naming, semantic fluency, digit span and coding. 
The BP2/ Best Intro project used both a brief and a comprehensive neurocognitive 
test battery. The brief battery formed the basis of Paper III of this thesis. It aimed to 
assess working memory, processing speed and verbal ability and was designed to 
withstand learning effects. It comprised Dichotic Listening, Trail Making A (TMA) 
and Trail Making B (TMB) from the Halsted-Reitan test set (Reitan, 1958), The 
Hopkins Verbal Learning Test (HVLT-R) (Benedict, Schretlen, Groninger, & Brandt, 
1998), WAIS-IV letter number sequencing (Wechsler, 1997a), and the Delis-Kaplan 
Executive Function System (D-KEFS)  verbal fluency tests (FAS) and Symbol 
Coding (Delis, Kramer, Kaplan, & Holdnack, 2004), administered in that order. 
Trained staff administered this assessment at baseline, 6 weeks, 6 and 12 months.  
The comprehensive battery lasted approximately 2-3 hours and was given at the 
three-month follow-up. This test battery provided data for Paper II of this thesis and 
consisted of Dichotic Listening and TMA and TMB from the Halsted Reitan test set 
(Reitan, 1958), the California Verbal Learning test (CVLT) (Delis, Kramer, Kaplan, 
& Ober, 2000), WAIS-III tests for vocabulary, similarities, number span, letter 
number sequencing, vocabulary, digit-symbol coding and block design (Wechsler, 
1997a), WMS spatial span (Wechsler, 1997b), the Grooved Pegboard Test (Bryden & 
Roy, 2005), D-KEFS Color Word Interference Test (CWIT) and FAS (Delis et al., 
2004), Rey Osterrieth Complex Figure Test (Shin, Park, Park, Seol, & Kwon, 2006), 
Digital vigilance test, the California Computerized Assessment Package Continuous 
performance test (E. Miller, 1990), and Wisconsin Card Sorting test (McGrath, 2011).  
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The POP project used a comprehensive cognitive test battery administered at 
baseline and consisting of Dichotic listening, Halsted-Reitan’s TMA and TMB, the 
CVLT, WAIS III tests for number span, letter number sequencing, vocabulary, and 
block design, WMS spatial span and the D-KEFS CWIT, and FAS verbal fluency 
tests. This battery was designed in order to be compatible with the BP2/Best Intro 
project test battery in terms of comparison. Data from this battery was used for Paper 
II of this project. 
3.4 Statistical analysis 
Statistical methods are described in detail in their respective papers. Following is a 
short summary of statistical procedures for each paper.  
SPSS was used to conduct descriptive analyses of clinical and demographic baseline 
characteristics in each paper. SPSS was also used for the main analyses in papers I 
and II. Categorical variables (e.g. gender) were compared between groups using 2, 
while one-way ANOVAs were used for continuous variables (e.g. age). In the event 
of ANOVAS indicating significant between-group differences, independent samples 
T-tests were applied to further explore the nature of these differences. 
3.4.1 Paper I 
Variables predicting cognitive change were assessed using sequential multiple linear 
regression analyses. We used two blocks with RBANS change scores as the 
dependent variable to assess the contribution of PANSS composites symptom load 
change. Block one consisted of gender, age, and baseline RBANS total and PANSS 
composite variable scores (Positive, Negative, Depressive, Excitatory and 
Disorganized) while in the second block, PANSS composite variable change scores 
were entered using forward stepwise selection (Criterion for inclusion: p < .05; 
criterion for exclusion: p < .1). Equivalent models were also made to assess change in 
each RBANS sub scale.  
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We also calculated the percentage of participants falling below the cut-off for 
cognitive impairment set at total RBANS score of t < 35, i.e. > 1.5 SD below 
population mean, corresponding impairment as conceptualised by Heaton et al. 
(1991). We compared cognitive scores at baseline and follow-up using two-tailed, 
paired t-tests. Pearson correlations between cognitive scores and PANSS scores at 
baseline were also calculated. We also compared cognitive change between the 
schizophrenia spectrum disorders group and other participants using a repeated 
measures ANOVA. The grouping variable was constructed by dividing the patients 
into a Schizophrenia spectrum disorders group (F20, F23.0 or F23.2, i.e. fulfilling the 
core symptomatic criteria for F20, but not necessarily the duration criteria) vs. a 
group with other psychotic disorders. We used the Greenhouse-Geisser correction for 
violations of the assumption of sphericity. 
3.4.2 Paper II  
We compared UHR cognitive performance with recent onset and longer onset 
schizophrenia groups by way of coordinated norms. Raw test scores were normalized 
by calculating z values relative to healthy control group baseline performance. 
Negative z-scores would indicate performance below controls. Using z-scores 
allowed cross-domain comparisons and also ensured our norms were appropriate for 
the young age UHR group for whom standardised test norms do not exist. We 
calculated a four-domain cognitive profile by grouping tests according to literature 
and neuropsychological conventions (46), with mean domain z-score based on for the 
tests comprising each domain. Domains used were speed of processing (TMA, WAIS 
digit symbol coding, CWIT colour and word reading conditions), working memory 
(TMB, WAIS number span and letter number sequencing, inhibition, and inhibition 
and switching conditions from D-KEFS CWIT), verbal learning, reasoning, and 
problem solving (D-KEFS FAS, WAIS vocabulary, and CVLT), and spatial 
reasoning (WAIS block design and WMS spatial span). Subscale z-scores were 
compared between groups using one-way ANOVAs. Post-hoc pairwise t-tests were 
used to assess significant between-group differences. We also calculated Pearson 
correlations between cognitive subscales and symptom scores, and antipsychotics 
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defined daily doses (DDD) and duration of illness for the F20 groups. We applied the 
Siddaq correction for multiple comparisons where applicable. 
3.4.3 Paper III 
The main analysis looked at cognitive change in intention-to-treat (ITT) 
randomization groups. ITT analysis entails analysis of trial participants in the group 
to which they were randomized (The Cochrane Collaboration, 2011). Supporting 
analyses were based on per-protocol (PP) groups based on the drug actually initiated 
for each participant. In both cases, analysis was done by way of linear mixed effects 
models (LME) (Pinheiro & Bates, 2000) using R software (R Core Team, 2013). 
LME was chosen for its ability to use all available data even when participants had 
completed different numbers of visits, as well as due to its ability to handle non-
ignorable missing data (Hedden et al., 2009). 
3.5 Funding, approvals and ethical considerations 
All three contributing projects (BPP, POP and BP2/ Best Intro) were conducted 
according to the World Medical Association Declaration of Helsinki (World Medical 
Association, 2013), and approved by the Regional Committee for Medical Research 
Ethics West-Norway and Norwegian Social Science Data Services.  
In addition, BP2/ Best Intro was also approved by the Norwegian Medicines Agency 
in Norway, Etikkommission der Medizinische Universität Innsbruck, and the 
Austrian Federal Office for Safety in Health Care in Austria. The project was 
monitored according to the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use: Guideline for Good Clinical 
Practice,(2016). In Norway, the Department of Research and Development, 
Haukeland University Hospital provided monitoring services, while the Clinical Trial 
Centre at the Medical University Innsbruck provided these services for the Austria 
site. The BP2/ Best Intro study was conducted in line with the Norwegian Health 
Research Act (Helse- og omsorgsdepartementet, 2008). 
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The BPP study was funded by the Norwegian research council and Haukeland 
University Hospital. The BP2 study was funded by the Norwegian research council 
(RCN) #213727 and the Western Norway Regional Health Authority  #911820 and 
#911679. The POP study was funded by a grant from the Norwegian Extra 
Foundation for Health and Rehabilitation (EXTRA funds no. 2011-1-27) and by the 
Western Norway Regional Health Authority (#911508 and #911881). None of the 
projects were financially supported nor linked to any pharmaceutical company. 
BPP enrollment procedure 
The Regional Committee for Medical Research Ethics allowed eligible participants 
for BPP to be included ahead of providing their informed consent, in order to 
maximise clinical representativeness. The project was divided into two phases: Phase 
one did not require informed consent as it ran from acute ward admission to discharge 
or up to 6 weeks, and included only measurements already a part of routine clinical 
practice. In order to enter the second phase, which included non-standard 
measurements and follow-up at 3, 6, 12 and 24 months after admission, participants 
were required to sign an informed consent form at discharge or 6 weeks at the latest.  
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4. RESULTS  
4.1 Paper I: Cognitive change during acute phase 
psychotic disorder 
4.1.1 Regression model of symptoms (PANSS)  
and cognitive change (RBANS)  
The mean time from baseline to follow-up was 4.1 weeks (SD = 1.9 weeks). Change 
in PANSS negative symptoms was the only PANSS change score to significantly 
predict improved overall RBANS performance (beta = -.307, p < .016). Changes in 
RBANS and PANSS are displayed in Figure 1.  




4.1.2 Correlation between PANSS and RBANS scores 
The only significant symptom-RBANS correlation was between PANSS disorganized 
scores and RBANS total mean (r = -.515, p < .001). Attention was also significantly 
correlated with PANSS disorganization, but not after applying a Bonferroni corrected 
alpha level of .002 (r = -.296, p = .006).  
4.1.3 Rate of cognitive impairment 
The proportion of participants performing below an RBANS t-score of 35 fell from 
28.6% (24/84) at baseline to 13.1% (11/84) at the point of follow-up. Mean total 
RBANS scores improved from 38.67 at baseline to 41.27 at follow-up (p < .001, d = 
.35). Mean attention scores similarly increased from 39.9 to 45.95 (p < .001, d = .75) 
while verbal scores went up from 30.32 to 33.93 (p < .001, d = -.39). Participants 
performed significantly below the norm average overall and for every RBANS 
subscale (all p < .001). 
4.1.4 Comparing schizophrenia spectrum disorders to other 
psychotic disorders 
There was no significant interaction between having a diagnosis of schizophrenia, 
and cognitive change over time as analysed by a repeated measures ANOVA 
including age and gender.  
4.2 Paper II: Neurocognitive profile in UHR  
The group with UHR scored significantly lower for cognitive performance in most 
domains than did healthy controls, as did both the group with recent-onset 
schizophrenia and the group with longer duration of illness.  
A one-way ANOVA of z-scores found significant between-group differences for 
speed of processing [F(3) = 18.24, p < 0.001], working memory [F(3) = 13.71, p < 
0.001) as well as for verbal learning, reasoning, and problem solving [F(3) = 4.94, p = 
0.003). The groups did not perform significantly differently for visual problem 
solving [F(3) = 1.16, p = 0.327]. Fig. 2 shows group cognitive profiles.  
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Pairwise t-tests indicated that healthy controls outperformed the UHR group for 
speed of processing (p < 0.001), working memory (p = 0.042), and verbal learning, 
reasoning, and problem solving (p = 0.007). The UHR group in turn outperformed the 
longer duration of illness schizophrenia group for speed of processing and working 
memory (both p < 0.001). However, the UHR group and the recent onset 
schizophrenia group performance did not significantly differ in any domain.  
No correlation between symptom scores or DDD and cognitive performance 
remained significant upon a Bonferroni correction for any of the groups.  
Figure 2: Cognitive profiles in UHR and groups with recent onset and longer duration 
schizophrenia. 
 
Note: UHR, ultra-high risk group; SZ1, group with recent onset schizophrenia (< 3); SZ2, 
group with remote onset schizophrenia (> 3 years). Error bars show 95% CI. 
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4.3 Paper III: The effect of atypical antipsychotic 
medication on cognitive performance over a 12-month 
period 
4.3.1 Study drug acceptance, dosage and additional 
antipsychotics 
A Chi square test found no significant between-group differences in acceptance of 
first study drug offered (X2=5.26, df=2, p=.074), nor any differences in Defined Daily 
Doses (DDD) to any follow-ups. There were no ITT group differences in medication 
naivety, with 42.3% of the overall group AP naïve at baseline. There were no ITT 
group differences in additional APs for any visit.  
4.3.2 Primary outcome: Cognitive change per medication group 
over time 
No significant differences were found between ITT groups in terms of overall 
cognitive change. According to the LME model, overall t-scores for the amisulpride 
group increased by 6.7% (2.9 points) on average over 12 months, with corresponding 
increases of 12.6 (5.0 points) and 12.2% (5.3 points) for aripiprazole and olanzapine 
respectively. Per-protocol (PP) analyses also failed to identify significant between-
group differences. Fig. 3 shows cognitive change over time, comparing amisulpride 
to aripiprazole and olanzapine. 
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Figure 3: Change in cognitive performance t-scores over 52 weeks per ITT group 
 
Note: Dashed line at 50 shows general population mean 
4.3.3 Cognitive performance and change scores 
Mean cognitive performance t-score improved from 46.39 at baseline to 47.53 at 52 
weeks. The total sample mean t-scores improved significantly to 6 (Δ2.0; p= .002), 
26 (Δ3.4; p< .001) and 52 (Δ4.2; p< .001) weeks, corresponding to a medium effect 
size (Cohen’s d=.53). The percentage showing cognitive impairment (defined as 
scoring at t<35) was 27.9% (n=29) at baseline, improving to 17.0% at 52 weeks.  
4.3.4 Schizophrenia vs. other psychoses 
Out of the F20 group, 33.3% had t-score below the cut-off for cognitive impairment, 
compared to 20.5% among the other participants. However, this difference was not 
significant (X2=2.094, df=1, p=.15). There were no significant differences in 
cognitive change between participants with schizophrenia and those with other 














5. DISCUSSION  
5.1 Short summary of main findings 
5.1.1 Paper I: Cognitive change happens in acute phase psychosis 
This study found that significant cognitive improvement can happen early in the 
course of acute psychosis treatment. Participants RBANS score increased 
significantly during the follow-up period, with the proportion of cognitively impaired 
subjects reducing from 28.6% to 13.1%. Neurocognitive improvement over the four-
week follow-up period was associated with a reduction of negative symptoms, but 
with no other symptom changes. The improvement, rather than baseline severity, 
appeared to be key to cognitive improvement, indicating a close relationship between 
cognition and negative symptoms.  
As far as we know this was the first study to show a correlation between acute phase 
improvement in negative symptoms and cognitive functioning in a sample not 
consisting exclusively of first episode psychosis participants. Our findings indicate 
that positive cognitive change is not limited to homogenous first episode psychosis 
samples. The schizophrenia subgroup did not differ from other participants in terms 
of cognitive change. 
5.1.2 Paper II: UHR group performs between healthy controls and 
established schizophrenia  
For overall test results, the UHR group significantly outperformed the group with 
longer duration schizophrenia, while underperforming compared to healthy controls. 
There were no significant differences between the UHR group and the recent onset 
schizophrenia group. This is in line with previous findings (Fusar-Poli et al., 2012; 
Giuliano et al., 2012) that cognitive performance is impaired in UHR groups but less 
so than in established schizophrenia. 
In terms of cognitive subscales, UHR scores were significantly worse than healthy 
controls for speed of processing and cognitive flexibility as well as for verbal skills. 
However, the UHR group had better processing speed and working memory 
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performance than the longer duration schizophrenia group. There were no significant 
subscale differences between UHR and recent onset schizophrenia group 
performances. Interestingly, neither of the clinical groups differed significantly from 
healthy controls in spatial abilities. Our findings support previous findings that UHR 
and psychosis groups show impaired speed of processing, working memory, and 
verbal ability (Tandon et al., 2009).  
5.1.3 Paper III: Atypical antipsychotics do not differentially affect 
cognitive change 
Total sample cognitive test scores improved significantly to each of the three follow-
ups at 6 weeks, 6 and 12 months, from the baseline level about one SD below the 
population mean. The majority of this improvement happened during the first six 
weeks. There were however no significant differences in cognitive change over 12 
months between our study groups for amisulpride, aripiprazole and olanzapine for 
neither ITT nor PP analyses. The subsample with schizophrenia also performed 
significantly better across the 12-month follow-up, with no significant differences in 
change from other participants.  
5.2 General findings 
5.2.1 Cognitive impairment exists across the course of illness, but 
it is subject to positive change 
A central finding of this thesis is that cognitive impairment is in flux throughout the 
course of illness. This is contrary to models of cognitive impairment as a static trait in 
psychotic disorders (Patel et al., 2010; Tyson, Laws, Roberts, & Mortimer, 2004). 
Despite impairment being present in the UHR group, the onset of treatment is 
associated with improved cognitive functioning, both through the acute phase (Paper 
I) and over the first year after starting antipsychotic treatment (Paper III). Although 
the onset of psychosis has been associated with a deterioration in cognitive 
functioning, there appears to be potential for positively influencing cognitive 
performance through follow- up and treatment. This is an important message to give 
to service users whom often strongly wish to participate in work and educational 
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activities (Iyer et al., 2011). In line with existing literature this thesis found that 
cognitive impairment exists across all stages of psychotic illness from UHR youth 
(Paper II), through the acute phase (Paper I) to groups of participants with a diagnosis 
of severe psychotic disorder like schizophrenia (Papers II and III). Impairment 
appears to be more severe in cases of well-established illness than in recent onset 
schizophrenia (Paper III). This confirms the view of cognitive impairment as a core 
aspect of schizophrenia in particular and primary psychotic disorders in general 
(Bora, 2015; Kahn & Keefe, 2013).  
In their comprehensive review of the field, Fusar-Poli et al. (2013) ask whether the 
intermediate cognitive impairment seen in UHR groups represents state risk factors 
likely to deteriorate as illness progresses, or whether group level UHR impairments 
are milder due to the presence of false positives. Our findings of an association 
between longer duration of schizophrenia and worse cognitive performance could be 
seen as supporting the first model of gradually worsening impairment in line with a 
neurodegenerative view of psychosis (Lieberman, 1999). However, although our 
cross-sectional data cannot fully illuminate this, it is more likely in my point of view 
that the worse performance in our Paper II chronic SZ group instead reflects the 
second scenario suggested by Fusar-Poli et al. (2013): A greater neurological 
variation in UHR and early schizophrenia groups as compared to chronic groups. The 
Paper II UHR group contains some “false positives” who will not develop psychotic 
disorder. Alongside these are found participants who will see persistent, multi-
episode illness, as well as an intermediate group who will develop psychosis but 
recover relatively quickly. Our UHR group is thus likely to include a greater range of 
neurological susceptibility and variation. This will be especially evident as compared 
to the longer duration SZ group which consists almost exclusively of multi-episode 
participants, the vast majority of whom are known to show a decrement in cognitive 
functioning (Tandon et al., 2009). This may explain why the longer duration 
schizophrenia group has more severe impairments across the subscales tested for.  
Although the results from this thesis are partly cross-sectional and unable to conclude 
definitively, the collective findings may be seen as supporting existing literature 
(Seidman, Giuliano, & Meyer, 2010) that poor cognitive functioning at the UHR 
 64
stage is a marker for poor prognosis, thus explaining the worse performance seen in 
the chronic schizophrenia group in Paper II. Showing weaker improvement after 
acute episodes may also be such an indicator, though this could only be explored by a 
longitudinal setup closely following participants through the early acute phase. 
Further large-sample longitudinal work should study individual paths in UHR youth, 
to reveal any correlations between individual or group patterns of cognitive change. 
Better cognitive functioning in an UHR individual may also potentially modify the 
course of illness by enabling the person to make better use of available support. This 
may hold true once symptoms of schizophrenia are established, with the recent onset 
group from Paper III including a group of individuals more able to adhere to 
treatment, increasing their possibilities for a quicker recovery. Only longitudinal 
studies from UHR to persistent psychotic disorder may however illuminate these 
ideas further. 
5.2.2 Which cognitive domains are impaired? 
All three papers found impaired overall cognitive performance in the groups with 
established psychosis of about one standard deviation below the population mean at 
baseline. The Paper II group with UHR performed about half a standard deviation 
below the control group mean.  
Impaired processing speed and working memory 
Tasks requiring speed and cognitive manipulation of information appeared to present 
challenges for both UHR and psychosis groups, with Paper II finding that healthy 
controls outperformed the UHR for both processing speed and cognitive flexibility as 
well as for verbal skills. However, the UHR group in turn outperformed the longer 
duration schizophrenia group for both processing speed and working memory. Our 
findings are in line with research indicating that psychosis is associated with 
impairment especially in processing speed, working memory and verbal abilities 
(Schaefer et al., 2013). 
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Unimpaired spatial skills in UHR 
One of the most interesting results from this thesis was that the Paper II UHR group 
performed almost on par with the healthy control group in spatial abilities measured 
by WAIS block design and WMS spatial span scores. Another recent study similarly 
found unimpaired visual skills in a clinical high-risk group, as opposed to in all other 
domains (Carrión et al., 2018). The seminal review of Heinrichs and Zakzanis (1998) 
interestingly also mentions block design as one of the tests with the smallest 
difference between schizophrenia groups and healthy controls. 
We suggest that the strong results in spatial abilities in our sample might in part be 
due to the use of tests involving use or manipulation of physical test objects. In 
contrast to these, many commonly used spatial skills tests are non-tactile and screen 
based, e.g. the delayed response task. Such tests are more abstract and most likely 
place heavier demands on the working memory and visuospatial sketchpad aspect of 
spatial task solving. Our findings indicate that support by physical objects may aid 
cognitive performance in this group. A useful avenue for future research might be to 
directly compare these two aspects of visuospatial functioning in both UHR and 
established psychosis groups. Better visual learning has been found to distinguish 
those of schizophrenia groups who are in regular employment (Kern et al., 2011), 
highlighting the potential clinical importance of this domain. 
5.2.3 No differential effects found between antipsychotic drugs 
The comparison of olanzapine, aripiprazole and amisulpride in Paper III of this thesis 
found no significant differences between these drugs in terms of effect on cognitive 
improvement. This was surprising especially for olanzapine, which has previously 
been found to outperform amisulpride for effect on cognition (Désaméricq et al., 
2014). Aripiprazole as a partial D2 agonist might also be expected to have a 
particularly beneficial effect on PFC dopamine and thus cognitive performance (Z. Li 
et al., 2004; Riedel, Spellmann, et al., 2010). However, Paper III findings are also 
supported by two major atypical antipsychotics comparison studies, CATIE and 
EUFEST, which found no differences for effect on neurocognitive functioning 
(Davidson et al., 2009; Keefe, Bilder, Davis, & et al., 2007). 
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A notable though non-significant trend across every follow-up was that the 
aripiprazole group underperformed the others. The difference was more notable 
during the first six weeks but remained through the year. It was mostly driven by 
lower performance speed, which is interesting in light of previous findings of motor 
coordination disturbances in animal models of aripiprazole (Burda et al., 2011). Also, 
although sometimes used to manage agitation, aripiprazole may also trigger 
aggression and activation, especially at the onset of treatment (Lea, Stoner, & 
LaFollette, 2007; Takeuchi & Remington, 2013). The partial D2 agonist action of this 
drug could potentially cause excessive dopaminergic activity in people who have 
upregulated levels of dopamine receptors due to previous use of receptor blocking 
drugs, which may in turn plausibly affect attention and cognitive test performance. 
The favourable trend for olanzapine and amisulpride may thus not exclusively reflect 
positive drug effects as much as detrimental side effects of aripiprazole. This angle 
should be further investigated with data including subjective and observed side effect 
ratings.  
Another possibility is that despite our best randomization efforts, the aripiprazole 
group differed in some way from the other groups. Although differences were not 
significant, this group had a younger mean age, had an earlier age of onset, less 
education (this perhaps due to age), and more frequent alcohol abuse. In this regard, 
the status of aripiprazole as the primary choice of drug for younger subjects in many 
clinical settings may be relevant. Site clinicians may harbour a bias for picking 
aripiprazole for younger participants. Although any such bias was not pronounced 
enough to create significant between group differences in acceptance of allocated 
study drugs, it may have contributed to our findings of the aripiprazole group 
performing differently.  
An important note is that despite the lack of between-drug differences, Paper III 
participants as a complete group improved significantly across the year. Although no 
placebo or healthy control group was used for this study, making it difficult to 
disentangle effects of atypical antipsychotic from those of time alone or even learning 
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effects, this is an important indicator of the potential for cognitive change after a 
psychotic episode. 
5.2.4 The relationship between cognition and other symptom 
dimensions 
In Paper I, acute phase changes in cognition were unrelated to both baseline positive 
symptoms as well as changes in these, despite the considerable reduction in positive 
symptom scores to follow-up. This is perhaps surprising as one might imagine e.g. 
voice hearing to interfere with verbal abilities. Cognitive improvement alongside 
general symptomatic recovery thus does not appear to merely reflect e.g. a reduction 
in positive symptoms that might have previously disturbed cognitive test 
performance. Our findings fit a two-pathway model of psychosis, where negative and 
disorganized symptom dimensions are associated with phenotypic neurocognitive 
impairment, less related to positive and affective symptom dimensions (de Gracia 
Dominguez et al., 2009).  
The link found in Paper I between impaired cognitive performance and negative 
symptoms might be explained by reduced drive, an integral part of the negative 
symptom dimension (Foussias & Remington, 2008). Reduced drive is associated with 
impaired motivation, which in turn negatively affects efforts made to complete or “do 
well” at a task. Brain reward responses are attenuated in schizophrenia (Waltz et al., 
2008), providing a possible explanation for this phenomenon. Low effort and 
amotivation might in fact account for up to a third of cognitive test result variance in 
schizophrenia (Foussias et al., 2015; Strauss, Morra, Sullivan, & Gold, 2015). 
Although in our sample, negative symptoms change only accounted for a limited 
amount of the variance in cognitive change, future research would benefit from trying 
to assess amotivation alongside other symptom dimensions.  
Change scores for the PANSS disorganized subscale failed to significantly explain 
cognitive change in Paper I. This was despite baseline disorganized symptoms and 
RBANS scores being significantly correlated, and the considerable mean 
improvement in disorganized symptoms. The inclusion of PANSS items for abstract 
thinking and poor attention in the disorganized composite score may go some way to 
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explain the high baseline correlation, though this would not account for the lack of 
covariation between disorganized and cognitive symptoms, often seen as closely 
related symptom dimensions (Minor & Lysaker, 2014). 
5.2.5 Cognition in schizophrenia vs. other psychosis 
Across the papers of this thesis, the subgroups with schizophrenia were not found to 
perform significantly worse than groups with other psychotic disorders. In Paper II 
we also found that performance for the recent onset schizophrenia group equalled that 
of the UHR group. This is in line with a metanalysis which concluded that 
neuropsychological studies overall do not support categorical differences between 
schizophrenia and other groups with psychosis (Bora et al., 2009). However, this 
same analysis suggested that more severe cognitive impairment in a subgroup of 
those with schizophrenia may be related to more severe negative symptoms, which 
resonates with the findings of Paper I that change in negative symptoms is key in 
predicting cognitive change.  
An alternative interpretation of the findings pertaining to schizophrenia groups in this 
thesis is that the similar potential for cognitive change across SZ and non-SZ 
psychosis groups might indicate problems with diagnostic validity. Might the 
distinction between schizophrenia and “other psychotic disorders” be a false one? An 
illness model based e.g. on total and general symptom load or symptom dimensions 
rather than narrow F20 criteria might go some way to remedy this, although the 
association between fulfilled F20 criteria and higher symptom load is likely high. It 
may also be argued that although the SZ-non SZ between-group differences were not 
statistically significant for Paper III, our samples were small, and the finding might 
still represent a clinically meaningful distinction in potential for cognitive change.  
The relatively small SZ sample sizes throughout this thesis means all interpretations 
should be read with caution. In Paper II however, UHR and recent onset SZ groups 
significantly outperformed longer duration SZ. Again, a neurodegenerative model of 
schizophrenia could account for this. In Paper III, the SZ subgroup also improved 
their cognitive performance score across the follow-up period with no significant 
difference to the group with other psychotic disorders in terms of change. It is of 
 69 
course possible that the majority of change happened in the recent onset segment of 
this group, as the Paper III SZ group encompassed both first episode psychosis and 
more chronically ill participants. However, I think the most important message to 
take from these findings is that positive cognitive change exists and happens across 
diagnostic groups, even in severe disorders like schizophrenia.  
5.3 Clinical implications 
The main clinical message of this thesis is one of hope. With treatment, positive 
cognitive change can and does happen after a psychotic episode, even in persons 
fulfilling diagnostic criteria for schizophrenia, where the symptom load is high. 
Cognitive impairment lacks specificity for diagnostic purposes, but impairment e.g. 
in speed of processing and working memory is more common in psychotic disorders, 
and this should inform clinicians in their work with patients who experience 
psychosis. Our findings also underscore the importance of assessing cognitive 
problems when working with UHR youth. The existence of cognitive impairment in 
this group lends support to the need for targeted interventions and support for 
cognitive challenges in e.g., academic settings in order to avoid further functional 
loss. Targeted interventions like psychoeducation about cognitive challenges, 
cognitive training, and physical exercise, may form part of this. Knowledge about 
patterns of cognitive impairment in psychosis and UHR enables clinicians to give 
accurate psychoeducation as well as conveying an understanding that cognitive 
functioning may fluctuate and improve across the course of illness. 
The lack of concurrence between drugs reducing positive symptom load and those 
aiding cognitive function complicates tailored treatment with antipsychotic drugs. 
This study underscores the importance of considering non-medication avenues like 
cognitive remediation training or physical exercise. Even small improvements in 
cognitive functioning might contribute to reducing both societal and personal costs of 
psychotic illness.  
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When to test? 
Clinicians and researchers alike commonly postpone neuropsychological testing for 
several months, waiting for the clinical picture to stabilise. While gathering data for 
this thesis I found that testing is indeed possible in the first few weeks after the onset 
of an acute episode. This is in line with findings that psychotic symptoms do not 
appear to affect the reliability of neuropsychological assessment (Heaton et al., 2001). 
Although cognition changes on a group level during the time after the onset of 
treatment for psychosis, many patients fall out of treatment quite shortly after being 
discharged from hospital. They thus end up not being neurocognitively assessed at 
all, and thus miss out on a valuable assessment of their cognitive strengths and 
weaknesses which might have been vital to assisting them to participation in work 
and education settings. Given the lack of correlation between cognitive performance 
and positive symptoms, I therefore believe that on suspicion of cognitive impairment 
in psychosis, testing should be done as soon as the person is willing and able to 
participate, despite any positive symptoms. 
In addition, our findings underscore the fact that cognitive performance fluctuates 
throughout the course of illness, and testing procedures should reflect this, perhaps by 
testing repeatedly during different phases and states in order to be able to inform the 
patient about her current condition.  
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6. METHODOLOGICAL CONSIDERATIONS 
6.1 Trial designs 
For the POP project, an important strength is the existence of a solid framework for 
recruitment of participants, in the form of Stavanger’s well established early 
intervention team for psychotic disorders. The recruitment of an age and gender 
matched control group is also a significant advantage. This aspect was particularly 
important to this thesis as the control group also completed neuropsychological 
assessment, allowing us to create age appropriate norms for our young UHR 
participants. A weakness pertaining to the sample contributing to Paper II of this 
thesis is the relatively small sample size. It might also be argued that a longitudinal 
design would have yielded better information about the Paper II research question of 
UHR cognitive profile compared with that in established schizophrenia. 
The open randomization design is a major strength of both the BPP and BP2/ Best 
Intro projects. This most likely made participation in the trials more tolerable to both 
patients and clinicians who might not have wished to participate in a closed 
randomization trial. This is especially pertinent given the high prevalence of paranoid 
symptoms in the target population, and may have strengthened generalizability the 
findings of this thesis.  
The lack of a placebo control group in BP2/ Best Intro meant that Paper III did not 
allow for distinguishing between atypical antipsychotic effects on cognition, and 
effects from treatment as usual (including both other drugs and psychosocial 
interventions / talking therapies) or the natural course of illness in itself. A double-
blinded placebo-controlled trial remains the gold standard of drug trials and might 
have minimized any existing bias. However, it was decided that the advantages of a 
pragmatic design outweighed the drawbacks. In addition, the considerable financial 
costs of double-blinded trials preclude most independent trials from implementing 
such designs.  
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As for Paper I, an important weakness is the variability in time to retest. Although the 
paper was able to conclude that cognitive change happens during the acute phase of 
psychosis, it would have been preferable to have a stricter window for re-testing. 
However, setting this at e.g. four or six weeks would most likely have exacerbated 
the amount of missing data as many subjects are hard to reach after hospital 
discharge. This may in turn have limited the generalizability of data. 
Especially for Paper III which followed participants over a full year, it would have 
been desirable to have more knowledge of non-medical interventions received across 
the follow-up period, e.g. family and individual psychotherapy or work participation 
programmes, as this may also have affected cognitive change. However, the 
randomisation procedure aimed to ensure any such effects were equally distributed 
between groups.  
All three projects were funded by industry independent sources, which is a 
considerable strength given findings that 90% of sponsored trials of antipsychotic 
drugs find in favour of the sponsor drug (Heres et al., 2006). Our independent 
funding meant the entire research process from design through inclusion and data 
collection, analyses and conclusions could be independently made with a clinically 
representative setting in mind. Both BPP and BP2/ Best Intro were designed where 
possible to resemble treatment as usual in order to strengthen ecological validity.  
6.1.1 Clinical inclusion criteria 
Determining symptom thresholds 
Inclusion in the POP study was based on SIPS interview scores of ≥3 on the SOPS 
scale or familial risk combined with recently developed functional impairment. 
Although these criteria have been validated and are widely used in UHR research, 
selection of participants remains a major challenge. Alternative paradigms exist for 
delimiting groups more likely to develop psychosis, e.g. basic symptoms (Schultze-
Lutter & Theodoridou, 2017). This complicates direct comparisons between studies 
and is a general challenge for studies of psychosis risk. Also, regardless of selection 
process UHR samples typically include a majority of “false positives”, i.e. youth who 
will not go on to develop psychotic disorders. This is problematic when trying to 
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extrapolate findings to “true” UHR subjects who do convert. However, the POP 
youth are help seeking and often in significant clinical distress, and POP findings 
may therefore be of clinical relevance outwith the scope of psychotic disorders.  
Inclusion based on psychotic symptoms screened with the PANSS, as done by the 
BPP and BP2/ Best Intro, may be considered the gold standard in studies of 
psychosis. The ≥ 4 points threshold is widely used in both drug trials and studies of 
cognitive functioning in psychosis.  
Diagnostic assessment 
Diagnosing patients presenting with psychotic symptoms remains challenging in part 
due to the nature of psychosis itself, which sometimes precludes the person from 
describing their inner state. In BP2/ Best Intro and also in POP, all participants were 
subjected to a SCID interview (or in the case of younger subjects, the K-SADS), 
ensuring a homogenous diagnostic process. In BPP, however, a range of diagnostic 
instruments including the SCID and Mini Plus were used as part of regular clinical 
practise. Although this gives a closer resemblance to how diagnoses are often 
determined in clinical practice, it means the process was less uniform and reliable, 
even for the diagnostic categorization for the current thesis which included only F20 
participants.  
The wide diagnostic inclusion range of the BPP and BP2/ Best Intro studies have the 
advantage of involving a more clinically relevant selection of people with psychosis. 
Drug induced psychosis, although often excluded from studies of cognition, was 
included given that many of these patients are known to be diagnosed with other 
psychotic disorders at a later stage (Whitty et al., 2005). The projects excluded only 
those whose condition resolved within a few days, in order to eliminate cases of acute 
intoxication as outlined by the ICD-10. Drug induced psychosis subjects made up 
about 18% of the Paper I BPP sample for this thesis.  
6.1.2 Follow-up time windows 
For BPP, the mean time to follow-up was 1.4 weeks with an SD of 1.9 weeks. 
Follow-up happened at discharge or at 6 weeks at the latest, giving a relatively wide 
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window. This wide range might have affected both symptomatic and cognitive 
change data. In hindsight, a narrower window would have been preferable, although 
the intention was to test as many patients as possible before hospital discharge.  
Based on experiences from the BPP, the BP2/ Best Intro follow-up windows were 
much stricter, allowing a maximum of 48h of deviation from the set time points. This 
means much of the bias introduced in BPP by the wide window was less problematic 
for BP2/ Best Intro data, even though more follow-ups were used from BP2/ Best 
Intro than from BPP in the current thesis.  
The time windows for POP follow-ups were more pragmatic. The baseline 
comprehensive neuropsychological assessment was at three months, but allowed for 
some flexible scheduling due to most subjects being in full-time education. This was 
done in order to maximise the number of subjects able to participate in assessment 
and is unlikely to have affected the results of this thesis. 
6.1.3 Consent procedures 
The BPP inclusion procedure with ethical approval for inclusion ahead of informed 
consent probably contributed to BPP s high attrition rates, as people dropped out 
before providing consent for the second phase of the project. The high attrition rate 
limits the generalizability of findings and might also be problematic when 
interpreting data as we do not know whether the followed-up group is representative 
of the baseline population. One way to combat this problem might have been to 
conduct targeted drop-out data gathering. Unfortunately this was not permitted in this 
project. However, the only significant baseline differences between drop-outs and 
those who completed the follow-up was that dropouts had higher baseline PANSS 
negative scores. Given that the change in negative symptoms was a significant 
predictor of cognitive change, if anything, participants with a higher PANSS negative 
score at baseline might have contributed to making this association stronger. 
 75 
6.2 The patient sample 
Enrolment in POP started in 2009 and still continues. Tailored screening logs 
unfortunately do not exist as screening was done as a part of the standard early 
intervention detection, with recruitment of those potentially eligible for POP 
happening after the initial assessment. Enrolment in BPP ran from March 2003 until 
June 2008. Due to lack of detail in the BPP screening logs in the period 2003-2006, 
the percentage included from all those screened and eligible is uncertain. Although 
the inclusion criteria for BPP were very wide, this means representativity is 
somewhat uncertain. For BP2, logs show that 40.1% of screened participants (n=144) 
were eligible and accepted randomization. Out of these, 104 completed 
neuropsychological assessment at baseline. Reasons given for not completing testing 
was known cognitive problems (e.g. cerebral palsy with cognitive impairment, or 
mental retardation), or not speaking / understanding the site language. This of course 
means any findings should not be generalized to such subgroups. No information has 
been systematically recorded about POP participant reasons for not completing 
cognitive testing, though not wanting to miss school and finding test situations 
uncomfortable were known reasons. It is therefore difficult to know how this might 
have affected data. 
Norway’s health care system is public, universal, and affordable. The early 
intervention services recruiting for the POP study forms a part of this public mental 
health care system. Although private mental health care facilities exist, they are 
mostly non-profit and catering to publicly funded patients. The vast majority of 
acutely ill people, as recruited by BPP and BP2/ Best Intro, will be referred via their 
GP or emergency room to a local and public psychiatric treatment facility. Thus, the 
participant sample is likely to be representative of the catchment area population. 
However, as all centres were urban areas, results may be less generalizable to rural 
settings.  
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6.2.1 Selection bias and representativeness 
Selection bias may arise in any study not employing random selection for 
recruitment. Further bias may arise because the decision to decline participation 
among eligible / approached potential participants is rarely random. For instance, 
macro- or micro cultural factors like views of the mental health care system or 
medication may systematically affect someone’s decision to participate. For Paper III, 
any selection bias affecting results may reasonably be assumed to be at least in part 
compensated for by the randomization procedure. However, representativeness in 
terms of important demographic variables of age, gender and ethnicity remains a 
challenge, in addition to the obvious selection bias due to the inability to grant 
informed consent among the eligible participants with the highest symptom loads. 
Gender 
Participants from the POP project for the sub study included in this thesis were 61.2% 
female. For BPP and BP2/ Best Intro on the other hand, respective percentages of 
females were 40.1% (Paper II) and 37.5% (Paper III) female. The overrepresentation 
of males is actually less than some former antipsychotic drug trials (Keefe et al., 
2007) but comparable to others (Davidson et al., 2009), and reflects the higher 
number of male patients in psychiatric care for psychotic disorders. It is interesting to 
note the overrepresentation of females in the UHR sample vs. their 
underrepresentation in acute psychotic populations, though the reasons for this cannot 
be ascertained.  
Age 
The mean age of participants from POP was 17 years while participants from BPP 
and BP2/ Best Intro were older at about 30 years on average. The POP project had a 
maximum age limit of 65, while the BPP and BP2 projects had none at all. POP 
eligible patients would at any rate be rare given the young average age of onset in 
psychotic disorders, but the low rate of older participants in BPP and BP2/ Best Intro 
is notable. Cognition in elderly patients with psychosis remains underexplored, and 
our data cannot necessarily be generalized to this age group. 
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Diagnostic diversity 
The BPP sample for Paper I was diagnostically highly diverse, with 23.8% fulfilling 
the diagnostic criteria for schizophrenia. This sample was recruited from a single 
acute psychiatric unit in Bergen. From the BP2/ Best Intro sample for Papers II and 
III, only data from participants with schizophrenia were included. Still, recruitment 
for this project tapped into both inpatients and outpatients from multiple sites, 
providing a different kind of diversity. This variability between projects presents 
some challenges in comparing results from the different papers, but samples aimed to 
be representative of their respective populations, i.e. acutely admitted inpatients with 
psychosis, and the more general population of people with psychosis starting a new 
course of treatment.  
Concomitant drug and alcohol use 
Further strengthening the clinical representativeness of all three contributing projects 
is that none of them excluded participants using drugs or alcohol, although for the 
POP project these could not form the primary cause for attenuated symptoms. Due to 
a singular focus on schizophrenia, drug efficacy trials in particular often exclude 
participants with drug- or alcohol disorders. Clinically, these make up a considerable 
proportion of patients, e.g. 17.9% in the BPP sample in Paper I. Given that 
underreporting of drug use as well as concomitant drug abuse is common in 
schizophrenia and related disorders, openly including these patients might give a 
more representative sample.  
Ethnic diversity 
Ethnic minorities were not widely represented in any of the samples in this project. 
To illustrate, in BP2/ Best Intro, the ethnic minority percentage was 6.7%, and 
included people identifying as African, Latin American, Asian, and mixed. In 
projects including neuropsychological testing, strict language requirements may have 
contributed to this. The percentage is also not far off the proportion of non-European 
ethnicities living in Stavanger (8.8%), Bergen (7.0%) and Trondheim (6.2%) 
(Statistisk Sentralbyrå, 2019). Although the rate may be representative, it is still 
problematic as it may limit the generalizability of results but more so because cultural 
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factors or the stress of having an ethnic minority status may both affect the trajectory 
of cognition in psychotic disorders. Without more closely exploring data from ethnic 
minority populations it may be difficult to adjust individual care programs to such 
factors. 
All POP participants were drug naïve as per project inclusion criteria. BPP and BP2/ 
Best Intro samples included 51.2% and 57.7% non-naïve participants respectively. 
However, the considerable proportion these samples with longer-standing illness 
(schizophrenia diagnosis with onset > 5 years ago) still means thesis findings are not 
directly comparable to first episode psychosis studies.  
Recruitment structure 
POP participants were recruited through the low-threshold early intervention services 
of TIPS in Stavanger University Hospital. The use of an experienced screening team 
might have strengthened reliability in recruiting eligible participants. The reasons for 
eligible youth to decline participation after initial TIPS assessment were not 
systematically assessed. However, this recruitment approach could also be seen as 
problematic, as recruitment exclusively from help-seeking populations is a known 
source of sampling bias (Fusar-Poli et al., 2016). A broader approach e.g. including 
direct recruitment from high schools and primary health care might have yielded a 
different and more representative sample. Reversely, youth with e.g. high levels of 
social withdrawal, anxiety and paranoia might have refused getting in touch with 
TIPS in the first place, either directly or through an attending clinician. The number 
of POP participants was at any rate far lower than the number expected to experience 
relevant symptoms in the catchment area. It is therefore difficult to assess the degree 
to which POP participants are representative of the UHR population in general. Bias 
arising from need for informed consent 
Participants in POP and BP2 had to be well enough to provide informed consent. The 
selection bias resulting from this is unavoidable in studies where consent is 
necessary. However, the most unwell participants are at great risk of being excluded. 
The exclusion of those in need of depot or clozapine treatment further exacerbates 
this trend, as these are often treatment resistant or poorly patients. In psychotic 
 79 
disorder research this is exacerbated by the fact that poorer condition is likely to be 
accompanied with paranoia, further reducing the likelihood that these people will 
agree to participate in research. This is a problem in all research relying on direct data 
collection and active participation from subjects. However, the BPP and BP2/ Best 
Intro participants studied in this thesis were all required to report a high symptom 
load above the cut-off for active psychosis. The very similar mean PANSS positive 
symptoms subscale score at baseline were 20.5 and 20.7 for Paper I and III 
respectively. These relatively high scores mean findings might still be relevant to the 
severely ill group which could not be included.  
Potential bias of neuropsychological results 
In addition to excluding those with the highest symptom load, research into 
neuropsychological variables in particular will further risk excluding those with the 
poorest cognitive functioning. All three projects excluded participants with known 
mental retardation. This is common in such studies and means we know very little 
about cognitive change in people with both mental retardation and psychotic disorder, 
despite the higher occurrence of e.g. schizophrenia in conditions like Downs 
syndrome (Dykens et al., 2015).  
It should also be noted that neuropsychological performance was a secondary 
outcome in all three projects, neither of which were designed to primarily target 
cognitive functioning. This is likely to have had a negative effect on statistical power, 
as projects were designed to detect phenomena with different thresholds from 
cognitive impairment. A more specific design would for also be better suited to 
gather data on premorbid academic and cognitive functioning which may be helpful 
when interpreting findings.  
The three contributing projects to this thesis did not systematically assess reasons for 
participants not completing cognitive testing. Notes from testing staff reveals that for 
POP, time was an important consideration given that many participants were still in 
school. At the Bergen site for BP2/ Best Intro, two people were excluded from testing 
due to known intellectual impairment, seven were excluded due to insufficient 
language comprehension. In addition, two were excluded due to questionable validity 
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of test results. For BPP and BP2/ Best Intro, a commonly recorded note was that 
general poor level of functioning precluded assessment. If poor functioning affected a 
larger fraction of those not tested, this might cause artificially strong test results in the 
remaining sample. This is a problem affecting every project looking at cognitive 
functioning, especially in psychosis and other severe mental health disorders. It is 
difficult to get a completely representative sample within the boundaries of sound 
ethical research conduct, and it is also possible normal instruments may never give an 
accurate picture given that they require a certain level of functioning for completion.  
6.2.2 Dropout 
Like most longitudinal studies of psychotic disorders in general, antipsychotic drug 
trials in particular, both BPP and BP2 had high attrition rates. This however did not 
greatly affect Paper I of this thesis, as the follow-up time was relatively short 
(average 4.2 weeks), when many participants were still inpatients and thus available 
to follow-up.  
Dropout was more problematic in the BP2/ Best Intro data for Paper III due to the 
longer follow-up period. The overall BP2/ Best Intro study designs attempted to 
discourage drop-out by allowing for flexible dosing and by not using a placebo group, 
as a strict RCT design might exacerbate drop-out (Kemmler, Hummer, 
Widschwendter, & Fleischhacker, 2005). Also, the opportunity to contact and remind 
participants ahead of each follow-up was intended to increase attendance. For the 
Stavanger site and my own work in particular I also found that having the opportunity 
to complete all assessments except blood samples for each participant made it easier 
to support participants to keep contributing to all follow-ups. This seemed like an 
advantage of running a smaller study site. However, lack of insight, cognitive 
impairment and disorganized symptoms remain challenges to attendance even despite 
every effort made.  
Reasons for dropout 
Like refusal to participate, dropout of subjects is a potential source of bias especially 
those with extreme scores on clinical or neurocognitive variables may especially have 
affected results. Reasons for drop-out from antipsychotic drug trials are diverse and 
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may be illness related such as an increase in paranoia. Drop-out might also be 
motivated by changing life circumstances not directly related to psychotic symptoms. 
To illustrate, stated reasons for dropout from the Stavanger site of BP2/ Best Intro 
included moving abroad, becoming asymptomatic and wishing to not be reminded of 
prior illness, as well as re-starting illicit drug use.  
6.3 Assessment 
6.3.1 Clinical assessment 
In terms of symptom rating for inclusion and follow-up, in BP2/ Best Intro, all 
participating raters passed PANSS reliability training and testing by the PANSS 
Institute (panss.org). For BPP, PANSS ratings were done by experienced clinicians. 
POP raters received SIPS training. They were able to discuss any rating questions at 
weekly consensus meetings. However, SIPS / SOPS interrater reliability rates are 
known to improve significantly with targeted training (T. J. Miller et al., 2003). The 
gold standard for both POP and BPP would have been similar to the BP2 procedure 
with formal reliability testing,  
For diagnostic assessment, in BPP this was left to the attending clinician’s discretion. 
Both MINI plus (Sheehan et al., 1998) and SCID (First et al., 1997) were used, both 
of which yield DSM-IV diagnoses. MINI has the advantage of being short and 
requiring no training for administration. However, SCID assesses in particular 
psychotic symptoms more thoroughly and is more commonly used in international 
research. It covers the interviewee’s subjective patient’s own account of events as 
well as symptoms, medical records, and co-lateral information. It also to a large 
extent avoids the risk with MINI of allocating an artificially high number of 
diagnoses. The lack of systematic use of the same diagnostic instrument in BPP might 
have limited diagnostic reliability. This realization motivated the strict use of SCID 
for diagnostic purposes in the BP2/ Best Intro design. These were carried out by 
experienced clinicians tied to the research group. For similar reasons, the POP project 
also strictly used SCID for diagnostic purposes, with challenging cases being 
discussed among researchers at the consensus meeting. 
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Gathering of data on drug and alcohol use was retrospective and based on self-report, 
which is inherently prone to recollection bias. However, AUDIT and DUDIT are 
well-established instruments known to have good reliability and validity, including 
for the Norwegian language version and for use with psychotic disorders (Berman, 
Bergman, Palmstierna, & Schlyter, 2005; Gundersen, Gundersen, Mordal, Berman, & 
Bramness, 2013; Hildebrand & Noteborn, 2015). 
6.3.2 Neurocognitive assessment 
The BPP used the established RBANS battery. This was selected for the brevity and 
ease of administration necessary for testing the acute phase patients in the BPP, as 
well as for its resistance to retest effects. BP2/ Best Intro and POP both used custom 
batteries described in detail in section 3.3.2. BP2/ Best Intro used both a brief test 
battery repeated four times (baseline, 6, 26 and 52 weeks) and designed to withstand 
retest effects, as well as a comprehensive battery administered only once. The long 
BP2/ Best Intro battery was developed to capture a more general neuropsychological 
profile of clinical value for everyday functioning, and more relevant for a comparison 
between UHR and established psychosis. In line with this, POP used only a 
comprehensive battery, designed to be comparable to the BP2/ Best Intro battery and 
repeated twice but at longer intervals (12 and 24 months). The short BP2/ Best Intro 
battery was designed specifically to target the effort-demanding processes 
hypothesised to be more likely to be influenced by antipsychotic medication, both 
psychologically and due to dopaminergic effects on the brain. In the case of BP2/ 
Best Intro and POP batteries, all tests were commonly used in research, well 
established and reliable.  
In retrospect, it might have been beneficial to use a consensus battery for BP2/ Best 
Intro, as the MATRICS battery (Nuechterlein & Green, 2006) was available by this 
stage. This would have eased comparison between our findings and those of future 
studies. Another possible improvement to Papers I and III would have been to repeat 
a comprehensive test rather than the brief ones used. However, this might have 
exacerbated any learning effects as alternative versions of certain tests are difficult to 
find (e.g. the Ray complex figure test or Block design). Also, repeated use of longer 
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tests is likely to have led to greater drop-out as they are less tolerable to participants. 
It should also be noted that RBANS results have been valid when compared to 
comprehensive test battery results (Loberg, Langeland, & Jorgensen, 2006). 
No reliability training or testing was done for neurocognitive assessment in any of the 
contributing studies. This might have affected the reliability of the main outcomes of 
this thesis. However, all neurocognitive batteries were designed with strict 
instructions, and administered by experienced testers, which would have strengthened 
reliability. 
Retest-effects for cognitive testing 
Papers I and III both rely on retesting for cognitive change assessment. This may 
clearly influence results as previous completion of tests may affect later scores due to 
learning effects. Apparent improvement like that seen in papers I and III may thus be 
resulting from prior knowledge of tests rather than clinically based change. However, 
both the RBANS and BP2/ Best Intro brief battery were chosen for their ability to 
withstand retest effects. The tests we used including HVLT-R, trail making, coding 
and letter-number sequencing were recently found to withstand learning effects 
relatively well (Rodriguez-Toscano et al., 2019). Still, a better way to distinguish 
learning effects from actual cognitive improvement would have been to use a control 
group. For Paper III, learning effects are also unlikely to have affected the main 
outcome of between-drugs difference as any such effects are likely to be evenly 
distributed between groups.  
6.3.3 Rater blindness in BPP and BP2.  
A double-blinded design remains the gold standard especially for medication 
research, and a rater blinded design as used by the BPP and BP2/ Best Intro will 
inevitably leave greater room for interpretation bias despite every care taken to ensure 
raters remained blinded. For instance, at the Stavanger site where I personally 
performed most of the recruitment and follow-up work, I would leave the room when 
blood samples were being labelled, and a separate member of staff was in charge of 
recording medication doses and blood sample results for each participant. This 
member of staff would also answer any questions pertaining to study medication to 
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ensure I remained blinded. One way to assess the impact of rater blindness would 
have been to survey raters regularly or at the end of data collection for potential 
problems with blinding. Use of entirely independent raters might also have been a 
better way to ensure blindness. Interestingly, few studies to my knowledge have 
carried out an extensive comparison of potential bias in fully-blinded and rater-
blinded studies of psychosis, perhaps because rater-blinded studies are less common.  
However, even a fully blinded design cannot preclude participants, clinicians and 
raters from speculating and possibly also guessing which drug has been allocated, 
especially in cases where the pharmacological profiles of study drugs differ. For 
instance olanzapine is known to lead to more fatigue and weight gain than other drugs 
(Ratzoni et al., 2002). It is also notable that the majority of double-blinded studies fail 
to report methods or success indicators of concealment (Leucht et al., 2013). A 
double-blind design would also have negated the pragmatic design intended to give 
better clinical validity and better information about efficacy. 
6.4 Antipsychotic treatment 
The naturalistic design of BPP and BP2/ Best Intro meant that both the length of 
cross-taper periods and any wash-out periods before randomization were left to the 
discretion of the attending clinician. Although these variables might be confounding 
factors, the randomization procedure would serve to evenly distribute them among 
the study drug groups.  
The study design as a head-to-head comparison of atypical antipsychotic only, with 
no placebo control, means that our data are not directly comparable to results from 
first-generation antipsychotic studies. However, a placebo controlled study would be 
unlikely to pass the Norwegian requirements for ethics in research, given the known 
efficacy of atypical antipsychotic in psychosis. Although an first-generation 
antipsychotics group might have added value to the results, this would have required 
a much larger sample, and costs of setting up a sufficiently powered trial would have 
been prohibitive.  
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For the purposes of cognition, a healthy control group was set up, but due to attrition 
in this group data from these participants were only used for Paper II in this thesis. 
It should be noted that the change in cognitive functioning described in Paper III 
happened at the same time as patients tended to come off benzodiazepines. Long-
term use of benzodiazepines are known to impact cognitive functioning, with 
impairment abating upon discontinuation of these drugs (Stewart, 2005). This should 
be considered when ascertaining how much of the overall cognitive change may be 
ascribed to atypical antipsychotics alone. However, any effects of stopping 
benzodiazepines could be expected to be evenly distributed between ITT and PP 
study medication groups, as there were no between-group differences in use of 
benzodiazepines.  
6.5 Statistical considerations 
Paper I used sequential multiple linear regression analyses to investigate cognitive 
change in acute psychosis. Multiple regression analysis allows for the examination of 
several predictors, and may thus reveal associations which might be masked by a 
series of simple regression models. The use of forwards stepwise selection was 
intended to create the most parsimonious model possible while still achieving a good 
fit to the data. This method is vulnerable to outliers (Slinker & Glantz, 2008), which 
might reasonably be expected to occur in cognitive scores from acutely ill 
participants. However, visual inspection of data indicated this was not an issue with 
our data set. 
Paper II created coordinated norms to compare UHR cognitive test performance to 
scores from two groups with schizophrenia. Z-score based norms were created based 
on a healthy control group, to allow for cross-domain comparison and age 
appropriateness for the young UHR group, for whom standardised norms do not exist 
for many tests. This was seen as a better alternative to using tests aimed at children, 
e.g. the Wechsler intelligence scale for children, which would have complicated 
comparison to adult groups. Between-group analyses were done using one-way 
ANOVAs. Although there was a greater than ideal difference in standard deviations 
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for scores between our groups, we believe this still to have been a robust choice of 
analysis. 
Paper III used linear mixed effects models (LME) which is commonly used in drug 
trials due to its robust handling of missing data and their ability to account for 
dependencies in the data due to repeated measurements from the same individuals. 
Although no longitudinal data were imputed in our model for dropped-out subjects, 
all their data up to drop-out were included in the model, and hence this strengthen the 
LME model compared to simpler models that require listwise deletion (i.e. patients 
without a complete set of observations are removed). However, LME has its own 
inherent limitations. It is more complex than more standardized models, and might 
therefore be considered less transparent and intuitive compared with the ANOVAs 
used in Paper II or multiple linear modelling as in Paper I. Still, given the high 
attrition to be expected from a drug trial with follow-up over 12 months, the ability of 
LME models to better handle missing data was considered paramount. The BP2 
attrition meant that information was clearly lost to the later follow-ups, making slopes 
of the LME analysis less certain towards the end of follow-up. However, attrition 
rates were similar across medication groups, and not related to known baseline 
characteristics.  
The advantage of LME models is their ability to handle both data where we have 
observations missing completely at random (MCAR) and missing at random (MAR). 
All model types and imputation techniques have problems if we have observations 
that are missing not at random (MNAR). The missing at random (MAR) assumption 
is difficult to verify without follow-up of the drop-outs. The uncertainty introduced 
by not collecting drop-out data would affect all types of analysis, and would best 
have been avoided by gathering data from those who did not complete the study. 
 87 
6.6 Ethical considerations 
6.6.1 Stigma and overtreatment for UHR groups 
The POP project was created in order to target psychotic disorders before the 
appearance of above-threshold positive symptoms, hoping ultimately to reduce the 
regional incidence of illness. Given the challenges in assessing risk for psychosis, 
UHR interventions inevitably end up targeting a majority of false positives. Some 
have criticized pre-psychosis intervention projects for potentially stigmatizing 
participants, as well as for possibly over-treating their mental health problems 
(Raven, Stuart, & Jureidini, 2012).  
Most UHR groups including the POP participants are help-seeking youth, often with 
a high symptom load regardless of conversion status, which we believe justify the 
interventions delivered, especially given the stepped approach where antipsychotic 
drug treatment is a rare last resort (McGorry & Mei, 2018). The experienced clinical 
team assessing potential POP participants is also able to signpost youth to wide range 
of mental health service providers, not just those targeting psychosis. In some cases, 
they are able to rule out serious mental illness and return the person to the community 
or low-threshold care. At the other end of the spectrum they may fast-track a severely 
ill person into specialized treatment. Somewhere in between these two extremes the 
average POP participants can be found: In most cases also able to get on with their 
daily lives, but in order to maintain function, it is paramount that they get appropriate 
support. The consequences of waiting for a further loss of function and potentially 
serious psychotic disorder are severe. We believe this justifies ultra-early intervention 
for this group. Although any clinical intervention will pose some interruption to a 
person’s life. However, interventions like family groups and CBT have few negative 
side effects and are also helpful for POP participants who “only” end up struggling 
with less severe mental health challenges than psychosis.  
Despite active work to reduce stigma attached to severe mental illness, schizophrenia 
remains associated with high levels of experienced stigma, alienation and shame 
(Gerlinger et al., 2013). However, we believe that the route to stigma reduction is 
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through informational work, psychosocial support, and openness rather than avoiding 
identification of youth in psychosis risk states. By providing excellent early 
intervention services we also hope to reduce the incidence of severe, untreated illness 
which is at the core of what makes schizophrenia so stigmatizing. Stigma and poor 
outcome may be related, as self-stigma is associated with lower adherence to 
treatment (Fung, Tsang, & Corrigan, 2008). A better way to achieve stigma reduction 
is to shift the public understanding of schizophrenia as associated with uniformly 
poor prognosis and an inability to meaningfully participate in society (Perkins, 
Raines, Tschopp, & Warner, 2008), which is exactly what we try to achieve by 
aiming to identify youth at risk. 
6.6.2 Inclusion before or after informed consent  
The BP2 / Bestintro and POP projects both required participants to give their 
informed consent before enrolling in the study. Informed consent poses a challenge 
for all research into severe psychotic disorder, given that psychosis affects a person’s 
ability to make qualified decisions based on objective information. Informed consent 
requires the participant to understand both the nature of the research project and what 
their participation entails. On top of symptoms such as delusions and disorganized 
thinking, the cognitive symptoms with which this thesis is concerned pose an 
additional obstacle to ensuring a mutual understanding of participation. The baseline 
part of the Bergen Psychosis project on the other hand was designed by our research 
group as a clinical site quality assurance project, and thus able to study results from 
assessments which formed part of routine hospital treatment and records for 
inpatients with psychosis. Informed consent was obtained before including 
participants in part II of the project, a research design following up patients over time.  
These contrasting approaches both have their advantages and disadvantages. 
Psychosis research requiring informed consent by nature excludes the most severely 
ill participants as these are unable to grant consent. At the same time this is a group 
for which more knowledge about how to help them is absolutely vital. However, the 
inclusion procedure of BPP might arguably be ethically problematic as data is 
gathered from participants without their agreement.  
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7. CONCLUSION 
Cognitive improvement may be identified in groups at high risk of psychosis, though 
at an attenuated level compared to groups with established schizophrenia (Paper II), 
Cognitive performance improves during early recovery from acute phase psychosis 
(Paper I). Improvement is unrelated to both baseline positive symptom load and 
change, and thus does not appear to merely reflect a reduction in potentially 
distracting other symptoms. Paper III replicated the finding of early acute phase 
improvement, and also found that this improvement continues at a slower pace 
throughout the first year after the initiation of antipsychotic treatment. However, the 
three antipsychotic drugs trialled in this thesis appeared to have similar associations 
with cognitive change, with no drug significantly outperforming the others. 
Seen together, this indicates that cognitive impairment is not a stable or uniform trait 
within each individual. Fluctuations and improvement in cognitive functioning 
happens not only in early psychotic disorder but also in established schizophrenia 
(Paper III). However, the existence of cognitive impairment in UHR indicates that 
impairment is not a temporary related to full-blown psychotic episodes. It should also 
be noted that in Paper III, 17% of participants still scored at least 1.5SD below the 
population mean at the ultimate follow-up 12 months, thus fulfilling our criteria for 
cognitive impairment. Although positive change does happen during recovery, this 
indicates that normal functioning may not be achievable for all.  
A possible way to reconcile the findings of cognitive impairment in psychosis as 
pervasive yet changing, is to assume that different trajectories exist between various 
aspects of cognition. They may develop differently, with some more affected by 
periods of active psychosis, and others more stable throughout. Although a decrement 
in functioning remains for many well past the acute phase, the majority of 
participants in Paper III (73%) scored above our cut-off for cognitive impairment 12 
months after inclusion in the study. In other words, many people with psychosis do 
recover towards the population norm, even if we do not know if they still showed a 
decrement relative to earlier individual functioning. This knowledge should inform a 
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message of hope to patients, and also encourage the development of targeted 
interventions for cognitive impairment in psychosis. These may in turn strengthen a 
person’s ability to understand, adhere to and benefit from other interventions and 
treatment options. 
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8. FUTURE PERSPECTIVES 
I have noticed while working on this thesis that qualitative studies of cognition in 
schizophrenia are very scarce. Given that this is such a central aspect of psychotic 
disorders in general and schizophrenia in particular, we need to know more about 
how people with psychosis experience their cognitive functioning with its strengths 
and weaknesses. Such knowledge could perhaps in turn inform the improvement of 
targeted interventions aiming to relieve subjective distress associated with cognitive 
issues. 
Another issue pertaining to perspectives on cognitive impairment is that despite 
notable exceptions, the field suffers from a relative lack of non-Western studies. The 
WHO estimates that at least 69% of those with schizophrenia receive appropriate care 
(Lora et al., 2012). Out of those that do not, 90% live in low- to middle- income 
countries where access to mental health services may be poor (WHO, 2020). The vast 
majority of schizophrenia research has studied the minority of people who access 
care, especially those who live in wealthy, Western societies. We need to investigate 
whether our truths about schizophrenia are representative of the large proportion of 
people not included in this relatively privileged group. Low- and middle- income 
countries have established promising primary health care services for psychotic 
disorders, where life and social skills training forms an important part of a recovery-
oriented approach. Knowledge about cognitive impairment and its importance to 
recovery is cheap to disseminate and might bolster the success rate of such 
programmes. Cognitive remediation interventions aiming to improve social cognition 
skills may be one avenue to explore. 
Also of interest would be further longitudinal explorations of potentially different 
individual trajectories of cognitive functioning from the UHR stage through acute 
psychosis and beyond, to look at what identifies whether subgroups of individuals 
improve, worsen, or remain stable in their cognitive impairment. One interesting 
angle would be the connection between emotion regulation and cognitive skills, and 
how it affects functioning. Closely related to this would be an exploration of how 
 92
early life trauma affects both emotion regulation, stress reactivity and cognition in 
psychosis.  
 
As for specific aspects of psychosis and cognition, cognition and motivation have 
often been studied separately. However, although motivation is linked to avolition 
and is an integral part of negative symptoms as they are currently conceptualized, it 
may be more closely associated with cognitive impairment than hitherto thought. The 
possibility of dopaminergic dysfunction affecting both of these phenomena is clear, 
and this overlap or interaction deserves research attention (Green & Harvey, 2014). A 
criticism levelled 20 years ago at research looking at cognitive impairment in 
psychosis was that it was too atheoretical (Green, Kern, Braff, & Mintz, 2000). To 
some extent this is still the case. However, the opportunity to view cognitive 
impairment to a greater extent in the light of more recent neurological, genetic, and 
psychological knowledge may pave the way for a more integrated approach. 
 93 
9. REFERENCES 
Addington, J., van Mastrigt, S., & Addington, D. (2003). Patterns of premorbid 
functioning in first-episode psychosis: initial presentation. Schizophrenia 
Research, 62(1), 23-30. doi:https://doi.org/10.1016/S0920-9964(02)00408-5 
Agid, O., Arenovich, T., Sajeev, G., Zipursky, R. B., Kapur, S., Foussias, G., & 
Remington, G. (2011). An algorithm-based approach to first-episode 
schizophrenia: response rates over 3 prospective antipsychotic trials with a 
retrospective data analysis. The Journal of clinical psychiatry, 72(11), 1439-
1444. doi:10.4088/jcp.09m05785yel 
Alderson, H. L., Semple, D. M., Blayney, C., Queirazza, F., Chekuri, V., & Lawrie, 
S. M. (2017). Risk of transition to schizophrenia following first admission 
with substance-induced psychotic disorder: a population-based longitudinal 
cohort study. Psychological medicine, 47(14), 2548-2555. 
doi:10.1017/S0033291717001118 
Aleman, A., Enriquez-Geppert, S., Knegtering, H., & Dlabac-de Lange, J. J. (2018). 
Moderate effects of noninvasive brain stimulation of the frontal cortex for 
improving negative symptoms in schizophrenia: Meta-analysis of controlled 
trials. Neuroscience & Biobehavioral Reviews, 89, 111-118. 
doi:https://doi.org/10.1016/j.neubiorev.2018.02.009 
Álvarez-Jiménez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. F. 
(2009). Preventing the Second Episode: A Systematic Review and Meta-
analysis of Psychosocial and Pharmacological Trials in First-Episode 
psychosis. Schizophrenia Bulletin, 37(3), 619-630. doi:10.1093/schbul/sbp129 
Alvarez-Jimenez, M., Priede, A., Hetrick, S. E., Bendall, S., Killackey, E., Parker, A. 
G., . . . Gleeson, J. F. (2012). Risk factors for relapse following treatment for 
first episode psychosis: A systematic review and meta-analysis of longitudinal 
studies. Schizophrenia Research, 139(1), 116-128. 
doi:https://doi.org/10.1016/j.schres.2012.05.007 
American Psychiatric Association. (2000). Diagnostic and statistical manual of 
mental disorders: DSM-IV-TR. Washington, DC, USA. 
American Psychiatric Association. (2013). Diagnostic and statistical manual of 
mental disorders : DSM-5. 
APA. (2006). American Psychiatric Association Practice Guidelines for the 
treatment of psychiatric disorders: Compendium: American Psychiatric Pub. 
Austin, S. F., Mors, O., Budtz-Jørgensen, E., Secher, R. G., Hjorthøj, C. R., 
Bertelsen, M., . . . Nordentoft, M. (2015). Long-term trajectories of positive 
and negative symptoms in first episode psychosis: A 10year follow-up study in 
the OPUS cohort. Schizophrenia Research, 168(1), 84-91. 
doi:https://doi.org/10.1016/j.schres.2015.07.021 
Baddeley, A. D. (2002). Is working memory still working? European psychologist, 
7(2), 85.  
Barch, D. M., & Ceaser, A. (2012). Cognition in schizophrenia: core psychological 
and neural mechanisms. Trends in Cognitive Sciences, 16(1), 27-34. 
doi:https://doi.org/10.1016/j.tics.2011.11.015 
 94
Barder, H. E., Sundet, K., Rund, B. R., Evensen, J., Haahr, U., Ten Velden Hegelstad, 
W., . . . Friis, S. (2013). Ten year neurocognitive trajectories in first-episode 
psychosis. Frontiers in human neuroscience, 7, 643-643. 
doi:10.3389/fnhum.2013.00643 
Bark, N. M. (1985). Did Shakespeare know Schizophrenia?: The Case of Poor Mad 
Tom in King Lear. British Journal of Psychiatry, 146(4), 436-438. 
doi:10.1192/bjp.146.4.436 
Barnett, J. H., Salmond, C. H., Jones, P. B., & Sahakian, B. J. (2006). Cognitive 
reserve in neuropsychiatry. Psychological medicine, 36(8), 1053-1064. 
doi:10.1017/S0033291706007501 
Beiser, M., Erickson, D., Fleming, J., & Iacono, W. G. (1993). Establishing the onset 
of psychotic illness. American Journal ofPsychiatry, 150, 1349-1354.  
Benedict, R. H., Schretlen, D., Groninger, L., & Brandt, J. (1998). Hopkins Verbal 
Learning Test–Revised: Normative data and analysis of inter-form and test-
retest reliability. The Clinical Neuropsychologist, 12(1), 43-55.  
Bentall, R. P. (2004). Madness explained: Psychosis and human nature: Penguin UK. 
Bergé, D., Carmona, S., Rovira, M., Bulbena, A., Salgado, P., & Vilarroya, O. 
(2011). Gray matter volume deficits and correlation with insight and negative 
symptoms in first‐psychotic‐episode subjects. Acta Psychiatrica Scandinavica, 
123(6), 431-439.  
Berman, A. H., Bergman, H., Palmstierna, T., & Schlyter, F. (2005). Evaluation of 
the Drug Use Disorders Identification Test (DUDIT) in criminal justice and 
detoxification settings and in a Swedish population sample. European 
addiction research, 11(1), 22-31.  
Berman, A. H., Palmstierna, T., Källmén, H., & Bergman, H. (2007). The self-report 
drug use disorders identification test—extended (DUDIT-E): reliability, 
validity, and motivational index. Journal of Substance Abuse Treatment, 
32(4), 357-369.  
Bilder, R. M., Lipschutz-Broch, L., Reiter, G., Geisler, S. H., Mayerhoff, D. I., & 
Lieberman, J. A. (1992). Intellectual Deficits in First-Episode Schizophrenia: 
Evidence for Progressive Deterioration. Schizophrenia Bulletin, 18(3), 437-
448. doi:10.1093/schbul/18.3.437 
Birchwood, M., Todd, P., & Jackson, C. (1998). Early intervention in psychosis. The 
critical period hypothesis. Br J Psychiatry Suppl, 172(33), 53-59. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/9764127 
Bjornestad, J., Davidson, L., Joa, I., Larsen, T. K., Hegelstad, W. t. V., Langeveld, J., 
. . . Bronnick, K. (2017). Antipsychotic treatment: experiences of fully 
recovered service users. Journal of Mental Health, 26(3), 264-270. 
doi:10.1080/09638237.2017.1294735 
Bonnett, L. J., Varese, F., Smith, C. T., Flores, A., & Yung, A. R. (2019). 
Individualised prediction of psychosis in individuals meeting at-risk mental 
state (ARMS) criteria: protocol for a systematic review of clinical prediction 
models. Diagnostic and Prognostic Research, 3(1), 21. doi:10.1186/s41512-
019-0066-5 
 95 
Bora, E. (2015). Neurodevelopmental origin of cognitive impairment in 
schizophrenia. Psychological medicine, 45(1), 1-9. 
doi:10.1017/S0033291714001263 
Bora, E., Yucel, M., & Pantelis, C. (2009). Cognitive functioning in schizophrenia, 
schizoaffective disorder and affective psychoses: meta-analytic study. British 
Journal of Psychiatry, 195(6), 475-482. doi:10.1192/bjp.bp.108.055731 
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Vieta, E., & Carvalho, A. F. (2015). 
Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic 
review of meta-analyses. Neuropsychiatric disease and treatment, 11, 3111-
3125. doi:10.2147/NDT.S76700 
Bowie, C. R., Leung, W. W., Reichenberg, A., McClure, M. M., Patterson, T. L., 
Heaton, R. K., & Harvey, P. D. (2008). Predicting Schizophrenia Patients’ 
Real-World Behavior with Specific Neuropsychological and Functional 
Capacity Measures. Biological Psychiatry, 63(5), 505-511. 
doi:https://doi.org/10.1016/j.biopsych.2007.05.022 
Boyle, M. (2014). Schizophrenia: A scientific delusion? : Routledge. 
Bozikas, V. P., & Andreou, C. (2011). Longitudinal studies of cognition in first 
episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry, 
45(2), 93-108. doi:10.3109/00048674.2010.541418 
Brown, A. S., & Derkits, E. J. (2010). Prenatal infection and schizophrenia: a review 
of epidemiologic and translational studies. American Journal of Psychiatry, 
167(3), 261-280.  
Bryden, P. J., & Roy, E. A. (2005). A new method of administering the Grooved 
Pegboard Test: Performance as a function of handedness and sex. Brain and 
Cognition, 58(3), 258-268. doi:http://dx.doi.org/10.1016/j.bandc.2004.12.004 
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. 
A., . . . Schizophrenia Patient Outcomes Research, T. (2010). The 2009 
schizophrenia PORT psychopharmacological treatment recommendations and 
summary statements. Schizophr Bull, 36(1), 71-93. doi:10.1093/schbul/sbp116 
Burda, K., Czubak, A., Kus, K., Nowakowska, E., Ratajczak, P., & Zin, J. (2011). 
Influence of aripiprazole on the antidepressant, anxiolytic and cognitive 
functions of rats. Pharmacological Reports, 63(4), 898-907. 
doi:10.1016/S1734-1140(11)70605-3 
Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). 
The AUDIT alcohol consumption questions (AUDIT-C): an effective brief 
screening test for problem drinking. Archives of Internal Medicine, 158(16), 
1789-1795.  
Cancel, A., Comte, M., Truillet, R., Boukezzi, S., Rousseau, P.-F., Zendjidjian, X. Y., 
. . . Fakra, E. (2015). Childhood neglect predicts disorganization in 
schizophrenia through grey matter decrease in dorsolateral prefrontal cortex. 
Acta Psychiatrica Scandinavica, 132(4), 244-256. doi:10.1111/acps.12455 
Carletti, F., Woolley, J. B., Bhattacharyya, S., Perez-Iglesias, R., Fusar Poli, P., 
Valmaggia, L., . . . McGuire, P. K. (2012). Alterations in white matter evident 
before the onset of psychosis. Schizophr Bull, 38(6), 1170-1179. 
doi:10.1093/schbul/sbs053 
 96
Carrión, R. E., Walder, D. J., Auther, A. M., McLaughlin, D., Zyla, H. O., 
Adelsheim, S., . . . Cornblatt, B. A. (2018). From the psychosis prodrome to 
the first-episode of psychosis: No evidence of a cognitive decline. Journal of 
psychiatric research, 96, 231-238. 
doi:https://doi.org/10.1016/j.jpsychires.2017.10.014 
Carroll, L. S., & Owen, M. J. (2009). Genetic overlap between autism, schizophrenia 
and bipolar disorder. Genome medicine, 1(10), 102.  
Caton, C. L., Hasin, D. S., Shrout, P. E., Drake, R. E., Dominguez, B., First, M. B., . . 
. Schanzer, B. (2007). Stability of early-phase primary psychotic disorders 
with concurrent substance use and substance-induced psychosis. The British 
Journal of Psychiatry, 190(2), 105-111.  
Chesney, E., Goodwin, G. M., & Fazel, S. (2014). Risks of all-cause and suicide 
mortality in mental disorders: a meta-review. World Psychiatry, 13(2), 153-
160. doi:10.1002/wps.20128 
Chew, M. L., Mulsant, B. H., Pollock, B. G., Lehman, M. E., Greenspan, A., 
Kirshner, M. A., . . . Gharabawi, G. (2006). A model of anticholinergic 
activity of atypical antipsychotic medications. Schizophrenia Research, 88(1), 
63-72. doi:https://doi.org/10.1016/j.schres.2006.07.011 
Chong, H. Y., Teoh, S. L., Wu, D. B.-C., Kotirum, S., Chiou, C.-F., & 
Chaiyakunapruk, N. (2016). Global economic burden of schizophrenia: a 
systematic review. Neuropsychiatric disease and treatment, 12, 357.  
Chua, S. E., & McKenna, P. J. (1995). Schizophrenia--a brain disease? A critical 
review of structural and functional cerebral abnormality in the disorder. Br J 
Psychiatry, 166(5), 563-582. doi:10.1192/bjp.166.5.563 
Conley, R. R., Ascher-Svanum, H., Zhu, B., Faries, D. E., & Kinon, B. J. (2007). The 
burden of depressive symptoms in the long-term treatment of patients with 
schizophrenia. Schizophrenia Research, 90(1), 186-197. 
doi:https://doi.org/10.1016/j.schres.2006.09.027 
Crumlish, N., Whitty, P., Clarke, M., Browne, S., Kamali, M., Gervin, M., . . . 
Larkin, C. (2009). Beyond the critical period: longitudinal study of 8-year 
outcome in first-episode non-affective psychosis. The British Journal of 
Psychiatry, 194(1), 18-24.  
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, 
R. S. E., . . . Rybakowski, J. K. (2009). Cognitive effects of antipsychotic 
drugs in first-episode schizophrenia and schizophreniform disorder: a 
randomized, open-label clinical trial (EUFEST). American Journal of 
Psychiatry, 166(6), 675-682.  
de Gracia Dominguez, M., Viechtbauer, W., Simons, C. J., van Os, J., & 
Krabbendam, L. (2009). Are psychotic psychopathology and neurocognition 
orthogonal? A systematic review of their associations. Psychological Bulletin, 
135(1), 157.  
Delis, D., Kramer, J., Kaplan, E., & Ober, B. (2000). CVLT-II. The Psychological 
Corporation.  
Delis, D., Kramer, J. H., Kaplan, E., & Holdnack, J. (2004). Reliability and validity 
of the Delis-Kaplan Executive Function System: an update. Journal of the 
International Neuropsychological Society, 10(2), 301-303.  
 97 
Désaméricq, G., Schurhoff, F., Meary, A., Szöke, A., Macquin-Mavier, I., Bachoud-
Lévi, A., & Maison, P. (2014). Long-term neurocognitive effects of 
antipsychotics in schizophrenia: a network meta-analysis. European journal of 
clinical pharmacology, 70(2), 127-134.  
Dickerson, F., Stallings, C., Origoni, A., Schroeder, J., Katsafanas, E., Schweinfurth, 
L., . . . Yolken, R. (2015). Inflammatory Markers in Recent Onset Psychosis 
and Chronic Schizophrenia. Schizophrenia Bulletin, 42(1), 134-141. 
doi:10.1093/schbul/sbv108 
Dickinson, D., Ramsey, M. E., & Gold, J. M. (2007). Overlooking the obvious: a 
meta-analytic comparison of digit symbol coding tasks and other cognitive 
measures in schizophrenia. Arch Gen Psychiatry, 64(5), 532-542. 
doi:10.1001/archpsyc.64.5.532 
Dieset, I., Andreassen, O. A., & Haukvik, U. K. (2016). Somatic Comorbidity in 
Schizophrenia: Some Possible Biological Mechanisms Across the Life Span. 
Schizophrenia Bulletin, 42(6), 1316-1319. doi:10.1093/schbul/sbw028 
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014). Second-generation 
antipsychotics and extrapyramidal adverse effects. BioMed research 
international, 2014.  
Dixon, L. B., Lehman, A. F., & Levine, J. (1995). Conventional antipsychotic 
medications for schizophrenia. Schizophr Bull, 21(4), 567-577. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8749885 
Dykens, E. M., Shah, B., Davis, B., Baker, C., Fife, T., & Fitzpatrick, J. (2015). 
Psychiatric disorders in adolescents and young adults with Down syndrome 
and other intellectual disabilities. Journal of neurodevelopmental disorders, 
7(1), 9.  
Elkis, H., Friedman, L., Wise, A., & Meltzer, H. Y. (1995). Meta-analyses of Studies 
of Ventricular Enlargement and Cortical Sulcal Prominence in Mood 
Disorders: Comparisons With Controls or Patients With Schizophrenia. 
Archives of General Psychiatry, 52(9), 735-746. 
doi:10.1001/archpsyc.1995.03950210029008 
Emsley, R., Rabinowitz, J., & Torreman, M. (2003). The factor structure for the 
Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. 
Schizophrenia Research, 61(1), 47-57. doi:https://doi.org/10.1016/S0920-
9964(02)00302-X 
Evensen, S., Wisløff, T., Lystad, J. U., Bull, H., Ueland, T., & Falkum, E. (2015). 
Prevalence, employment rate, and cost of schizophrenia in a high-income 
welfare society: a population-based study using comprehensive health and 
welfare registers. Schizophrenia Bulletin, 42(2), 476-483.  
Falkai, P., Rossner, M. J., Schulze, T., Hasan, A., Brzózka, M. M., Malchow, B., . . . 
Schmitt, A. (2015). Kraepelin revisited: schizophrenia from degeneration to 
failed regeneration. Molecular psychiatry, 20(6), 671.  
Falkenberg, I., Valmaggia, L., Byrnes, M., Frascarelli, M., Jones, C., Rocchetti, M., . 
. . Fusar-Poli, P. (2015). Why are help-seeking subjects at ultra-high risk for 
psychosis help-seeking? Psychiatry research, 228(3), 808-815. 
doi:http://dx.doi.org/10.1016/j.psychres.2015.05.018 
 98
Faria, M. A., Jr. (2013). Violence, mental illness, and the brain - A brief history of 
psychosurgery: Part 1 - From trephination to lobotomy. Surgical neurology 
international, 4, 49-49. doi:10.4103/2152-7806.110146 
Fervaha, G., Foussias, G., Agid, O., & Remington, G. (2014). Impact of primary 
negative symptoms on functional outcomes in schizophrenia. European 
Psychiatry, 29(7), 449-455. doi:https://doi.org/10.1016/j.eurpsy.2014.01.007 
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (1997). User's guide for 
the Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician 
version: American Psychiatric Pub. 
Fitzsimmons, J., Kubicki, M., & Shenton, M. E. (2013). Review of functional and 
anatomical brain connectivity findings in schizophrenia. Current opinion in 
psychiatry, 26(2), 172-187. doi:10.1097/YCO.0b013e32835d9e6a 
Foussias, G., & Remington, G. (2008). Negative symptoms in schizophrenia: 
avolition and Occam's razor. Schizophrenia Bulletin, 36(2), 359-369.  
Foussias, G., Siddiqui, I., Fervaha, G., Mann, S., McDonald, K., Agid, O., . . . 
Remington, G. (2015). Motivated to do well: An examination of the 
relationships between motivation, effort, and cognitive performance in 
schizophrenia. Schizophrenia Research, 166(1–3), 276-282. 
doi:http://dx.doi.org/10.1016/j.schres.2015.05.019 
Fung, K. M. T., Tsang, H. W. H., & Corrigan, P. W. (2008). Self-stigma of people 
with schizophrenia as predictor of their adherence to psychosocial treatment. 
Psychiatric Rehabilitation Journal, 32(2), 95-104. 
doi:10.2975/32.2.2008.95.104 
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., & et al. (2013). The psychosis high-risk 
state: A comprehensive state-of-the-art review. JAMA Psychiatry, 70(1), 107-
120. doi:10.1001/jamapsychiatry.2013.269 
Fusar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A. R., Howes, O., . . . 
Borgwardt, S. (2012). Cognitive functioning in prodromal psychosis: a meta-
analysis. Archives of General Psychiatry, 69(6), 562-571. Retrieved from 
http://archpsyc.jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/236
51/yma110002_562_571.pdf 
Fusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M. C., . . . 
McGuire, P. K. (2010). Abnormal frontostriatal interactions in people with 
prodromal signs of psychosis: a multimodal imaging study. Arch Gen 
Psychiatry, 67(7), 683-691. doi:10.1001/archgenpsychiatry.2010.77 
Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., 
& McGuire, P. (2014). Treatments of Negative Symptoms in Schizophrenia: 
Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophrenia 
Bulletin, 41(4), 892-899. doi:10.1093/schbul/sbu170 
Fusar-Poli, P., Schultze-Lutter, F., Cappucciati, M., Rutigliano, G., Bonoldi, I., Stahl, 
D., . . . Perkins, D. O. (2016). The dark side of the moon: meta-analytical 
impact of recruitment strategies on risk enrichment in the clinical high risk 
state for psychosis. Schizophrenia Bulletin, 42(3), 732-743.  
Gallhofer, B., Bauer, U., Lis, S., Krieger, S., & Gruppe, H. (1996). Cognitive 
dysfunction in schizophrenia: comparison of treatment with atypical 
antipsychotic agents and conventional neuroleptic drugs. European 
 99 
Neuropsychopharmacology, 6, 13-20. doi:https://doi.org/10.1016/0924-
977X(96)00010-7 
Gerlinger, G., Hauser, M., De Hert, M., Lacluyse, K., Wampers, M., & Correll, C. U. 
(2013). Personal stigma in schizophrenia spectrum disorders: a systematic 
review of prevalence rates, correlates, impact and interventions. World 
Psychiatry, 12(2), 155-164. doi:10.1002/wps.20040 
Giuliano, A. J., Li, H., I. Mesholam-Gately, R., M. Sorenson, S., A. Woodberry, K., 
& J. Seidman, L. (2012). Neurocognition in the Psychosis Risk Syndrome: A 
Quantitative and Qualitative Review. Current pharmaceutical design, 18(4), 
399-415. doi:10.2174/138161212799316019 
Gold, J. M., Queern, C., Iannone, V. N., & Buchanan, R. W. (1999). Repeatable 
battery for the assessment of neuropsychological status as a screening test in 
schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry, 156(12), 
1944-1950. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10588409 
González-Blanch, C., Perez-Iglesias, R., Pardo-García, G., Rodríguez-Sánchez, J., 
Martínez-García, O., Vázquez-Barquero, J., & Crespo-Facorro, B. (2010). 
Prognostic value of cognitive functioning for global functional recovery in 
first-episode schizophrenia. Psychological medicine, 40(06), 935-944.  
Green, M. F. (1996). What are the functional consequences of neurocognitive deficits 
in schizophrenia? The American journal of psychiatry.  
Green, M. F., & Harvey, P. D. (2014). Cognition in schizophrenia: Past, present, and 
future. Schizophrenia Research: Cognition, 1(1), e1-e9. 
doi:https://doi.org/10.1016/j.scog.2014.02.001 
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive Deficits 
and Functional Outcome in Schizophrenia: Are We Measuring the “Right 
Stuff”? Schizophrenia Bulletin, 26(1), 119-136. 
doi:10.1093/oxfordjournals.schbul.a033430 
Green, M. F., Kern, R. S., & Heaton, R. K. (2004). Longitudinal studies of cognition 
and functional outcome in schizophrenia: implications for MATRICS. 
Schizophrenia Research, 72(1), 41-51.  
Greenwood, T. A., Braff, D. L., Light, G. A., & et al. (2007). Initial heritability 
analyses of endophenotypic measures for schizophrenia: The consortium on 
the genetics of schizophrenia. Archives of General Psychiatry, 64(11), 1242-
1250. doi:10.1001/archpsyc.64.11.1242 
Gundersen, Ø. H., Gundersen, Ø. H., Mordal, J., Berman, A. H., & Bramness, J. G. 
(2013). Evaluation of the Alcohol Use Disorders Identification Test and the 
Drug Use Disorders Identification Test among Patients at a Norwegian 
Psychiatric Emergency Ward. European addiction research, 19(5), 252-260. 
doi:10.1159/000343485 
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. 
(1993). Improvement in cognitive functions and psychiatric symptoms in 
treatment-refractory schizophrenic patients receiving clozapine. Biological 
Psychiatry, 34(10), 702-712.  
Hambrecht, M., Lammertink, M., Klosterkötter, J., Matuschek, E., & Pukrop, R. 
(2002). Subjective and objective neuropsychological abnormalities in a 
 100
psychosis prodrome clinic. British Journal of Psychiatry, 181(S43), s30-s37. 
doi:10.1192/bjp.181.43.s30 
Hartmann, J. A., Schmidt, S. J., McGorry, P. D., Berger, M. E., Berger, G. E., Chen, 
E. Y. H., . . . Nelson, B. (2019). Trajectories of symptom severity and 
functioning over a three-year period in a psychosis high-risk sample: A 
secondary analysis of the Neurapro trial. Behaviour research and therapy, 
103527. doi:https://doi.org/10.1016/j.brat.2019.103527 
Heaton, R. K., Gladsjo, J. A., Palmer, B. W., Kuck, J., Marcotte, T. D., & Jeste, D. V. 
(2001). Stability and course of neuropsychological deficits in schizophrenia. 
Archives of General Psychiatry, 58(1), 24.  
Heaton, R. K., Grant, I., & Matthews, C. G. (1991). Comprehensive norms for an 
expanded Halstead-Reitan battery: demographic corrections, research 
findings, and clinical applications; with a supplement for the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R): Psychological Assessment Resources. 
Heaton, R. K., Paulsen, J. S., McAdams, L. A., Kuck, J., Zisook, S., Braff, D., . . . 
Jeste, D. V. (1994). Neuropsychological Deficits in Schizophrenics: 
Relationship to Age, Chronicity, and Dementia. Archives of General 
Psychiatry, 51(6), 469-476. doi:10.1001/archpsyc.1994.03950060033003 
Heaton, R. K., & Pendleton, M. G. (1981). Use of Neuropsychological tests to predict 
adult patients' everyday functioning. Journal of consulting and clinical 
psychology, 49(6), 807.  
Hedden, S. L., Woolson, R. F., Carter, R. E., Palesch, Y., Upadhyaya, H. P., & 
Malcolm, R. J. (2009). The impact of loss to follow-up on hypothesis tests of 
the treatment effect for several statistical methods in substance abuse clinical 
trials. J Subst Abuse Treat, 37(1), 54-63. doi:S0740-5472(08)00159-1 [pii] 
10.1016/j.jsat.2008.09.011 
Hegelstad, W. t. V., Joa, I., Heitmann, L., Johannessen, J. O., & Langeveld, J. (2019). 
Job- and schoolprescription: A local adaptation to individual placement and 
support for first episode psychosis. Early intervention in psychiatry, 13(4), 
859-866. doi:10.1111/eip.12686 
Heinrichs, R. W., & Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: 
a quantitative review of the evidence. Neuropsychology, 12(3), 426-445.  
Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006). Why 
olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine 
beats olanzapine: an exploratory analysis of head-to-head comparison studies 
of second-generation antipsychotics. American Journal of Psychiatry, 163(2), 
185-194.  
Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granström, O., & De Hert, M. 
(2013). Medication adherence in schizophrenia: factors influencing adherence 
and consequences of nonadherence, a systematic literature review. Therapeutic 
Advances in Psychopharmacology, 3(4), 200-218. 
doi:10.1177/2045125312474019 
Hildebrand, M., & Noteborn, M. G. C. (2015). Exploration of the (Interrater) 
Reliability and Latent Factor Structure of the Alcohol Use Disorders 
Identification Test (AUDIT) and the Drug Use Disorders Identification Test 
 101 
(DUDIT) in a Sample of Dutch Probationers. Substance Use & Misuse, 
50(10), 1294-1306. doi:10.3109/10826084.2014.998238 
Hilker, R., Helenius, D., Fagerlund, B., Skytthe, A., Christensen, K., Werge, T. M., . . 
. Glenthøj, B. (2018). Heritability of Schizophrenia and Schizophrenia 
Spectrum Based on the Nationwide Danish Twin Register. Biological 
Psychiatry, 83(6), 492-498. doi:10.1016/j.biopsych.2017.08.017 
Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years of 
potential life lost and life expectancy in schizophrenia: a systematic review 
and meta-analysis. The Lancet Psychiatry, 4(4), 295-301. 
doi:https://doi.org/10.1016/S2215-0366(17)30078-0 
Hor, K., & Taylor, M. (2010). Review: Suicide and schizophrenia: a systematic 
review of rates and risk factors. Journal of Psychopharmacology, 24(4_suppl), 
81-90. doi:10.1177/1359786810385490 
Hou, C.-L., Xiang, Y.-T., Wang, Z.-L., Everall, I., Tang, Y., Yang, C., . . . Jia, F.-J. 
(2016). Cognitive functioning in individuals at ultra-high risk for psychosis, 
first-degree relatives of patients with psychosis and patients with first-episode 
schizophrenia. Schizophrenia Research, 174(1-3), 71-76.  
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & 
Kapur, S. (2012). The nature of dopamine dysfunction in schizophrenia and 
what this means for treatment. Arch Gen Psychiatry, 69(8), 776-786. 
doi:10.1001/archgenpsychiatry.2012.169 
Howes, O. D., & Kapur, S. (2009). The Dopamine Hypothesis of Schizophrenia: 
Version III—The Final Common Pathway. Schizophrenia Bulletin, 35(3), 549-
562. doi:10.1093/schbul/sbp006 
Howes, O. D., & Nour, M. M. (2016). Dopamine and the aberrant salience hypothesis 
of schizophrenia. World Psychiatry, 15(1), 3.  
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, 
N., . . . Cipriani, A. (2019). Comparative efficacy and tolerability of 32 oral 
antipsychotics for the acute treatment of adults with multi-episode 
schizophrenia: a systematic review and network meta-analysis. The Lancet, 
394(10202), 939-951.  
Hutton, P., & Taylor, P. J. (2014). Cognitive behavioural therapy for psychosis 
prevention: a systematic review and meta-analysis. Psychological medicine, 
44(3), 449-468. doi:10.1017/S0033291713000354 
Institute for Health Metrics and Evaluation. (2019). Global Burden of Disease Tool. 
Retrieved from http://ghdx.healthdata.org/gbd-results-tool 
Iyer, S. N., Mangala, R., Anitha, J., Thara, R., & Malla, A. K. (2011). An 
examination of patient‐identified goals for treatment in a first‐episode 
programme in Chennai, India. Early intervention in psychiatry, 5(4), 360-365.  
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., . . . 
Murray, C. J. L. (2018). Global, regional, and national incidence, prevalence, 
and years lived with disability for 354 diseases and injuries for 195 countries 
and territories, 1990–2017: a systematic analysis for the Global Burden of 
Disease Study 2017. The Lancet, 392(10159), 1789-1858. 
doi:https://doi.org/10.1016/S0140-6736(18)32279-7 
 102
Jauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Laws, K. R. (2014). 
Cognitive–behavioural therapy for the symptoms of schizophrenia: systematic 
review and meta-analysis with examination of potential bias. British Journal 
of Psychiatry, 204(1), 20-29. doi:10.1192/bjp.bp.112.116285 
Jirsaraie, R. J., Sheffield, J. M., & Barch, D. M. (2018). Neural correlates of global 
and specific cognitive deficits in schizophrenia. Schizophrenia Research, 201, 
237-242. doi:https://doi.org/10.1016/j.schres.2018.06.017 
Joa, I., Gisselgård, J., Brønnick, K., McGlashan, T. H., & Johannessen, J. O. (2015). 
Primary prevention of psychosis through interventions in the symptomatic 
prodromal phase, a pragmatic Norwegian Ultra High Risk study. BMC 
psychiatry, 15(1), 89.  
Joa, I., Johannessen, J. O., Larsen, T. K., & McGlashan, T. H. (2008). Information 
campaigns: 10 years of experience in the Early Treatment and Intervention in 
Psychosis (TIPS) study. Psychiatric Annals, 38(8).  
Johnstone, E., Frith, C., Crow, T., Husband, J., & Kreel, L. (1976). Cerebral 
ventricular size and cognitive impairment in chronic schizophrenia. The 
Lancet, 308(7992), 924-926.  
Kahn, R. S., & Keefe, R. S. E. (2013). Schizophrenia is a cognitive illness: time for a 
change in focus. JAMA Psychiatry, 70(10), 1107-1112.  
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-
resistant schizophrenic: a double-blind comparison with chlorpromazine. 
Archives of General Psychiatry, 45(9), 789-796.  
Karlsgodt, K. H., Niendam, T. A., Bearden, C. E., & Cannon, T. D. (2009). White 
Matter Integrity and Prediction of Social and Role Functioning in Subjects at 
Ultra-High Risk for Psychosis. Biological Psychiatry, 66(6), 562-569. 
doi:https://doi.org/10.1016/j.biopsych.2009.03.013 
Kaufman, J., Birmaher, B., Brent, D., Rao, U. M. A., Flynn, C., Moreci, P., . . . Ryan, 
N. (1997). Schedule for Affective Disorders and Schizophrenia for School-
Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability 
and Validity Data. Journal of the American Academy of Child & Adolescent 
Psychiatry, 36(7), 980-988. doi:https://doi.org/10.1097/00004583-199707000-
00021 
Kavanagh, D. H., Tansey, K. E., O'Donovan, M. C., & Owen, M. J. (2015). 
Schizophrenia genetics: emerging themes for a complex disorder. Mol 
Psychiatry, 20(1), 72-76. doi:10.1038/mp.2014.148 
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome 
Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin, 13(2), 261-276. 
doi:10.1093/schbul/13.2.261 
Keefe, R. S. E., Bilder, R. M., Davis, S. M., & et al. (2007). Neurocognitive effects of 
antipsychotic medications in patients with chronic schizophrenia in the CATIE 
trial. Archives of General Psychiatry, 64(6), 633-647. 
doi:10.1001/archpsyc.64.6.633 
Keefe, R. S. E., Bollini, A. M., & Silva, S. G. (1999). Do novel antipsychotics 
improve cognition? A report of a meta-analysis. Psychiatric Annals, 29(11), 
623-629.  
 103 
Keefe, R. S. E., Eesley, C. E., & Poe, M. P. (2005). Defining a cognitive function 
decrement in schizophrenia. Biological Psychiatry, 57(6), 688-691.  
Keefe, R. S. E., Mohs, R. C., Bilder, R. M., Harvey, P. D., Green, M. F., Meltzer, H. 
Y., . . . Sano, M. (2003). Neurocognitive Assessment in the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) Project 
Schizophrenia Trial: Development, Methodology, and Rationale. 
Schizophrenia Bulletin, 29(1), 45-55. 
doi:10.1093/oxfordjournals.schbul.a006990 
Kemmler, G., Hummer, M., Widschwendter, C., & Fleischhacker, W. W. (2005). 
Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of 
Antipsychotic Drugs: A Meta-analysis. Archives of General Psychiatry, 
62(12), 1305-1312. doi:10.1001/archpsyc.62.12.1305 
Kern, R. S., Gold, J. M., Dickinson, D., Green, M. F., Nuechterlein, K. H., Baade, L. 
E., . . . Marder, S. R. (2011). The MCCB impairment profile for schizophrenia 
outpatients: Results from the MATRICS psychometric and standardization 
study. Schizophrenia Research, 126(1), 124-131. 
doi:https://doi.org/10.1016/j.schres.2010.11.008 
Kern, R. S., Green, M. F., Cornblatt, B. A., Owen, J. R., McQuade, R. D., Carson, W. 
H., . . . Marcus, R. (2006). The neurocognitive effects of aripiprazole: an open-
label comparison with olanzapine. Psychopharmacology, 187(3), 312-320. 
doi:10.1007/s00213-006-0428-x 
Keshavan, M. S., DeLisi, L. E., & Seidman, L. J. (2011). Early and broadly defined 
psychosis risk mental states. Schizophrenia Research, 126(1), 1-10. 
doi:https://doi.org/10.1016/j.schres.2010.10.006 
Khandaker, G. M., Barnett, J. H., White, I. R., & Jones, P. B. (2011). A quantitative 
meta-analysis of population-based studies of premorbid intelligence and 
schizophrenia. Schizophrenia Research, 132(2), 220-227. 
doi:https://doi.org/10.1016/j.schres.2011.06.017 
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. 
(2015). Inflammation and immunity in schizophrenia: implications for 
pathophysiology and treatment. The Lancet Psychiatry, 2(3), 258-270. 
doi:https://doi.org/10.1016/S2215-0366(14)00122-9 
Khoury, B., Lecomte, T., Gaudiano, B. A., & Paquin, K. (2013). Mindfulness 
interventions for psychosis: A meta-analysis. Schizophrenia Research, 150(1), 
176-184. doi:https://doi.org/10.1016/j.schres.2013.07.055 
Killackey, E., Allott, K., Woodhead, G., Connor, S., Dragon, S., & Ring, J. (2017). 
Individual placement and support, supported education in young people with 
mental illness: an exploratory feasibility study. Early intervention in 
psychiatry, 11(6), 526-531. doi:10.1111/eip.12344 
Kirkpatrick, B., & Miller, B. J. (2013). Inflammation and Schizophrenia. 
Schizophrenia Bulletin, 39(6), 1174-1179. doi:10.1093/schbul/sbt141 
Koutsouleris, N., Davatzikos, C., Bottlender, R., Patschurek-Kliche, K., 
Scheuerecker, J., Decker, P., . . . Meisenzahl, E. M. (2011). Early recognition 
and disease prediction in the at-risk mental states for psychosis using 
neurocognitive pattern classification. Schizophrenia Bulletin, 38(6), 1200-
1215.  
 104
Kraan, T., Velthorst, E., Koenders, L., Zwaart, K., Ising, H. K., van den Berg, D., . . . 
van der Gaag, M. (2016). Cannabis use and transition to psychosis in 
individuals at ultra-high risk: review and meta-analysis. Psychological 
medicine, 46(4), 673-681. doi:10.1017/S0033291715002329 
Kraan, T., Velthorst, E., Smit, F., de Haan, L., & van der Gaag, M. (2015). Trauma 
and recent life events in individuals at ultra high risk for psychosis: Review 
and meta-analysis. Schizophrenia Research, 161(2), 143-149. 
doi:https://doi.org/10.1016/j.schres.2014.11.026 
Kraepelin, E. (1919). Dementia praecox and paraphrenia (RM Barclay, Trans.). 
Huntingdon, NY: Krieger.  
Kremen, W. S., Seidman, L. J., Faraone, S. V., Toomey, R., & Tsuang, M. T. (2000). 
The paradox of normal neuropsychological function in schizophrenia. Journal 
of Abnormal Psychology, 109(4), 743.  
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010). The 
schizophrenia patient outcomes research team (PORT): updated treatment 
recommendations 2009. Schizophrenia bulletin, 36(1), 94-103.  
Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: a 
review. British Medical Bulletin, 114(1), 169-179. doi:10.1093/bmb/ldv017 
Larsen, T. K., Melle, I., Auestad, B., Haahr, U., Joa, I., Johannessen, J. O., . . . 
Simonsen, E. (2011). Early detection of psychosis: positive effects on 5-year 
outcome. Psychological medicine, 41(7), 1461-1469.  
Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014). Excess Early Mortality in 
Schizophrenia. Annual review of clinical psychology, 10(1), 425-448. 
doi:10.1146/annurev-clinpsy-032813-153657 
Lea, J. W., Stoner, S. C., & LaFollette, J. (2007). Agitation Associated with 
Aripiprazole Initiation. Pharmacotherapy: The Journal of Human 
Pharmacology and Drug Therapy, 27(9), 1339-1342. 
doi:10.1592/phco.27.9.1339 
Lencz, T., Knowles, E., Davies, G., Guha, S., Liewald, D. C., Starr, J. M., . . . 
Malhotra, A. K. (2014). Molecular genetic evidence for overlap between 
general cognitive ability and risk for schizophrenia: a report from the 
Cognitive Genomics consorTium (COGENT). Molecular psychiatry, 19(2), 
168-174. doi:10.1038/mp.2013.166 
Lepage, M., Bodnar, M., & Bowie, C. R. (2014). Neurocognition: clinical and 
functional outcomes in schizophrenia. The Canadian Journal of Psychiatry, 
59(1), 5-12.  
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., . . . Davis, J. 
M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in 
schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 
951-962. doi:https://doi.org/10.1016/S0140-6736(13)60733-3 
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). 
Second-generation versus first-generation antipsychotic drugs for 
schizophrenia: a meta-analysis. The Lancet, 373(9657), 31-41. 
doi:https://doi.org/10.1016/S0140-6736(08)61764-X 
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. 
M. (2012). Antipsychotic drugs versus placebo for relapse prevention in 
 105 
schizophrenia: a systematic review and meta-analysis. The Lancet, 379(9831), 
2063-2071.  
Lezak, M. D., Howieson, D. B., Loring, D. W., & Fischer, J. S. (2004). 
Neuropsychological assessment: Oxford University Press, USA. 
Li, S., Hu, N., Zhang, W., Tao, B., Dai, J., Gong, Y., . . . Lui, S. (2019). 
Dysconnectivity of Multiple Brain Networks in Schizophrenia: A Meta-
Analysis of Resting-State Functional Connectivity. Frontiers in Psychiatry, 
10(482). doi:10.3389/fpsyt.2019.00482 
Li, Z., Ichikawa, J., Dai, J., & Meltzer, H. Y. (2004). Aripiprazole, a novel 
antipsychotic drug, preferentially increases dopamine release in the prefrontal 
cortex and hippocampus in rat brain. European journal of pharmacology, 
493(1-3), 75-83.  
Lieberman, J. A. (1999). Is schizophrenia a neurodegenerative disorder? A clinical 
and neurobiological perspective. Biological Psychiatry, 46(6), 729-739.  
Linscott, R. J., & van Os, J. (2013). An updated and conservative systematic review 
and meta-analysis of epidemiological evidence on psychotic experiences in 
children and adults: on the pathway from proneness to persistence to 
dimensional expression across mental disorders. Psychological medicine, 
43(6), 1133-1149. doi:10.1017/S0033291712001626 
Løberg, E.-M., Gjestad, R., Posserud, M.-B., Kompus, K., & Lundervold, A. J. 
(2019). Psychosocial characteristics differentiate non-distressing and 
distressing voices in 10,346 adolescents. European child & adolescent 
psychiatry, 28(10), 1353-1363. doi:10.1007/s00787-019-01292-x 
Løberg, E.-M., & Hugdahl, K. (2009). Cannabis use and cognition in schizophrenia. 
Frontiers in human neuroscience, 3(53). doi:10.3389/neuro.09.053.2009 
Loberg, E., Langeland, M., & Jorgensen, H. (2006). Reliability and validity of a 
Norwegian translation of the repeatable battery for the assessment of 
neuropsychological status in patients with psychosis. Nevropsykologi, 9, 36.  
Lora, A., Kohn, R., Levav, I., McBain, R., Morris, J., & Saxena, S. (2012). Service 
availability and utilization and treatment gap for schizophrenic disorders: a 
survey in 50 low- and middle-income countries. Bull World Health Organ, 
90(1), 47-54, 54a-54b. doi:10.2471/blt.11.089284 
Lysaker, P. H., & Dimaggio, G. (2014). Metacognitive capacities for reflection in 
schizophrenia: implications for developing treatments. Schizophrenia Bulletin, 
40(3), 487-491.  
Malaspina, D., Owen, M. J., Heckers, S., Tandon, R., Bustillo, J., Schultz, S., . . . 
Carpenter, W. (2013). Schizoaffective Disorder in the DSM-5. Schizophrenia 
Research, 150(1), 21-25. doi:https://doi.org/10.1016/j.schres.2013.04.026 
McFarlane, W. R. (2016). Family Interventions for Schizophrenia and the Psychoses: 
A Review. Family Process, 55(3), 460-482. doi:10.1111/famp.12235 
McGlashan, T. H. (2006). Schizophrenia in Translation: Is Active Psychosis 
Neurotoxic? Schizophrenia Bulletin, 32(4), 609-613. 
doi:10.1093/schbul/sbl032 
McGlashan, T. H., & Fenton, W. S. (1993). Subtype progression and 
pathophysiologic deterioration in early schizophrenia. Schizophrenia Bulletin, 
19(1), 71-84.  
 106
McGorry, P. D., Killackey, E., & Yung, A. (2008). Early intervention in psychosis: 
concepts, evidence and future directions. World Psychiatry, 7(3), 148-156.  
McGorry, P. D., & Mei, C. (2018). Ultra-high-risk paradigm: lessons learnt and new 
directions. Evidence Based Mental Health, 21(4), 131-133. 
doi:10.1136/ebmental-2018-300061 
McGrath, M. C. (2011). Wisconsin Card Sorting Test. In S. Goldstein & J. A. 
Naglieri (Eds.), Encyclopedia of Child Behavior and Development (pp. 1571-
1572). Boston, MA: Springer US. 
Medalia, A., & Saperstein, A. M. (2013). Does cognitive remediation for 
schizophrenia improve functional outcomes? Current opinion in psychiatry, 
26(2), 151-157.  
Mednick, S. A., & McNeil, T. F. (1968). Current methodology in research on the 
etiology of schizophrenia: Serious difficulties which suggest the use of the 
high-risk-group method. Psychological Bulletin, 70(6, Pt.1), 681-693. 
doi:10.1037/h0026836 
Meltzer, H. Y. (1999). The Role of Serotonin in Antipsychotic Drug Action. 
Neuropsychopharmacology, 21(1), 106-115. doi:10.1016/S0893-
133X(99)00046-9 
Meltzer, H. Y., & McGurk, S. R. (1999). The Effects of Clozapine, Risperidone, and 
Olanzapine on Cognitive Function in Schizophrenia. Schizophrenia Bulletin, 
25(2), 233-256. doi:10.1093/oxfordjournals.schbul.a033376 
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. 
(2009). Neurocognition in first-episode schizophrenia: a meta-analytic review. 
Neuropsychology, 23(3), 315.  
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., 
Quarantelli, M., . . . Berman, K. F. (2002). Reduced prefrontal activity predicts 
exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci, 
5(3), 267-271. doi:10.1038/nn804 
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., . . . 
Young, L. J. (2012). Cognitive dysfunction in psychiatric disorders: 
characteristics, causes and the quest for improved therapy. Nature Reviews 
Drug Discovery, 11(2), 141-168. doi:10.1038/nrd3628 
Miller, B. J., Culpepper, N., Rapaport, M. H., & Buckley, P. (2013). Prenatal 
inflammation and neurodevelopment in schizophrenia: A review of human 
studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 
42, 92-100. doi:https://doi.org/10.1016/j.pnpbp.2012.03.010 
Miller, E. (1990). California computerized assessment package. Los Angeles: 
Norland Software.  
Miller, T. J., McGlashan, T. H., Rosen, J. L., Cadenhead, K., Cannon, T., Ventura, J., 
. . . Woods, S. W. (2003). Prodromal assessment with the structured interview 
for prodromal syndromes and the scale of prodromal symptoms: predictive 
validity, interrater reliability, and training to reliability. Schizophrenia 
Bulletin, 29(4), 703-715.  
Minor, K. S., & Lysaker, P. H. (2014). Necessary, but not sufficient: Links between 
neurocognition, social cognition, and metacognition in schizophrenia are 
 107 
moderated by disorganized symptoms. Schizophrenia Research, 159(1), 198-
204. doi:https://doi.org/10.1016/j.schres.2014.08.005 
Misiak, B., Krefft, M., Bielawski, T., Moustafa, A. A., Sąsiadek, M. M., & Frydecka, 
D. (2017). Toward a unified theory of childhood trauma and psychosis: A 
comprehensive review of epidemiological, clinical, neuropsychological and 
biological findings. Neuroscience & Biobehavioral Reviews, 75, 393-406. 
doi:https://doi.org/10.1016/j.neubiorev.2017.02.015 
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005). Treatments for 
schizophrenia: a critical review of pharmacology and mechanisms of action of 
antipsychotic drugs. Molecular psychiatry, 10(1), 79-104. 
doi:10.1038/sj.mp.4001556 
Møller, P., & Husby, R. (2000). The initial prodrome in schizophrenia: searching for 
naturalistic core dimensions of experience and behavior. Schizophrenia 
Bulletin, 26(1), 217.  
Mollon, J., & Reichenberg, A. (2018). Cognitive development prior to onset of 
psychosis. Psychological medicine, 48(3), 392-403. 
doi:10.1017/S0033291717001970 
Mondelli, V., Cattaneo, A., Murri, M. B., Di Forti, M., Handley, R., Hepgul, N., . . . 
Aitchison, K. J. (2011). Stress and inflammation reduce BDNF expression in 
first-episode psychosis: a pathway to smaller hippocampal volume. The 
Journal of clinical psychiatry, 72(12), 1677.  
Morin, L., & Franck, N. (2017). Rehabilitation Interventions to Promote Recovery 
from Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 8(100). 
doi:10.3389/fpsyt.2017.00100 
Mørkved, N. J., E; Kroken, RA; Gjestad, R; Winje, D; Thimm, J; Fathian, F; 
Rettenbacher, M; Anda, LG; Løberg, EM. (2020). Does childhood trauma 
influence cognitive functioning in schizophrenia? The association of childhood 
trauma and cognition in schizophrenia spectrum disorders. Schizophrenia 
Research: Cognition, 21, 100179.  
Moskowitz, A., & Heim, G. (2011). Eugen Bleuler's Dementia Praecox or the Group 
of Schizophrenias (1911): A Centenary Appreciation and Reconsideration. 
Schizophrenia Bulletin, 37(3), 471-479. doi:10.1093/schbul/sbr016 
Mueser, K. T., Drake, R. E., Clark, R. E., McHugo, G. J., Mercer-McFadden, C., & 
Ackerson, T. H. (1995). Toolkit for evaluating substance abuse in persons 
with severe mental illness. Cambridge, M: Evaluation Center, Human Services 
Research Institute. 
Mwansisya, T. E., Hu, A., Li, Y., Chen, X., Wu, G., Huang, X., . . . Liu, Z. (2017). 
Task and resting-state fMRI studies in first-episode schizophrenia: A 
systematic review. Schizophrenia Research, 189, 9-18. 
doi:https://doi.org/10.1016/j.schres.2017.02.026 
NICE. (2014). Psychosis and schizophrenia in adults. National Collaborating Centre 
for Mental Health 
Niemi-Pynttäri, J. A., Sund, R., Putkonen, H., Vorma, H., Wahlbeck, K., & Pirkola, 
S. P. (2013). Substance-induced psychoses converting into schizophrenia: a 
register-based study of 18,478 Finnish inpatient cases. The Journal of clinical 
psychiatry, 74(1), e94-99.  
 108
Norwegian Directorate of Health. (2013). Nasjonal faglig retningslinje for 
psykoselidelser.  Retrieved from 
https://www.helsedirektoratet.no/retningslinjer/psykoselidelser 
Nuechterlein, K. H., & Green, M. F. (2006). MATRICS consensus cognitive battery 
manual. Los Angeles, CA: MATRICS Assessment Inc.  
Nuechterlein, K. H., Subotnik, K. L., Green, M. F., Ventura, J., Asarnow, R. F., 
Gitlin, M. J., . . . Mintz, J. (2011). Neurocognitive Predictors of Work 
Outcome in Recent-Onset Schizophrenia. Schizophrenia Bulletin, 37(Suppl 2), 
S33-S40. doi:10.1093/schbul/sbr084 
OED. (Ed.) (n.d.-a) Oxford English Dictionary. Oxford, UK: Oxford University 
Press. 
OED. (Ed.) (n.d.-b) Oxford English Dictionary. Oxford, UK: Oxford University 
Press. 
Onwumere, J., Bebbington, P., & Kuipers, E. (2011). Family interventions in early 
psychosis: specificity and effectiveness. Epidemiology and psychiatric 
sciences, 20(2), 113-119.  
Opler, L. A., Kay, S. R., Lindenmayer, J. P., & Fiszbein, A. (1999) Structured 
clinical interview: The positive and negative syndrome scale (SCI-PANSS). 
Multi-Health Systems, North Tonawanda, NY. 
Orlovska-Waast, S., Köhler-Forsberg, O., Brix, S. W., Nordentoft, M., Kondziella, 
D., Krogh, J., & Benros, M. E. (2019). Cerebrospinal fluid markers of 
inflammation and infections in schizophrenia and affective disorders: a 
systematic review and meta-analysis. Molecular psychiatry, 24(6), 869-887. 
doi:10.1038/s41380-018-0220-4 
Ortiz-Gil, J., Pomarol-Clotet, E., Salvador, R., Canales-Rodríguez, E. J., Sarro, S., 
Gomar, J. J., . . . Junque, C. (2011). Neural correlates of cognitive impairment 
in schizophrenia. The British Journal of Psychiatry, 199(3), 202-210.  
Palmer, B. W., Dawes, S. E., & Heaton, R. K. (2009). What do we know about 
neuropsychological aspects of schizophrenia? Neuropsychology Review, 19(3), 
365-384.  
Patel, D., Laws, K., Padhi, A., Farrow, J., Mukhopadhaya, K., Krishnaiah, R., & 
Fineberg, N. (2010). The neuropsychology of the schizo-obsessive subtype of 
schizophrenia: a new analysis. Psychological medicine, 40(06), 921-933.  
Penttilä, M., Jääskeläinen, E., Hirvonen, N., Isohanni, M., & Miettunen, J. (2014). 
Duration of untreated psychosis as predictor of long-term outcome in 
schizophrenia: systematic review and meta-analysis. The British Journal of 
Psychiatry, 205(2), 88-94.  
Perkins, D. V., Raines, J. A., Tschopp, M. K., & Warner, T. C. (2008). Gainful 
Employment Reduces Stigma Toward People Recovering from Schizophrenia. 
Community Mental Health Journal, 45(3), 158. doi:10.1007/s10597-008-9158-
3 
Pinheiro, C., & Bates, D. (2000). Mixed effects models in S and S-plus. New York: 
Springer. 
Piskulic, D., Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., 
Heinssen, R., . . . McGlashan, T. H. (2012). Negative symptoms in individuals 
 109 
at clinical high risk of psychosis. Psychiatry research, 196(2), 220-224. 
doi:https://doi.org/10.1016/j.psychres.2012.02.018 
Plomin, R., & Deary, I. J. (2015). Genetics and intelligence differences: five special 
findings. Molecular psychiatry, 20(1), 98-108. doi:10.1038/mp.2014.105 
Plum, F. (1972). Prospects for research on schizophrenia. 3. Neurophysiology. 
Neuropathological findings. Neurosciences Research Program Bulletin, 10(4), 
384-388.  
Popovic, D., Benabarre, A., Crespo, J., Goikolea, J., González‐Pinto, A., Gutiérrez‐
Rojas, L., . . . Vieta, E. (2014). Risk factors for suicide in schizophrenia: 
systematic review and clinical recommendations. Acta Psychiatrica 
Scandinavica, 130(6), 418-426.  
R Core Team. (2013). R: A language and environment for statistical computing. 
Retrieved from http://www.r-project.org/ 
Rajji, T. K., Miranda, D., & Mulsant, B. H. (2014). Cognition, Function, and 
Disability in Patients With Schizophrenia: A Review of Longitudinal Studies. 
Canadian Journal of Psychiatry, 59(1), 13.  
Randolph, C. (1998). RBANS Repeatable Battery for the Assessment of 
Neuropsychological Status. Manual. . San Antonio: The Psychological 
Corporation. 
Ratzoni, G., Gothelf, D., Brand-Gothelf, A., Reidman, J., Kikinzon, L., Gal, G., . . . 
Weizman, R. (2002). Weight Gain Associated With Olanzapine and 
Risperidone in Adolescent Patients: A Comparative Prospective Study. 
Journal of the American Academy of Child & Adolescent Psychiatry, 41(3), 
337-343. doi:https://doi.org/10.1097/00004583-200203000-00014 
Raven, M., Stuart, G. W., & Jureidini, J. (2012). ‘Prodromal’ diagnosis of psychosis: 
Ethical problems in research and clinical practice. Australian & New Zealand 
Journal of Psychiatry, 46(1), 64-65. doi:10.1177/0004867411428917 
Read, J., & Sacia, A. (2020). Using Open Questions to Understand 650 People’s 
Experiences With Antipsychotic Drugs. Schizophrenia Bulletin. 
doi:10.1093/schbul/sbaa002 
Reichenberg, A., Caspi, A., Harrington, H., Houts, R., Keefe, R. S. E., Murray, R. 
M., . . . Moffitt, T. E. (2010). Static and dynamic cognitive deficits in 
childhood preceding adult schizophrenia: a 30-year study. American Journal 
of Psychiatry.  
Reichenberg, A., Harvey, P. D., Bowie, C. R., Mojtabai, R., Rabinowitz, J., Heaton, 
R. K., & Bromet, E. (2008). Neuropsychological Function and Dysfunction in 
Schizophrenia and Psychotic Affective Disorders. Schizophrenia Bulletin, 
35(5), 1022-1029. doi:10.1093/schbul/sbn044 
Reitan, R. M. (1958). Validity of the Trail Making Test as an indicator of organic 
brain damage. Perceptual and motor skills, 8(3), 271-276.  
Riedel, M., Schennach-Wolff, R., Musil, R., Dehning, S., Cerovecki, A., Opgen-
Rhein, M., . . . Spellmann, I. (2010). Neurocognition and its influencing 
factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, 
quetiapine and risperidone. Human Psychopharmacology: Clinical and 
Experimental, 25(2), 116-125. doi:10.1002/hup.1101 
 110
Riedel, M., Spellmann, I., Schennach-Wolff, R., Musil, R., Dehning, S., Cerovecki, 
A., . . . Möller, H. J. (2010). Effect of Aripiprazole on Cognition in the 
Treatment of Patients with Schizophrenia. Pharmacopsychiatry, 43(02), 50-
57. doi:10.1055/s-0029-1239539 
Rigucci, S., Santi, G., Corigliano, V., Imola, A., Rossi-Espagnet, C., Mancinelli, I., . . 
. Comparelli, A. (2016). White matter microstructure in ultra-high risk and 
first episode schizophrenia: A prospective study. Psychiatry Research: 
Neuroimaging, 247, 42-48. 
doi:https://doi.org/10.1016/j.pscychresns.2015.11.003 
Rodriguez-Toscano, E., López, G., Mayoral, M., Lewis, S., Lees, J., Drake, R., . . . 
Rapado-Castro, M. (2019). A longitudinal comparison of two neurocognitive 
test batteries in patients with schizophrenia and healthy volunteers: Time 
effects on neuropsychological performance and their relation to functional 
outcome. Schizophrenia Research. 
doi:https://doi.org/10.1016/j.schres.2019.11.018 
Ruhrmann, S., Paruch, J., Bechdolf, A., Pukrop, R., Wagner, M., Berning, J., . . . 
Klosterkötter, J. (2008). Reduced subjective quality of life in persons at risk 
for psychosis. Acta Psychiatrica Scandinavica, 117(5), 357-368. 
doi:10.1111/j.1600-0447.2008.01152.x 
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., 
. . . Leucht, S. (2012). Second-generation antipsychotic drugs and 
extrapyramidal side effects: a systematic review and meta-analysis of head-to-
head comparisons. Schizophrenia Bulletin, 38(1), 167-177.  
Rund, B. R. (1998). A Review of Longitudinal Studies of Cognitive Functions in 
Schizophrenia Patients. Schizophrenia Bulletin, 24(3), 425-435. 
doi:10.1093/oxfordjournals.schbul.a033337 
Rus-Calafell, M., & Schneider, S. (2020). Are we there yet?!-a literature review of 
recent digital technology advances for the treatment of early psychosis. 
mHealth, 6, 3-3. doi:10.21037/mhealth.2019.09.14 
Samartzis, L., Dima, D., Fusar-Poli, P., & Kyriakopoulos, M. (2014). White Matter 
Alterations in Early Stages of Schizophrenia: A Systematic Review of 
Diffusion Tensor Imaging Studies. Journal of Neuroimaging, 24(2), 101-110. 
doi:doi:10.1111/j.1552-6569.2012.00779.x 
Schaefer, J., Giangrande, E., Weinberger, D. R., & Dickinson, D. (2013). The global 
cognitive impairment in schizophrenia: consistent over decades and around the 
world. Schizophrenia Research, 150(1), 42-50.  
Schultze-Lutter, F., & Theodoridou, A. (2017). The concept of basic symptoms: its 
scientific and clinical relevance. World psychiatry : official journal of the 
World Psychiatric Association (WPA), 16(1), 104-105. doi:10.1002/wps.20404 
Seidman, L. J., Giuliano, A. J., & Meyer, E. C. (2010). Neuropsychology of the 
prodrome to psychosis in the NAPLS consortium: Relationship to family 
history and conversion to psychosis. Archives of General Psychiatry, 67(6), 
578-588. doi:10.1001/archgenpsychiatry.2010.66 
Seidman, L. J., Shapiro, D. I., Stone, W. S., Woodberry, K. A., Ronzio, A., Cornblatt, 
B. A., . . . Cannon, T. D. (2016). Association of neurocognition with transition 
 111 
to psychosis: baseline functioning in the second phase of the North American 
prodrome longitudinal study. JAMA Psychiatry, 73(12), 1239-1248.  
Sendt, K. V., Tracy, D. K., & Bhattacharyya, S. (2015). A systematic review of 
factors influencing adherence to antipsychotic medication in schizophrenia-
spectrum disorders. Psychiatry Res, 225(1-2), 14-30. 
doi:10.1016/j.psychres.2014.11.002 
Sharma, T., & Mockler, D. (1998). The Cognitive Efficacy of Atypical 
Antipsychotics in Schizophrenia. Journal of Clinical Psychopharmacology, 
18(2), 12S-19S. Retrieved from 
https://journals.lww.com/psychopharmacology/Fulltext/1998/04001/The_Cog
nitive_Efficacy_of_Atypical_Antipsychotics.4.aspx 
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., . . 
. Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview 
(M.I.N.I.): the development and validation of a structured diagnostic 
psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry, 59 Suppl 20, 
22-33;quiz 34-57. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/9881538 
Sheffield, J. M., & Barch, D. M. (2016). Cognition and resting-state functional 
connectivity in schizophrenia. Neuroscience & Biobehavioral Reviews, 61, 
108-120. doi:https://doi.org/10.1016/j.neubiorev.2015.12.007 
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001). A review of 
MRI findings in schizophrenia. Schizophrenia Research, 49(1), 1-52. 
doi:https://doi.org/10.1016/S0920-9964(01)00163-3 
Shevlin, M., McElroy, E., Bentall, R. P., Reininghaus, U., & Murphy, J. (2016). The 
psychosis continuum: testing a bifactor model of psychosis in a general 
population sample. Schizophrenia Bulletin, 43(1), 133-141.  
Shim, G., Oh, J. S., Jung, W. H., Jang, J. H., Choi, C.-H., Kim, E., . . . Kwon, J. S. 
(2010). Altered resting-state connectivity in subjects at ultra-high risk for 
psychosis: an fMRI study. Behavioral and Brain Functions, 6(1), 58.  
Shin, M.-S., Park, S.-Y., Park, S.-R., Seol, S.-H., & Kwon, J. S. (2006). Clinical and 
empirical applications of the Rey–Osterrieth complex figure test. Nature 
protocols, 1(2), 892-899.  
Simon, A. E., & Umbricht, D. (2010). High remission rates from an initial ultra-high 
risk state for psychosis. Schizophrenia Research, 116(2), 168-172. 
doi:https://doi.org/10.1016/j.schres.2009.10.001 
Simon, A. E., Velthorst, E., Nieman, D. H., Linszen, D., Umbricht, D., & de Haan, L. 
(2011). Ultra high-risk state for psychosis and non-transition: A systematic 
review. Schizophrenia Research, 132(1), 8-17. 
doi:https://doi.org/10.1016/j.schres.2011.07.002 
Simonsen, C., Sundet, K., Vaskinn, A., Birkenaes, A. B., Engh, J. A., Færden, A., . . . 
Andreassen, O. A. (2009). Neurocognitive Dysfunction in Bipolar and 
Schizophrenia Spectrum Disorders Depends on History of Psychosis Rather 
Than Diagnostic Group. Schizophrenia Bulletin, 37(1), 73-83. 
doi:10.1093/schbul/sbp034 
Slinker, B. K., & Glantz, S. A. (2008). Multiple Linear Regression. Circulation, 
117(13), 1732-1737. doi:doi:10.1161/CIRCULATIONAHA.106.654376 
 112
Slotema, C. W., Blom, J. D., van Lutterveld, R., Hoek, H. W., & Sommer, I. E. C. 
(2014). Review of the Efficacy of Transcranial Magnetic Stimulation for 
Auditory Verbal Hallucinations. Biological Psychiatry, 76(2), 101-110. 
doi:https://doi.org/10.1016/j.biopsych.2013.09.038 
Snitz, B. E., MacDonald III, A. W., & Carter, C. S. (2006). Cognitive deficits in 
unaffected first-degree relatives of schizophrenia patients: a meta-analytic 
review of putative endophenotypes.  
Snyder, S. H. (1976). The dopamine hypothesis of schizophrenia: focus on the 
dopamine receptor. The American journal of psychiatry.  
Sohler, N., Adams, B., Barnes, D., Cohen, G., Prins, S., & Schwartz, S. (2016). 
Weighing the Evidence for Harm From Long-Term Treatment With 
Antipsychotic Medications: A Systematic Review. The American journal of 
orthopsychiatry, 86(5), 477-485.  
Spitzer, R. L., Williams, J. B., Gibbon, M., & First, M. B. (1992). The structured 
clinical interview for DSM-III-R (SCID): I: history, rationale, and description. 
Archives of General Psychiatry, 49(8), 624-629.  
Sponheim, S. R., Jung, R. E., Seidman, L. J., Mesholam-Gately, R. I., Manoach, D. 
S., O’Leary, D. S., . . . Schulz, S. C. (2010). Cognitive deficits in recent-onset 
and chronic schizophrenia. Journal of psychiatric research, 44(7), 421-428. 
doi:https://doi.org/10.1016/j.jpsychires.2009.09.010 
Statistisk Sentralbyrå. (2019). 09817: Innvandrere og norskfødte med 
innvandrerforeldre, etter landbakgrunn, år, statistikkvariabel, 
innvandringskategori og region - for Stavanger og Bergen og Trondheim. In. 
Steen, N. E., Aas, M., Simonsen, C., Dieset, I., Tesli, M., Nerhus, M., . . . 
Andreassen, O. A. (2017). Serum levels of second-generation antipsychotics 
are associated with cognitive function in psychotic disorders. The World 
Journal of Biological Psychiatry, 18(6), 471-482. 
doi:10.1080/15622975.2016.1245441 
Stewart, S. A. (2005). The Effects of Benzodiazepines on Cognition. The Journal of 
clinical psychiatry, 66(Suppl2), 9-13.  
Stone, J. M., Howes, O. D., Egerton, A., Kambeitz, J., Allen, P., Lythgoe, D. J., . . . 
McGuire, P. (2010). Altered relationship between hippocampal glutamate 
levels and striatal dopamine function in subjects at ultra high risk of psychosis. 
Biol Psychiatry, 68(7), 599-602. doi:10.1016/j.biopsych.2010.05.034 
Strauss, G. P., Morra, L. F., Sullivan, S. K., & Gold, J. M. (2015). The role of low 
cognitive effort and negative symptoms in neuropsychological impairment in 
schizophrenia. Neuropsychology, 29(2), 282-291. doi:10.1037/neu0000113 
Swildens, W., Termorshuizen, F., de Ridder, A., Smeets, H., & Engelhard, I. M. 
(2016). Somatic Care with a Psychotic Disorder. Lower Somatic Health Care 
Utilization of Patients with a Psychotic Disorder Compared to Other Patient 
Groups and to Controls Without a Psychiatric Diagnosis. Administration and 
Policy in Mental Health and Mental Health Services Research, 43(5), 650-
662. doi:10.1007/s10488-015-0679-0 
Takeuchi, H., & Remington, G. (2013). A systematic review of reported cases 
involving psychotic symptoms worsened by aripiprazole in schizophrenia or 
 113 
schizoaffective disorder. Psychopharmacology, 228(2), 175-185. 
doi:10.1007/s00213-013-3154-1 
Takeuchi, H., Suzuki, T., Remington, G., Bies, R. R., Abe, T., Graff-Guerrero, A., . . 
. Uchida, H. (2013). Effects of Risperidone and Olanzapine Dose Reduction 
on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, 
Randomized, Controlled, Pilot Study. Schizophrenia Bulletin, 39(5), 993-998. 
doi:10.1093/schbul/sbt090 
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009). Schizophrenia, "just the 
facts" 4. Clinical features and conceptualization. Schizophr Res, 110(1-3), 1-
23. doi:10.1016/j.schres.2009.03.005 
ten Velden Hegelstad, W., Larsen, T. K., Auestad, B., Evensen, J., Haahr, U., Joa, I., . 
. . Opjordsmoen, S. (2012). Long-term follow-up of the TIPS early detection 
in psychosis study: effects on 10-year outcome. American Journal of 
Psychiatry.  
The Cochrane Collaboration. (2011). Cochrane Handbook for Systematic Reviews of 
Interventions 5.1.0 (updated March 2011). Retrieved from 
http://www.cochrane.org/training/cochrane-handbook 
Trépanier, M. O., Hopperton, K. E., Mizrahi, R., Mechawar, N., & Bazinet, R. P. 
(2016). Postmortem evidence of cerebral inflammation in schizophrenia: a 
systematic review. Molecular psychiatry, 21(8), 1009-1026. 
doi:http://dx.doi.org/10.1038/mp.2016.90 
Tyson, P. J., Laws, K. R., Roberts, K., & Mortimer, A. M. (2004). Stability of set-
shifting and planning abilities in patients with schizophrenia. Psychiatry 
research, 129(3), 229-239.  
van Os, J., Gilvarry, C., Bale, R., van Horn, E., Tattan, T., White, I., & Murray, R. 
(2000). Diagnostic value of the DSM and ICD categories of psychosis: an 
evidence-based approach. UK700 Group. Soc Psychiatry Psychiatr Epidemiol, 
35(7), 305-311. doi:10.1007/s001270050243 
van Os, J., Kenis, G., & Rutten, B. P. (2010). The environment and schizophrenia. 
Nature, 468(7321), 203-212. doi:10.1038/nature09563 
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. 
(2009). A systematic review and meta-analysis of the psychosis continuum: 
evidence for a psychosis proneness–persistence–impairment model of 
psychotic disorder. Psychological medicine, 39(2), 179-195.  
van Os, J., & Reininghaus, U. (2016). Psychosis as a transdiagnostic and extended 
phenotype in the general population. World Psychiatry, 15(2), 118-124.  
Van Ruitenbeek, P., Vermeeren, A., & Riedel, W. (2010). Histamine H1 receptor 
antagonist cetirizine impairs working memory processing speed, but not 
episodic memory. British journal of pharmacology, 161(2), 456-466.  
Vance, D. E., Roberson, A. J., McGuinness, T. M., & Fazeli, P. L. (2010). How 
neuroplasticity and cognitive reserve protect cognitive functioning. Journal of 
psychosocial nursing and mental health services, 48(4), 23-30.  
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, 
R., . . . Baler, R. (2016). Effects of Cannabis Use on Human Behavior, 
Including Cognition, Motivation, and Psychosis: A Review. JAMA Psychiatry, 
73(3), 292-297. doi:10.1001/jamapsychiatry.2015.3278 
 114
Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R., & Dickinson, D. 
(2012). Searching for a consensus five-factor model of the Positive and 
Negative Syndrome Scale for schizophrenia. Schizophrenia Research, 137(1-
3), 246-250. doi:10.1016/j.schres.2012.01.031 
Waltz, J. A., Schweitzer, J. B., Gold, J. M., Kurup, P. K., Ross, T. J., Jo Salmeron, B., 
. . . Stein, E. A. (2008). Patients with Schizophrenia have a Reduced Neural 
Response to Both Unpredictable and Predictable Primary Reinforcers. 
Neuropsychopharmacology, 34(6), 1567-1577. 
doi:http://www.nature.com/npp/journal/v34/n6/suppinfo/npp2008214s1.html 
Wechsler, D. (1997a). Wechsler adult intelligence scale-III. In: San Antonio, TX: The 
Psychological Corporation. 
Wechsler, D. (1997b). Wechsler memory scale (WMS-III) (Vol. 14): Psychological 
corporation San Antonio, TX. 
Wechsler, D. (2008). Wechsler adult intelligence scale–Fourth Edition (WAIS–IV). 
San Antonio, TX: NCS Pearson, 22(498), 816-827.  
Weinberger, D. R., Torrey, E. F., Neophytides, A. N., & Wyatt, R. J. (1979). Lateral 
cerebral ventricular enlargement in chronic schizophrenia. Archives of General 
Psychiatry, 36(7), 735-739.  
Welch, K. A., Lawrie, S. M., Muir, W., & Johnstone, E. C. (2011). Systematic 
Review of the Clinical Presentation of Schizophrenia in Intellectual Disability. 
Journal of Psychopathology and Behavioral Assessment, 33(2), 246-253. 
doi:10.1007/s10862-011-9224-y 
West, A. R., Floresco, S. B., Charara, A., Rosenkranz, J. A., & Grace, A. A. (2003). 
Electrophysiological interactions between striatal glutamatergic and 
dopaminergic systems. Ann N Y Acad Sci, 1003, 53-74. Retrieved from 
https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1196/annals.1300.004 
Whitty, P., Clarke, M., McTigue, O., Browne, S., Kamali, M., Larkin, C., & 
O'Callaghan, E. (2005). Diagnostic stability four years after a first episode of 
psychosis. Psychiatric Services, 56(9), 1084-1088.  
WHO. (2020). Schizophrenia. Newsroom Fact Sheets. Retrieved from 
https://www.who.int/news-room/fact-sheets/detail/schizophrenia 
Woodberry, K. A., Giuliano, A. J., & Seidman, L. J. (2008). Premorbid IQ in 
schizophrenia: a meta-analytic review. American Journal of Psychiatry, 
165(5), 579-587.  
World Health Organization. (2007). International Statistical Classification of 
Diseases and Related Health Problems, 10th Revision. Retrieved from 
http://apps.who.int/classifications/icd10/browse/2010/en 
World Health Organization. (2009). ICD 10 : international statistical classification of 
diseases and related health problems. Geneva: World Health Organization. 
World Health Organization. (2018a). ICD-11 : International Classification of 
Diseases. Geneva: World Health Organization. 
World Health Organization. (2018b). Schizophrenia. Retrieved from 
https://www.who.int/news-room/fact-sheets/detail/schizophrenia 
World Medical Association. (2013). World Medical Association Declaration of 
Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 
Retrieved from http://www.wma.net/en/30publications/10policies/b3/ 
 115 
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). 
Recovery in remitted first-episode psychosis at 7 years of follow-up of an 
early dose reduction/discontinuation or maintenance treatment strategy: long-
term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 70(9), 
913-920. doi:10.1001/jamapsychiatry.2013.19 
Wyatt, R. J. (1991). Neuroleptics and the natural course of schizophrenia. 
Schizophrenia Bulletin, 17(2), 325-351.  
Yung, A. R., & McGorry, P. D. (1996). The Prodromal Phase of First-episode 
Psychosis: Past and Current Conceptualizations. Schizophrenia Bulletin, 22(2), 
353-370. doi:10.1093/schbul/22.2.353 
Yung, A. R., Woods, S. W., Ruhrmann, S., Addington, J., Schultze-Lutter, F., 
Cornblatt, B. A., . . . Borgwardt, S. (2012). Whither the attenuated psychosis 
syndrome? Schizophrenia Bulletin, 38(6), 1130-1134.  
Zhu, Y., Li, C., Huhn, M., Rothe, P., Krause, M., Bighelli, I., . . . Leucht, S. (2017). 
How well do patients with a first episode of schizophrenia respond to 
antipsychotics: A systematic review and meta-analysis. European 
Neuropsychopharmacology, 27(9), 835-844. 
doi:https://doi.org/10.1016/j.euroneuro.2017.06.011 
Zimmermann, G., Favrod, J., Trieu, V., & Pomini, V. (2005). The effect of cognitive 
behavioral treatment on the positive symptoms of schizophrenia spectrum 
















































Doctoral Theses at The Faculty of Psychology, 









Myhrer, Trond, Dr. philos. Behavioral Studies after selective disruption of 
hippocampal inputs in albino rats. 
1982 
 
Svebak, Sven, Dr. philos. The significance of motivation for task-induced tonic 
physiological changes. 
1983 Myhre, Grete, Dr. philos. The Biopsychology of behavior in captive Willow 
ptarmigan. 
 Eide, Rolf, Dr. philos.   PSYCHOSOCIAL FACTORS AND INDICES OF 
HEALTH RISKS. The relationship of psychosocial 
conditions to subjective complaints, arterial blood 
pressure, serum cholesterol, serum triglycerides and 










Kolstad, Arnulf, Dr. philos. Til diskusjonen om sammenhengen mellom sosiale 
forhold og psykiske strukturer. En epidemiologisk 
undersøkelse blant barn og unge. 
 Løberg, Tor, Dr. philos. Neuropsychological assessment in alcohol dependence. 
1985 
 
Hellesnes, Tore, Dr. philos. Læring og problemløsning. En studie av den 
perseptuelle analysens betydning for verbal læring. 




Hagtvet, Knut A., Dr. philos.  The construct of test anxiety: Conceptual and 
methodological issues. 
 Jellestad, Finn K., Dr. philos. Effects of neuron specific amygdala lesions on fear-
motivated behavior in rats. 
1987 Aarø, Leif E., Dr. philos.  Health behaviour and sosioeconomic Status. A survey 
among the adult population in Norway. 




Laberg, Jon C., Dr. philos. Expectancy and classical conditioning in alcoholics' 
craving. 
 Vollmer, Fred, Dr. philos.  Essays on explanation in psychology. 
 Ellertsen, Bjørn, Dr. philos. Migraine and tension headache: Psychophysiology, 
personality and therapy. 
 170








Havik, Odd E., Dr. philos.  After the myocardial infarction: A medical and 
psychological study with special emphasis on perceived 
illness. 
 
1989 Bråten, Stein, Dr. philos.  Menneskedyaden. En teoretisk tese om sinnets 
dialogiske natur med informasjons- og 






Wold, Bente, Dr. psychol. Lifestyles and physical activity. A theoretical and 
empirical analysis of socialization among children and 
adolescents. 
1990 Flaten, Magne A., Dr. psychol. The role of habituation and learning in reflex 
modification. 
1991 Alsaker, Françoise D.,  
Dr. philos.  




Kraft, Pål, Dr. philos.  AIDS prevention in Norway. Empirical studies on 
diffusion of knowledge, public opinion, and sexual 
behaviour. 
 Endresen, Inger M., Dr. philos. Psychoimmuniological stress markers in working life. 
 Faleide, Asbjørn O., Dr. philos.  Asthma and allergy in childhood. Psychosocial and 
psychotherapeutic problems. 
1992 Dalen, Knut, Dr. philos.  Hemispheric asymmetry and the Dual-Task Paradigm: 
An experimental approach. 
 Bø, Inge B., Dr. philos. Ungdoms sosiale økologi. En undersøkelse av 14-16 





Nivison, Mary E., Dr. philos.  The relationship between noise as an experimental and 
environmental stressor, physiological changes and 
psychological factors. 
 Torgersen, Anne M., Dr. philos.  Genetic and environmental influence on temperamental 
behaviour. A longitudinal study of twins from infancy to 
adolescence. 
 




Nordhus, Inger Hilde, Dr. 
philos.  
Family caregiving. A community psychological study with 
special emphasis on clinical interventions. 
 Thuen, Frode, Dr. psychol.  Accident-related behaviour among children and young 
adolescents: Prediction and prevention. 
 Solheim, Ragnar, Dr. philos.  Spesifikke lærevansker. Diskrepanskriteriet anvendt i 
seleksjonsmetodikk. 
 171 
 Johnsen, Bjørn Helge,  
Dr. psychol.   
Brain assymetry and facial emotional expressions: 
Conditioning experiments. 
1994 Tønnessen, Finn E., Dr. philos.  The etiology of Dyslexia. 
 Kvale, Gerd, Dr. psychol. Psychological factors in anticipatory nausea and 
vomiting in cancer chemotherapy. 
 Asbjørnsen, Arve E.,  
Dr. psychol.  
Structural and dynamic factors in dichotic listening: An 
interactional model. 
 Bru, Edvin, Dr. philos.  The role of psychological factors in neck, shoulder and 
low back pain among female hospitale staff. 
 Braathen, Eli T., Dr. psychol.  Prediction of exellence and discontinuation in different 
types of sport: The significance of  motivation and EMG. 
 
 Johannessen, Birte F.,  
Dr. philos.  
Det flytende kjønnet. Om lederskap, politikk og identitet. 
 
1995 Sam, David L., Dr. psychol. Acculturation of young immigrants in Norway: A 
psychological and socio-cultural adaptation. 
 
 Bjaalid, Inger-Kristin, Dr. philos. Component processes in word recognition. 
 Martinsen, Øyvind, Dr. philos.  Cognitive style and insight. 
 
 Nordby, Helge, Dr. philos. Processing of auditory deviant events: Mismatch 
negativity of event-related brain potentials. 
 Raaheim, Arild, Dr. philos. Health perception and health behaviour, theoretical 
considerations, empirical studies, and practical 
implications. 
 
 Seltzer, Wencke J., Dr. philos. Studies of Psychocultural Approach to Families in 
Therapy. 
 
 Brun, Wibecke, Dr. philos. Subjective conceptions of uncertainty and risk. 
 
 Aas, Henrik N., Dr. psychol. Alcohol expectancies and socialization: 
Adolescents learning to drink. 
 
 Bjørkly, Stål, Dr. psychol. Diagnosis and prediction of intra-institutional 
aggressive behaviour in psychotic patients 
1996 Anderssen, Norman,  
Dr. psychol. 
Physical activity of young people in a health perspective: 
Stability, change and social influences. 
 Sandal, Gro Mjeldheim,  
Dr. psychol. 
Coping in extreme environments: The role of personality. 
 Strumse, Einar, Dr. philos. The psychology of aesthetics: explaining visual 
preferences for agrarian landscapes in Western Norway. 
 
 Hestad, Knut, Dr. philos. Neuropsychological deficits in HIV-1 infection. 
 172
  Lugoe, L.Wycliffe, Dr. philos. Prediction of Tanzanian students’ HIV risk and 
preventive behaviours 
 Sandvik, B. Gunnhild,  
Dr. philos. 
Fra distriktsjordmor til institusjonsjordmor. Fremveksten 
av en profesjon og en profesjonsutdanning 
 
 Lie, Gro Therese, Dr. psychol. The disease that dares not speak its name: Studies on 
factors of  importance for coping  with HIV/AIDS in 
Northern Tanzania 
 
 Øygard, Lisbet, Dr. philos. Health behaviors among young adults. A psychological 
and sociological approach 
 Stormark, Kjell Morten,  
Dr. psychol. 
Emotional modulation of selective attention: 
Experimental and clinical evidence. 
 Einarsen, Ståle, Dr. psychol. Bullying and harassment at work: epidemiological and 
psychosocial aspects. 
1997 Knivsberg, Ann-Mari, Dr. philos. Behavioural abnormalities and childhood 
psychopathology: Urinary peptide patterns as a potential 
tool in diagnosis and remediation. 
 
 Eide, Arne H., Dr. philos. Adolescent drug use in Zimbabwe. Cultural orientation in 
a global-local perspective and use of psychoactive 
substances among secondary school students. 
 
 Sørensen, Marit, Dr. philos. The psychology of initiating and maintaining exercise 
and diet behaviour. 
 Skjæveland, Oddvar,  
Dr. psychol. 
Relationships between spatial-physical neighborhood 
attributes and social relations among neighbors. 
 Zewdie, Teka, Dr. philos. Mother-child relational patterns in Ethiopia. Issues of 
developmental theories and intervention programs. 
 
 Wilhelmsen, Britt Unni,  
Dr. philos. 
Development and evaluation of two educational 
programmes designed to prevent alcohol use among 
adolescents. 
 
 Manger, Terje, Dr. philos. Gender differences in mathematical achievement among 
Norwegian elementary school  students. 
1998 
V 
Lindstrøm, Torill Christine,  
Dr. philos. 
 
«Good Grief»: Adapting to Bereavement. 
 Skogstad, Anders, Dr. philos. Effects of  leadership behaviour on job satisfaction, 
health and efficiency. 
 
 Haldorsen, Ellen M. Håland,     
Dr. psychol. 
Return to work in low back pain patients. 
 Besemer, Susan P., Dr. philos. Creative Product Analysis: The Search for a Valid Model 
for Understanding Creativity in Products. 
 
 173 
H Winje, Dagfinn, Dr. psychol. Psychological adjustment after severe trauma. A 
longitudinal study of adults’ and children’s posttraumatic 
reactions and coping after the bus accident in 
Måbødalen, Norway 1988. 
 
 Vosburg, Suzanne K.,  
Dr. philos. 
The effects of mood on creative problem solving. 





Jakobsen, Reidar, Dr. psychol. 
 
Empiriske studier av kunnskap og holdninger om hiv/aids 




Mikkelsen, Aslaug, Dr. philos. Effects of learning opportunities and learning climate on 
occupational health. 
 
 Samdal, Oddrun, Dr. philos. The school environment as a risk or resource for 
students’ health-related behaviours and subjective well-
being. 
 
 Friestad, Christine, Dr. philos. Social psychological approaches to smoking. 
 Ekeland, Tor-Johan, Dr. philos. 
 
 
Meining som medisin. Ein analyse av placebofenomenet 
og implikasjoner for terapi og terapeutiske teoriar. 
 
H Saban, Sara, Dr. psychol. Brain Asymmetry and Attention: Classical Conditioning 
Experiments. 
 Carlsten, Carl Thomas,  
Dr. philos. 
God lesing – God læring. En aksjonsrettet studie av 
undervisning i fagtekstlesing. 
 Dundas, Ingrid, Dr. psychol. Functional and dysfunctional closeness. Family 
interaction and children’s adjustment. 
 Engen, Liv, Dr. philos. 
 
 
Kartlegging av leseferdighet på småskoletrinnet og 





Hovland, Ole Johan, Dr. philos. Transforming a self-preserving “alarm” reaction into a 
self-defeating emotional response: Toward an integrative 
approach to anxiety as a human phenomenon. 
 
 Lillejord, Sølvi, Dr. philos. Handlingsrasjonalitet og spesialundervisning. En analyse 
av aktørperspektiver. 
 Sandell, Ove, Dr. philos. Den varme kunnskapen. 
 Oftedal, Marit Petersen,  
Dr. philos. 
 
Diagnostisering av ordavkodingsvansker: En 
prosessanalytisk tilnærmingsmåte. 
H Sandbak, Tone, Dr. psychol. Alcohol consumption and preference in the rat: The 
significance of individual differences and relationships to 
stress pathology 
 
 Eid, Jarle, Dr. psychol. 
 
 
Early predictors of PTSD symptom reporting;  




Skinstad, Anne Helene,  
Dr. philos. 
Substance dependence and borderline personality 
disorders. 
 
 Binder, Per-Einar, Dr. psychol. Individet og den meningsbærende andre. En teoretisk 
undersøkelse av de mellommenneskelige 
forutsetningene for psykisk liv og utvikling med 
utgangspunkt i Donald Winnicotts teori. 
 
 Roald, Ingvild K., Dr. philos. 
 
 
Building of concepts. A study of Physics concepts of 
Norwegian deaf students. 
H Fekadu, Zelalem W., Dr. philos. Predicting contraceptive use and intention among a 
sample of adolescent girls. An application of the theory 
of planned behaviour in Ethiopian context. 
 
 Melesse, Fantu, Dr. philos. 
 
The more intelligent and  sensitive child  (MISC) 
mediational intervention in an Ethiopian context: An 
evaluation study. 
 
 Råheim, Målfrid, Dr. philos. Kvinners kroppserfaring og livssammenheng. En 
fenomenologisk – hermeneutisk studie av friske kvinner 
og kvinner med kroniske muskelsmerter. 
 
 Engelsen, Birthe Kari,  
Dr. psychol. 
 
Measurement of the eating problem construct. 
 Lau, Bjørn, Dr. philos. Weight and eating concerns in adolescence. 
2002 
V 
Ihlebæk, Camilla, Dr. philos. Epidemiological studies of subjective health complaints. 
 Rosén, Gunnar O. R.,  
Dr. philos. 
The phantom limb experience. Models for understanding 
and treatment of pain with hypnosis. 
 Høines, Marit Johnsen,  
Dr. philos. 
Fleksible språkrom. Matematikklæring som tekstutvikling. 
 Anthun, Roald Andor,  
Dr. philos. 
School psychology service quality. 
Consumer appraisal, quality dimensions, and 
collaborative improvement potential 
 
 Pallesen, Ståle, Dr. psychol. Insomnia in the elderly. Epidemiology, psychological 
characteristics and treatment. 
 Midthassel, Unni Vere,  
Dr. philos. 
Teacher involvement in school development activity. A 
study of teachers in Norwegian compulsory schools 




Teachers, schools and implementation of the Olweus 
Bullying Prevention Program. 
 
H Ofte, Sonja Helgesen,  
Dr. psychol. 
Right-left discrimination in adults and children. 
 Netland, Marit, Dr. psychol. Exposure to political violence. The need to estimate our 
estimations. 
 175 
 Diseth, Åge, Dr. psychol. Approaches to learning: Validity and  prediction of 
academic performance. 
 Bjuland, Raymond, Dr. philos. 
 
 
Problem solving in geometry. Reasoning processes of 





Arefjord, Kjersti, Dr. psychol. After the myocardial infarction – the wives’ view. Short- 
and long-term adjustment in wives of myocardial 
infarction patients. 
 
 Ingjaldsson, Jón  Þorvaldur,  
Dr. psychol. 
Unconscious Processes and Vagal Activity in Alcohol 
Dependency. 
 Holden, Børge, Dr. philos. Følger av atferdsanalytiske forklaringer for 
atferdsanalysens tilnærming til utforming av behandling. 
 
 Holsen, Ingrid, Dr. philos. 
 
Depressed mood from adolescence to ’emerging 
adulthood’. Course and longitudinal influences of body 
image and parent-adolescent relationship. 
 
 Hammar, Åsa Karin,  
Dr. psychol. 
Major depression and cognitive dysfunction- An 
experimental study of the cognitive effort hypothesis. 
 Sprugevica, Ieva, Dr. philos. The impact of enabling skills on early reading acquisition. 
 Gabrielsen, Egil, Dr. philos. LESE FOR LIVET. Lesekompetansen i den norske 
voksenbefolkningen sett i lys av visjonen om en 
enhetsskole. 
 
H  Hansen, Anita Lill, Dr. psychol. The influence of heart rate variability in the regulation of 
attentional and memory processes. 
 Dyregrov, Kari, Dr. philos. 
 
 
The loss of child by suicide, SIDS, and accidents: 
Consequences, needs and provisions of help. 
2004 
V 
Torsheim, Torbjørn,  
Dr. psychol. 
Student role strain and subjective health complaints: 
Individual, contextual, and longitudinal perspectives. 
 
 Haugland, Bente Storm Mowatt 
Dr. psychol. 
 
Parental alcohol abuse. Family functioning and child 
adjustment. 
 Milde, Anne Marita, Dr. psychol. Ulcerative colitis and the role of stress. Animal studies of 
psychobiological factors in  relationship to experimentally 
induced colitis. 
 
 Stornes, Tor, Dr. philos. Socio-moral behaviour in sport. An investigation of 
perceptions of sportspersonship in handball related to 
important factors of socio-moral influence. 
 
 Mæhle, Magne, Dr. philos. Re-inventing the child in family therapy: An investigation 
of the relevance and applicability of theory and research 
in child development for family therapy involving children. 
 
 Kobbeltvedt, Therese,  
Dr. psychol. 
Risk and feelings: A field approach. 
2004  
H 
Thomsen, Tormod, Dr. psychol. Localization of attention in the brain. 
 176
 Løberg, Else-Marie,  
Dr. psychol. 
Functional laterality and attention modulation in 
schizophrenia: Effects of clinical variables. 
 Kyrkjebø, Jane Mikkelsen,  
Dr. philos. 
Learning to improve: Integrating continuous quality 
improvement learning into nursing education. 
 Laumann, Karin,  Dr. psychol. Restorative and stress-reducing effects of natural 
environments: Experiencal, behavioural and 
cardiovascular indices. 
 
 Holgersen, Helge, PhD 
 
Mellom oss -  Essay i relasjonell psykoanalyse. 
2005 
V 
Hetland, Hilde, Dr. psychol. Leading to the extraordinary?  
Antecedents and outcomes of transformational 
leadership. 
 
 Iversen, Anette Christine,  
Dr. philos. 
Social differences in health behaviour: the motivational 
role of perceived control and coping. 
2005  
H 
Mathisen, Gro Ellen, PhD Climates for creativity and innovation: Definitions, 
measurement, predictors and consequences. 
 Sævi, Tone, Dr. philos. Seeing disability pedagogically – The lived experience of 
disability in the pedagogical encounter. 
 
 Wiium, Nora, PhD Intrapersonal factors, family and school norms: 
combined and interactive influence on adolescent 
smoking behaviour. 
 
 Kanagaratnam, Pushpa, PhD Subjective and objective correlates of Posttraumatic 
Stress in immigrants/refugees exposed to political 
violence. 
 
 Larsen, Torill M. B. , PhD Evaluating principals` and teachers` implementation of 
Second Step. A case study of four Norwegian primary 
schools. 
 
 Bancila, Delia, PhD 
 
 
Psychosocial stress and distress among Romanian 
adolescents and adults. 
2006 
V 
Hillestad, Torgeir Martin,   
Dr. philos. 
Normalitet og avvik. Forutsetninger for et objektivt 
psykopatologisk avviksbegrep. En psykologisk, sosial, 
erkjennelsesteoretisk og teorihistorisk framstilling. 
 
 Nordanger, Dag Øystein,   
Dr. psychol. 
Psychosocial discourses and responses to political 
violence in post-war Tigray, Ethiopia. 
 Rimol, Lars Morten, PhD Behavioral and fMRI studies of auditory laterality and 
speech sound processing. 
 Krumsvik, Rune Johan,  
Dr. philos. 
ICT in the school. ICT-initiated school development in 
lower secondary school. 
 
 Norman, Elisabeth, Dr. psychol. Gut feelings and unconscious thought:  




 Israel, K Pravin, Dr. psychol. Parent involvement in the mental health care of children 
and adolescents. Emperical studies from clinical care 
setting. 
 
 Glasø, Lars, PhD Affects and emotional regulation in leader-subordinate 
relationships. 
 Knutsen, Ketil, Dr. philos. HISTORIER UNGDOM LEVER – En studie av hvordan 
ungdommer bruker historie for å gjøre livet meningsfullt. 
 Matthiesen, Stig Berge, PhD Bullying at work. Antecedents and outcomes. 
2006  
H 
Gramstad, Arne, PhD Neuropsychological assessment of cognitive and 
emotional functioning in patients with epilepsy. 
 
 Bendixen, Mons, PhD Antisocial behaviour in early adolescence: 
Methodological and substantive issues. 
 
 Mrumbi, Khalifa Maulid, PhD Parental illness and loss to HIV/AIDS as experienced by 
AIDS orphans aged between 12-17 years from Temeke 
District, Dar es Salaam, Tanzania: A study of the 
children’s psychosocial health and coping responses. 
 
 Hetland, Jørn, Dr. psychol. The nature of subjective health complaints in 
adolescence: Dimensionality, stability, and psychosocial 
predictors 
 
 Kakoko, Deodatus Conatus 
Vitalis, PhD 
Voluntary HIV counselling and testing service uptake 
among primary school teachers in Mwanza, Tanzania: 
assessment of socio-demographic, psychosocial and 
socio-cognitive aspects 
 
 Mykletun, Arnstein, Dr. psychol. Mortality and work-related disability as long-term 
consequences of anxiety and depression: Historical 
cohort designs based on the HUNT-2 study 
 




Singhammer, John, Dr. philos. Social conditions from before birth to early adulthood – 
the influence on health and health behaviour 
 
 Janvin, Carmen Ani Cristea, 
PhD  
Cognitive impairment in patients with Parkinson’s 
disease: profiles and implications for prognosis 
 
 Braarud, Hanne Cecilie, 
Dr.psychol. 
Infant regulation of distress: A longitudinal study of 
transactions between mothers and infants 
 
 Tveito, Torill Helene, PhD Sick Leave and Subjective Health Complaints 
 
 Magnussen, Liv Heide, PhD Returning disability pensioners with back pain to work 
 Thuen, Elin Marie, Dr.philos. Learning environment, students’ coping styles and 
emotional and behavioural problems. A study of 
Norwegian secondary school students. 
 
 178
 Solberg, Ole Asbjørn, PhD Peacekeeping warriors – A longitudinal study of 
Norwegian peacekeepers in Kosovo 
2007  
H 
Søreide, Gunn Elisabeth, 
Dr.philos. 
 
Narrative construction of teacher identity 
 Svensen, Erling, PhD WORK & HEALTH. Cognitive Activation Theory of Stress 
applied in an organisational setting. 
 Øverland, Simon Nygaard, PhD Mental health and impairment in disability benefits. 
Studies applying linkages between health surveys and 
administrative registries. 
 
 Eichele, Tom, PhD Electrophysiological and Hemodynamic Correlates of 
Expectancy in Target Processing 
 Børhaug, Kjetil, Dr.philos. Oppseding til demokrati. Ein studie av politisk oppseding 
i norsk skule. 
 Eikeland, Thorleif, Dr.philos. Om å vokse opp på barnehjem og på sykehus. En 
undersøkelse av barnehjemsbarns opplevelser på 
barnehjem sammenholdt med sanatoriebarns 
beskrivelse av langvarige sykehusopphold – og et forsøk 
på forklaring. 
 
 Wadel, Carl Cato, Dr.philos. Medarbeidersamhandling og medarbeiderledelse i en 
lagbasert organisasjon 
 Vinje, Hege Forbech, PhD Thriving despite adversity: Job engagement and self-
care among community nurses 




Breivik, Kyrre, Dr.psychol. The Adjustment of Children and Adolescents in Different 
Post-Divorce Family Structures. A Norwegian Study of 
Risks and Mechanisms. 
 
 Johnsen, Grethe E., PhD Memory impairment in patients with posttraumatic stress 
disorder 
 Sætrevik, Bjørn, PhD Cognitive Control in Auditory Processing 
 Carvalhosa, Susana Fonseca, 
PhD 
Prevention of bullying in schools: an ecological model 
2008 
H 
Brønnick, Kolbjørn Selvåg Attentional dysfunction in dementia associated with 
Parkinson’s disease. 
 Posserud, Maj-Britt Rocio Epidemiology of autism spectrum disorders 
 Haug, Ellen Multilevel correlates of physical activity in the school 
setting 
 Skjerve, Arvid Assessing mild dementia – a study of brief cognitive 
tests. 
 179 
 Kjønniksen, Lise  The association between adolescent experiences in  
physical activity and leisure time physical activity in  
adulthood: a ten  year longitudinal study 
 
 Gundersen, Hilde  The effects of alcohol and expectancy on brain function 
 
 Omvik, Siri Insomnia – a night and day problem 
2009 
V 
Molde, Helge Pathological gambling: prevalence, mechanisms and 
treatment outcome. 
 
 Foss, Else Den omsorgsfulle væremåte. En studie av voksnes 
væremåte i forhold til barn i barnehagen. 
 Westrheim, Kariane Education in a Political Context: A study of Konwledge 
Processes and Learning Sites in the PKK. 
 Wehling, Eike Cognitive and olfactory changes in aging 
 Wangberg, Silje C. Internet based interventions to support health behaviours: 
The role of self-efficacy. 
 Nielsen, Morten B. Methodological issues in research on workplace bullying. 
Operationalisations, measurements and samples. 
 Sandu, Anca Larisa MRI measures of brain volume and cortical complexity in 
clinical groups and during development. 
 Guribye, Eugene Refugees and mental health interventions 
 Sørensen, Lin Emotional problems in inattentive children – effects on 
cognitive control functions. 
 Tjomsland, Hege E. Health promotion with teachers. Evaluation of the 
Norwegian Network of Health Promoting Schools: 
Quantitative and qualitative analyses of predisposing, 
reinforcing and enabling conditions related to teacher 
participation and program sustainability. 
 






Dagliglivet i en psykiatrisk institusjon: En analyse av 
miljøterapeutiske praksiser 
 
 Andreassen, Cecilie Schou WORKAHOLISM – Antecedents and Outcomes 
 Stang, Ingun Being in the same boat: An empowerment intervention in 
breast cancer self-help groups 
 
 Sequeira, Sarah Dorothee Dos 
Santos  
The effects of background noise on asymmetrical speech 
perception 
 
 Kleiven, Jo, dr.philos. The Lillehammer scales: Measuring common motives for 
vacation and leisure behavior 
 Jónsdóttir, Guðrún  Dubito ergo sum? Ni jenter møter naturfaglig kunnskap. 
 180
 Hove, Oddbjørn Mental health disorders in adults with intellectual 
disabilities - Methods of assessment and prevalence of 
mental health disorders and problem behaviour 
 
 Wageningen, Heidi Karin van The role of glutamate on brain function 
 Bjørkvik, Jofrid God nok? Selvaktelse og interpersonlig fungering hos 
pasienter innen psykisk helsevern: Forholdet til 
diagnoser, symptomer og behandlingsutbytte 
 
 Andersson, Martin A study of attention control in children and elderly using 
a forced-attention dichotic listening paradigm 
 
 Almås, Aslaug Grov Teachers in the Digital Network Society: Visions and 
Realities. A study of teachers’ experiences with the use 
of ICT in teaching and learning. 
 




Skår, Randi Læringsprosesser i sykepleieres profesjonsutøvelse.  
En studie av sykepleieres læringserfaringer. 
 
 Roald, Knut Kvalitetsvurdering som organisasjonslæring mellom 
skole og skoleeigar 
 Lunde, Linn-Heidi Chronic pain in older adults. Consequences, assessment 
and treatment. 
 Danielsen, Anne Grete Perceived psychosocial support, students’ self-reported 
academic initiative and perceived life satisfaction 
 Hysing, Mari Mental health in children with chronic illness 
 Olsen, Olav Kjellevold Are good leaders moral leaders? The relationship 
between effective military operational leadership and 
morals 
 
 Riese, Hanne Friendship and learning. Entrepreneurship education 
through mini-enterprises. 
 Holthe, Asle Evaluating the implementation of the Norwegian 
guidelines for healthy school meals: A case study 
involving three secondary schools 
 
H Hauge, Lars Johan Environmental antecedents of workplace bullying:  
A multi-design approach 
 
 Bjørkelo, Brita Whistleblowing at work: Antecedents and consequences 
 Reme, Silje Endresen Common Complaints – Common Cure?  
Psychiatric comorbidity and predictors of treatment 
outcome in low back pain and irritable bowel syndrome 
 
 Helland, Wenche Andersen Communication difficulties in children identified with 
psychiatric problems 
 181 
 Beneventi, Harald Neuronal correlates of working memory in dyslexia 
 Thygesen, Elin Subjective health and coping in care-dependent old 
persons living at home 
 Aanes, Mette Marthinussen Poor social relationships as a threat to belongingness 
needs. Interpersonal stress and subjective health 
complaints: Mediating and moderating factors. 
 
 Anker, Morten Gustav Client directed outcome informed couple therapy 
 Bull, Torill Combining employment and child care: The subjective 
well-being of single women in Scandinavia and in 
Southern Europe 
 
 Viig, Nina Grieg Tilrettelegging for læreres deltakelse i helsefremmende 
arbeid. En kvalitativ og kvantitativ analyse av 
sammenhengen mellom organisatoriske forhold og 
læreres deltakelse i utvikling og implementering av 
Europeisk Nettverk av Helsefremmende Skoler i Norge 
 
 Wolff, Katharina To know or not to know? Attitudes towards receiving 
genetic information among patients and the general 
public. 
 
 Ogden, Terje, dr.philos. Familiebasert behandling av alvorlige atferdsproblemer 
blant barn og ungdom. Evaluering og implementering av 
evidensbaserte behandlingsprogrammer i Norge. 
 
 Solberg, Mona Elin Self-reported bullying and victimisation at school: 
Prevalence, overlap and psychosocial adjustment. 
2011 
V 
Bye, Hege Høivik Self-presentation in job interviews. Individual and cultural 
differences in applicant self-presentation during job 
interviews and hiring managers’ evaluation 
 
 Notelaers, Guy Workplace bullying. A risk control perspective. 
 Moltu, Christian Being a therapist in difficult therapeutic impasses.  
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Page 9-10:  
Deleted the following abbreviations from abbreviation lists:  
AAs: Atypical ("second-generation) antipsychotic drugs 
FEP: First episode psychosis 
FGA: First-generation antipsychotic drugs 
GAF: Global Assessment of Functioning Scale – Split version 
GAF-S: Global Assessment of Functioning Scale – Symptom subscale  
GAF-F: Global Assessment of Functioning Scale – Functioning subscale 
IGSIN: International Graduate School in Integrated Neuroscience 
ITT: Intention to treat 
NOS: Psychotic disorder not otherwise specified 
SID: Substance induced psychosis 
SSD: Schizophrenia spectrum disorders 
TMA: Trail Making Test A  
TMB: Trail Making Test B 
 
Inserted the following abbreviations into list:  
CBT: Cognitive-behavioural therapy 
DSM-5: Diagnostic and Statistical Manual for Mental Disorders, 5th edition 
D2: Dopamine 2 receptor 
fMRI: Functional magnetic resonance imaging 
PP: Per protocol 
SIPS: Structured Interview for Prodromal Symptoms 
 




Inserted "the tests of the Repeatable Battery for the Assessment of Neuropsychological 
Status" 
Inserted brackets around  "RBANS" abbreviation 
Deleted "neurocognitive test battery" 
Inserted "the Positive and Negative Syndrome Scale" and brackets around "PANSS" 
 
 Page 12 
Inserted "deemed at ultra high risk for psychotic disorder" 
Inserted brackets around "UHR" 
 
Page 20 
Inserted Diagnostic and Statistical Manual of Mental Disorders, 4th edition and  
brackets around "DSM-IV" 
Diagnostic and Statistical Manual of Mental Disorders, 5th edition. 
Inserted brackets around "DSM-5" 
Inserted dopamine 2 and brackets around "D2"   
 
Page 21 
Inserted "dopamine" ahead of D1 receptor abbreviation   
 3 
Corrected reference (Siris, 2000) formatting  
 
Page 22 
Inserted "International Statistical Classification of Diseases, 11th edition" and brackets 
around "ICD-11" 
  
Page 23  
Replaced "(SSD)"  with "schizophrenia spectrum disorders" throughout page 
 
Page 24  
Expanded "UHR" to "a group of youth at ultra high risk for psychotic illness" and added 
brackets to "UHR" 
 
Page 25 
Replaced "SID" with "substance induced psychosis"   
Replaced "SSD" with "schizophrenia spectrum disorders"  





Pages 29, 31, 39, 42, 49, 71, 79, 89 
Replaced "FEP" with "first episode psychosis" throughout pages 
 
Page 32 
Replaced "CT" with "computed tomography" 
   
Page 33  
Replaced "MRI" with "magnetic resonance imaging" throughout page 
Replaced "DTI" with "diffusion tensor imaging" throughout page 
Inserted "functional magnetic resonance imaging" and added brackets around "fMRI" 
Replaced "WM" with "white matter" 
 
Page 34 
Replaced "PET" with "positron emission tomography" 
Corrected reference formatting (Read, van Os, Morrison, & Ross, 2005) 
 
Page 35 





Page 36, 47, 97 
Replaced "FGA" with "First-generation antipsychotic drugs" throughout pages 
 
Page 37 
Inserted brackets around "CBT" and added "cognitive-behavioural therapy" 





Replaced "VR" with "virtual reality"  
 
Page 41 
Replaced "WWII" with "World War II" 
 
Page 44 
Replaced "DLPFC" with dorsolateral prefrontal cortex   
Replaced "IFG" with "inferior frontal gyrus"  
 
Page 45 
Replaced "PFC" with "prefrontal cortex"   
Repaired reference formatting "(Samartzis et al., 2014)"   
 
Pages 46, 47, 48, 50, 76, 77, 82, 97 
Replaced "(AA)" with atypical antipsychotics throughout pages  
  
Page 47 
Replaced "5hT2" with "5-hydroxytryptamine"   
Replaced M3 with "muscarinic acetylcholine"   
Replaced "H1" with "Histamine 1" 
Corrected formatting of reference "(Chew et al., 2006)" 
  
Page 52:  
Inserted "including the BestIntro antipsychotic drug trial" to clarify 
Deleted "(RCMRE)"   
 
Page 53:  
Inserted "Positive and Negative Syndrome Scale" and added brackets around "PANSS" 
throughout page 
Replaced "AP"s with "antipsychotic drugs" throughout page 
Page 54 
Replaced "SOPS scale" with "Scale of Prodromal Symptoms"  
 
Page 55 
Replaced "K-SADS" with "Kiddie Schedule for Affective Disorders and Schizophrenia" 
Inserted "Structured Clinical Interview for the DSM-IV" and added brackets around "SCID".  
Deleted "I" from "SCID-I" 
 
Page 58 
Replaced "SCI-PANSS" with "Structured Clinical Interview: Positive and Negative 
Syndrome Scale" 
Deleted "(CDUS/CAUS)"   
Deleted "(GAF-F)"   
 
Page 59 
Inserted Delis Kaplan Executive Function System and added brackets to "D-KEFS" 
Deleted "verbal fluency tests"  
Deleted "DVT" 
 5 
Replaced "CALCAP" with "California Computerized Assessment Package" 
 
Page 60 
Replaced Arabic numerals 1 and 2 with Roman numerals I and II  
 
Page 61 
Replaced "Fig 3" with "Note" in caption 
 
Page 62 
Inserted "defined daily doses" and added brackets to "DDD"   
Deleted (RGs)   
Deleted (BASG)   
Replaced "ICH GCP (ICH)" with "International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use: Guideline for Good Clinical Practice" 
Pages 63 and 64 
Replaced "(WNRHA)" with "Western Norway Regional Health Authority" 
 
Page 65 
Inserted missing part of figure 
 
Page 67 
Deleted "Figure 2" and replaced with "Note:"   
  
Page 68 
Replaced "AP" with "antipsychotic" into heading 
    
Page 69 
Corrected figure number in caption 
 
Page 71 




Replaced "AAs" with "Atypical antipsychotics" in heading 
 
Page 74, 78, 79 
Replaced "SZ" with "schizophrenia" throughout pages 
 




Inserted "those of"   
 
Page 92 
Replaced "avg." with "average"  
Page 93 
Deleted "-I" twice from "SCID-I"  
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